

NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS AND RISK BEHAVIOUR SURVEY REPORT

2004 AND 2007



Prevalence of
HIV, hepatitis C,
hepatitis B, and
risk behaviours
among Australian
prison entrants

NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS AND RISK BEHAVIOUR SURVEY 2004 & 2007


Prevalence of HIV, HBV, HCV, and risk behaviours
among Australian prison entrants

NATIONAL REPORT
2004 & 2007

Report prepared by Tony Butler and Cerissa Papanastasiou

National Drug Research Institute, Curtin University of Technology

September 2008



Suggested citation:

Butler T, Papanastasiou C. National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey Report 2004 & 2007. National Drug Research Institute (Curtin University) & National Centre in HIV Epidemiology and Clinical Research (University of New South Wales). 2008. ISBN: 1 74067 582 7

CONTENTS

CONTENTS	2
ACKNOWLEDGEMENTS	3
FOREWORD.....	5
EXECUTIVE SUMMARY	6
Background.....	6
Methods	6
Results.....	6
Implications of the Findings.....	8
INTRODUCTION	10
METHODS.....	11
Study Sample	11
Sample Selection.....	11
Recruitment.....	11
Survey Sites	11
Screening Procedures	12
Blood Testing	12
Questionnaire	12
Statistical Analysis	13
Interviewers.....	13
Ethics Approval	13
Reporting of Results.....	13
RESULTS.....	13
Response Rate	13
Summary	16
National.....	19
HIV antibody prevalence.....	25
HCV antibody prevalence	26
HBV prevalence	31
New South Wales	40
HIV antibody prevalence.....	46
HCV antibody prevalence	46
HBV prevalence	51
Queensland	59
HIV antibody prevalence.....	65
HCV antibody prevalence	65
HBV prevalence	70
Tasmania	78
HIV antibody prevalence.....	84
HCV antibody prevalence	84
HBV prevalence	89
Victoria.....	97
HIV antibody prevalence.....	103
HCV antibody prevalence	103
HBV prevalence	108
Western Australia.....	116
HIV antibody prevalence.....	122
HCV antibody prevalence	122
HBV prevalence	127
Methodological Notes.....	135
Appendix 1 – Blood Tests, Test Kits and Testing Laboratories	136
Appendix 2 - Questionnaire.....	137
List of Tables.....	140
References	146

ACKNOWLEDGEMENTS

We are grateful to the project management team and the site co-coordinators:

Project steering committee:

A/Professor Tony Butler (National Drug Research Institute); ACT: Gayle Berthold and A/Professor Michael Levy (ACT Corrections Health); NSW: Leng Boonwaat, Gary Forrest and Devon Indig (NSW Justice Health); Qld: Dr Alun Richards and Stacy Kambouris (Queensland Corrective Services); SA: Dr Peter Frost, Raylee Kinnear and Sue Rex (South Australian Prison Health Service) ; Tas: Dr Chris Wake, Matthew Chick (Tasmanian Correctional Primary Health Services) ; Vic: Frankie Boardman, Geraldine Thomson, Rory Wilby (deceased) (Justice Health and Corrections Victoria); and WA: Holly Beasley (Western Australia Corrective Services).

Site co-ordinators:

ACT: Gayle Berthold; NSW: Shalin Kumar; Qld: Stacy Kambouris; SA: Sue Rex; Tas: Matthew Chick; Vic: Nyree Chung, Kim Messieh, Lyn Pierce; and WA: Holly Beasley.

The following individuals conducted the interviews:

ACT: Roger Butcher and Jenny Kuzek.

NSW: Marian Bloomfield, Susan Howlett, Nicole Keyes, Shalin Kumar, and Jing Prideaux.

Qld: Stacy Kambouris and Sandra Wolfenden.

SA: Trevor Aylett, Dianne Few, Milan Gligic, Cheryl Hyland, Robynne Lowe, Clare McRoberts and David Smith.

Tas: Matthew Chick, Karen Glover, Kelly Shaw and Deborah Siddall.

Vic: Nyree Chung, Kim Messieh and Lyn Pierce.

WA: Shona Curni, Dianne Delaney, Clyde DuBois, Dr Marisa Gilles, Alison Slater and David Venables.

We wish to thank everyone who assisted in the development and conduct of the National Prison Entrants' Bloodborne Virus & Risk Behaviour Survey including all the participants, the health professionals at the survey sites, the prison managers, and prison officers for their cooperation in accommodating the survey teams, the laboratory staff, and those involved in providing the results back to participants.

We are grateful for the assistance provided by staff at the National Centre in HIV Epidemiology and Clinical Research (NCHECR), particularly Ms Jenny Ivers. Mr David Coombe and Errol

Banford from the National Centre for Social Applications of GIS, the University of Adelaide assisted with the Accessibility/Remoteness Index of Australia (ARIA). Mr Leng Boonwaat for assistance with interpreting the hepatitis B immunity results. Imedla Butler for proof reading. Ms Lisa Bastian for supporting the launch of the report.

Financial support:

The cost of the data collection and screening was borne by the jurisdictions. Financial support for the co-ordination and report writing was provided by a one-off payment of \$8000 NSW, Vic, Qld, and WA. The Western Australian Communicable Disease Control Directorate supported the launch of the report. Associate Professor Tony Butler is supported by an NHMRC Career Award (ID #:350992).


FOREWORD

The first National Prison Entrants' Bloodborne Virus & Risk Behaviour Survey (NPEBBV&RBS) was conducted in 2004 and we are pleased to present the second, 2007 national report.

This survey is one of the few prisoner health research projects to be conducted nationally. The 2007 survey includes seven out of eight possible jurisdictions. It is unique in the world in providing ongoing surveillance on the prevalence of blood-borne viruses (HIV, hepatitis B, hepatitis C) among this population group on a national basis. The NPEBBV&RBS is an important adjunct to the community National Needle and Syringe Program Survey. The survey not only screens those prisoners who report injecting drug use but also collects information on people with no history of injecting drug use who are likely to be exposed to blood-borne viruses from other routes of transmission such as tattooing and other blood-to-blood contact.

The NPEBBV&RBS has several features that enhance our knowledge of blood-borne virus epidemiology in Australia: it provides unique access to groups known to be over-represented in prisons such as Indigenous Australians (24% of Australia's prisoners are Indigenous), the survey tests for hepatitis B immunity, venous blood samples are used which provides a high degree of test accuracy, the results are provided back to participants with appropriate counselling, and the questionnaire information is collected via a face-to-face interview.

Monitoring blood-borne viruses among prisoners is important for the community's response to preventing the spread of infectious diseases and the planning of appropriate prevention strategies. The prevalence of hepatitis C is known to be forty times higher among prisoners than the general community, highlighting the challenge facing prisons. The findings from the 2004 survey have been used extensively by the states and territories in planning and policy development and for educational purposes.



Professor Steve Allsop
National Drug Research Institute



Professor John Kaldor
National Centre in HIV
Epidemiology & Clinical Research

EXECUTIVE SUMMARY

Background

Prisoner populations are characterised by engagement in a range of risk behaviours, most notably injecting drug use. Consequently they are at an increased risk of exposure to blood-borne viruses such as hepatitis B, hepatitis C and HIV. Previous Australian research had shown that hepatitis C is up to forty times higher in prisoners compared with the general community. Monitoring this population for the presence of blood-borne pathogens and trends in risk behaviours is important in planning effective prevention strategies for this population. This is the second prison entrants' survey to have been conducted; the first was undertaken in 2004.

Methods

- The study represents a consecutive survey of prison entrants conducted over two weeks in October 2004 and 2007. Participants were 740¹ of the 992 consecutive prison entrants in all jurisdictions except the Northern Territory. Eighteen reception centres in the Australian Capital Territory (ACT), New South Wales (NSW), South Australia (SA), Queensland (Qld), Tasmania (Tas), Victoria (Vic) and Western Australia (WA) participated in the study.

The survey screened for the following markers: HIV antibody and antigen, hepatitis B surface-antibody, hepatitis B core-antibody, hepatitis B surface-antigen, and hepatitis C antibody.

Risk factor and demographic information was collected using a short risk-behaviour questionnaire covering injecting drug use, body piercing, tattooing, sexual activity, hepatitis B immunisation status, and smoking status.

Results

Demographic & criminographic characteristics

- The response rate to the survey was extremely high at 76%.
- In 2007, 18% of the sample was Indigenous which is lower than the national census proportion of Indigenous prisoners (24%²). This could be due to the Northern Territory not taking part in the survey (84% Indigenous prisoner population) or that the profile of the

¹ Note that 14 participants consented to participate in the 2007 survey but were excluded due to missing information for the main classification variable (injecting drug user status). The 2007 results report the findings for the 740 participants for whom complete data were available.

² Prisoners in Australia. Australian Bureau of Statistics 2007. Canberra. Cat. #4517.

reception prisoner population, which includes remandees, differs from the snapshot population described by the annual national census of prison inmates.

- In 2004 and 2007, eight out of ten prisoners with histories of injecting drug use reported this was not their first time in prison compared with half of non-injector prisoners.
- Most of those taking part in the 2007 survey (86%) had spent most time in 'highly accessible' and 'accessible' areas according to the ARIA index in the 12 months before coming into prison.

Blood-borne viruses

- The prevalence of HIV was low at less than 1% nationally in both men and women in both 2004 and 2007. However, in both 2004 and 2007 all but one case self-reported they were HIV negative but tested positive.³
- In 2007, the overall prevalence of hepatitis C was 35%; it was highest in New South Wales and Victoria (42% and 41%) and lowest in Western Australia (21%).
- Hepatitis C prevalence was higher among those with a history of injecting drug use compared with those who had not injected (60% versus 4% in 2007), and higher among women injectors compared with men (78% versus 58% in 2007).
- Nationally, the prevalence of hepatitis B core-antibody among prisoners screened in 2007 was highest in New South Wales and Western Australia (27% and 28%) and lowest in Queensland and Tasmania (9%).
- Between 2004 and 2007, there was an increase among Indigenous IDU in the prevalence of hepatitis B core-antibody (29% and 42%) and hepatitis C antibody (38% and 43%).
- Half of those screened in 2007 showed no evidence of immunity against hepatitis B infection. The proportion of prisoners susceptible to hepatitis B infection ranged from 59% in Victoria to 14% in Tasmania.
- In 2007, of the 214 individuals tested who reported they had been vaccinated against hepatitis B, only 57% had hepatitis B surface-antibody levels considered as providing immunity.

³ Note that in 2007 self-reported HIV status was missing for 1 case.

Risk behaviours

- Overall 55% of those screened in 2007 had ever injected and, of these, 60% had done so in the past month.
- Amphetamine was the most common drug injected in the previous month (58% in 2004 and 59% in 2007) followed by heroin (32% in 2004 and 31% in 2007).
- In 2007, New South Wales and Victoria reported the lowest levels of injecting amphetamine (49%) as the last drug injected while South Australia and Western Australia reported the highest levels (94% and 85%).
- Over 90% of injecting drug users had injected for more than 3 years suggesting that the prisoner population is characterised by more serious and longer term drug use.
- 85% of prisoners reported they were current tobacco smokers. The median age of first smoking was 14 years.

Implications of the Findings

- Prison provides an opportunity to screen high-risk populations for exposure to blood-borne infections and initiate prevention and treatment measures. To this end, national surveillance is beneficial to identify trends in blood-borne virus exposure and changes in patterns of risk behaviours that need to be addressed by prison health authorities.
- Given the high prevalence of hepatitis C and hepatitis B in this population compared with the community, it is desirable that this survey be conducted on a regular basis to inform the policy formulation and health services planning process for this [at-risk] group to ensure they are not a 'forgotten' population.
- Prevention initiatives need to target prison entrants, particularly those with a history of injecting drugs who are in prison for the first time. This group was less likely to have been exposed to hepatitis C.
- Nationally, the survey found that half of all prison entrants who had not been exposed to HBV were unimmunised and therefore vulnerable to infection. This group should be vaccinated as a matter of priority, as indeed staff working in this setting have access to free vaccination. A Danish study reported that a three-week HBV vaccination schedule was more efficient for prisoners than the standard six-month schedule due to compliance with the follow-up immunisation shots required by the standard schedule.¹

- While the prevalence of HIV remained low across all jurisdictions between 2004 and 2007, this survey has an important role to play in monitoring trends in high-risk groups who are over represented in prisons and are likely to be excluded from community-based surveys such as IDU, Indigenous IDU, and the mentally ill.
- Screening for blood-borne viruses on entry to prison is an important step in preventing the spread of these infections to the wider community. In 2004, 2 out of 3 cases of HIV reported that they were HIV negative but tested positive, and in 2007, 2 out of 2 cases of HIV reported they were HIV negative but tested positive. Awareness of one's status with regard to HIV and hepatitis is important in preventing the further spread of these infections.
- In 2004, 18% of those who reported they were negative for hepatitis C tested positive for HCV antibodies; the corresponding figure for 2007 was 16%.
- The increase over time in the prevalence of hepatitis B and hepatitis C among Indigenous injecting drug users suggests that culturally appropriate prevention strategies including education, hepatitis B vaccination, and hepatitis C treatment should target this group.
- In 2007, only 1 (0.5%) hepatitis C antibody positive prisoner reported receiving treatment for hepatitis C (*cf.* 2 [2%] in 2004). No Indigenous prisoners reported receiving treatment for hepatitis C in either the 2004 or 2007 surveys. This suggests that this population is underserved with regard to treatment for hepatitis C infection and would benefit from the development of comprehensive prison-based treatment programmes.
- Amphetamine was the most frequently reported drug last injected by prison entrants in both 2004 and 2007. Amphetamine substitution therapies should be investigated and service providers need to ensure that staff receive training in recognising and managing amphetamine withdrawal on entry to prison.
- Tobacco smoking is at epidemic proportions in this population group with around 9 out of 10 prisoners reporting they currently smoke. This needs to be addressed as a matter of national health priority. Incarceration is an important, but underutilised, public health opportunity to initiate quit smoking programmes among this group.

INTRODUCTION

Prisoner populations are characterised by engagement in a range of health risk behaviours, most notably injecting drug use.²⁻⁴ Consequently they are at an increased risk of exposure to blood-borne viruses such as HIV and viral hepatitis.⁵⁻¹⁰ Australian and overseas studies have consistently shown prisoner populations to have rates of blood-borne viruses many times that of the community.¹¹ The prison setting has been shown to be a high risk environment for blood-borne virus transmission from sharing contaminated injecting equipment, tattooing, and other blood-to-blood contact.^{8;12;13}

Monitoring blood-borne virus infections in Australia occurs through ad hoc prevalence surveys of prisoners in the states, and through routine screening of prison receptions.^{6;14;15} However, routine screening strategies vary across Australia in terms of both scope and coverage. The Northern Territory and Tasmania engage in compulsory HIV testing of prisoners, Queensland, South Australia, and Western Australia have voluntary screening, and New South Wales has a targeted approach. HIV screening coverage varies across the states. In 2006, Queensland and the Northern Territory screened 100% of all men for HIV on entry to prison, New South Wales 31%, South Australia 28%, Tasmania 21%, Victoria 19% and Western Australia 42%.¹⁶

Since 1995, the National Centre in HIV Epidemiology and Clinical Research (NCHECR) has monitored blood-borne viruses in high-risk groups in Australia.¹⁷ Injecting drug users at community Needle and Syringe Programs (NSP) are invited to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of blood to test for HIV and hepatitis C. The survey is conducted annually over a one-week period.

Following discussions with the NCHECR, it was agreed to adapt the NSP survey and apply it to the prison setting in an effort to provide systematic information on blood-borne virus prevalence across Australia and to enable comparisons with NSP survey data.

This report presents the findings of the 2004 and 2007 surveys.

METHODS

Study Sample

The study was a consecutive cross-section of prison entrants over two weeks during October 2007. The prison survey was designed to run at the same time as the community NSP survey to minimise the overlap of participants in the two surveys. Participants were 740⁴ of the 992 (75%) consecutive prison entrants in seven out of the eight Australian correctional jurisdictions.

Sample Selection

New receptions at 17 sentinel sites were invited to participate in the assessment. New receptions were defined as individuals entering prison from the community and did not include remanded inmates returning from court appearances or prisoners transiting through the survey site *en route* to other prisons.

Recruitment

We aimed to minimise disruption to the prison reception process by conducting the survey immediately after the initial health and welfare assessments. Those unable to be seen at the time of reception were called up within approximately twenty-four hours of entry into the prison and invited to participate.

Participants were given an outline of the project by a member of the survey team. The explanation emphasised the following: involvement was voluntary, the structure of the assessment consisted of a short questionnaire followed by blood testing, there was no obligation to answer any questions deemed intrusive or sensitive, and information would remain confidential. Participants were also informed that every effort would be made to return the blood test results and that post-test counselling would be provided and referral made to specialist services if necessary. Signed consent was obtained from all participants.

Confidentiality was maintained on the questionnaires and serology requests through the use of a code comprising the first two letters of each participant's surname and first name, their date of birth and a unique inmate identifier number.

Survey Sites

Seventeen sentinel reception sites in six states and one territory participated in the 2007 study (Table 1). These centres receive both men and women prisoners directly from the community. In all jurisdictions, prisoners are received into the correctional system through a limited number

⁴ Note that 14 participants consented to participate in the 2007 survey but were excluded due to missing information for the main classification variable (injecting drug user status). The 2007 results report the findings for the 740 participants for whom complete data were available.

of reception sites. Therefore by targeting these sites we could be certain that we were accessing most of the eligible prison receptions across the participating jurisdictions. For example, in Victoria all male receptions are processed through the Melbourne Assessment Prison, and in New South Wales, the Metropolitan Reception and Remand Centre (MRRC) in Sydney processes approximately two-thirds of the state's prisoners. Overall, the 2007 survey screened 73% of all prisoners entering the Australian correctional system via the reception sites given in Table 1.

Screening Procedures

Screening was divided into several stages to provide a consistent structure to the survey. Broadly, this involved recruiting participants and obtaining consent, administering the questionnaire, providing pre-test counselling for those who consented to blood testing, and collecting the blood specimen. Pre-test discussion included psychological assessment of the inmate's ability to deal with a positive result, provision of information about the possible consequences of infection with blood-borne viruses, transmission risks, confidentiality and notification requirements related to blood tests and treatment options for those who tested positive. Those who consented to the blood test were also informed that face-to-face post-test counselling would be provided as soon as results became available for both positive and negative test results.

Blood Testing

Screening for blood-borne viruses included testing for the following markers:

- HIV antibody and antigen
- Hepatitis B surface-antibody
- Hepatitis B (IgM & IgG) core-antibody
- Hepatitis B surface-antigen, and if positive hepatitis B e-antigen and e-antibody
- Hepatitis C antibody

Details of test kits used for the blood testing by the laboratories are given in Appendix 1.

Questionnaire

The NSP survey questionnaire was originally designed for the community setting to collect behavioural risk factor information on body piercing, tattooing, injecting drug use, sexual activity, and immunisation status. A small number of modifications were made to this screening instrument to adapt it to the correctional setting (Appendix 2). The questionnaire was piloted in each jurisdiction to ensure it was appropriate for a prisoner population.

Statistical Analysis

All data was analysed using SPSS version 15. Associations between demographic and behavioural variables and exposure to blood-borne viruses were assessed using the χ^2 test.

Interviewers

Interviewers were recruited from nursing staff within each state's and territory correctional health system. Training of site co-ordinators was undertaken via a number of teleconferences with the principal investigator (TB) who in turn trained the local interviewers. Aboriginal health workers were recruited in Western Australia to facilitate data collection among Indigenous prisoners (approximately 43% of prisoners in Western Australia are Indigenous).

Ethics Approval

Approval for the project was obtained from the human research and ethics committees in the ACT, NSW, SA, Tas, and WA. In addition to the health-based ethics committees, approval was sought separately from corrective services' ethics committees in Qld, Vic, and WA. In WA, approval was granted by the Western Australia Aboriginal Health and Information Ethics Committee. The study was also approved by the Curtin University of Technology HREC.

Reporting of Results

The following sections present the findings from the survey stratified by injecting drug user status. For this reason, only those for whom we have information regarding IDU status have been included in the analysis. Percentages have been rounded to the nearest whole number. In this report, the words prison entrant and inmate are used interchangeably as are reception centre and prison.

RESULTS

Response Rate

A number of inmates declined to participate in the survey ('refusers') while others agreed to answer the questionnaire but opted not to provide blood. A small number initially agreed to provide a blood sample but were unable to do so due to poor venous access. Some of the reasons given by the 'refusers' included a perceived lack of personal gain from participation, needle phobia, and feeling fatigued or stressed during the reception process.⁵

⁵ The reception process is often conducted at the end of the day and sometimes in the early hours of the morning. This is because the courts process people during the day and those receiving a custodial sentence or remanded into custody are taken to the reception prison at the end of the day. Once at the prison there is often a waiting period in a holding cell before they are seen by welfare and medical staff. The high response rate seen in this survey is a credit to the skill of the reception nurses in highlighting the benefits of the survey to prisoners in what is perhaps one of the most stressful and harrowing periods of the participants' lives.

The response rate was calculated as follows⁶:

$$\frac{\text{Total participants}}{\text{Total receptions}} \times 100$$

The overall response rate to the survey was 76% and, for those agreeing to participate, the response rate for the blood testing was 80%. Men were more likely than women to agree to participate in the survey - the response rate was 82% for men and 62% for women. Similar proportions of Indigenous and non-Indigenous prison entrants responded to the questionnaire (75% Indigenous vs. 81% non-Indigenous). Screening rates varied between reception sites (Table 1). Low screening rates were often attributable to local conditions at the site such as overcrowding and consequent inmate dissatisfaction, and staff shortages.

⁶ The response rate includes the 14 individuals who participated in the survey but were not included in the analysis due to missing data for the main classification variable – injector status.

Table 1 Reception centre, sex of prison receptions, participants screened, and total number of receptions, 2007 NPEBBV&RBS*

State	Reception Site	Sex of prisoners	Total N° of receptions**	N° screened (%)
ACT	Belconnen Remand Centre	Men and women	4	4 (100)
NSW	Metropolitan Reception & Remand Centre	Men	234	179 (76)
	Silverwater Women's	Women	63	41 (65)
	Parklea	Men	36	25 (69)
	<i>Total</i>		333	245 (74)
Qld	Arthur Gorrie	Men	167	157 (94)
SA	Adelaide Remand Centre	Men	36	17 (47)
	City Watch House	Men and women	26	10 (38)
	Port Augusta Prison	Men and women	10	1 (10)
	<i>Total</i>		72	28 (39)
Tas	Hobart Remand Centre	Men and women	34	20 (59)
	Launceston Remand Centre	Men and women	33	23 (70)
	Mary Hutchinson Prison	Women	3	3 (100)
	<i>Total</i>		70	46 (66)
VIC	Dame Phyllis Frost Centre	Women	16	13 (81)
	Melbourne Assessment Prison	Men	179	149 (83)
	<i>Total</i>		195	162 (83)
WA	Hakea	Men	131	78 (60)
	Bandyup	Women	20	8 (40)
	Greenough	Men and women	9	5 (56)
	Roebourne	Men and women	8	7 (88)
	<i>Total</i>		168	98 (58)
Total			1009	740 (73)

* Completed questionnaire and/or serological testing.

** Taken from the running sheets provided by jurisdictions for the survey period: 8th - 22nd October 2007.

Over half (55%) of the respondents reported current or previous injecting drug use (Table 2).

Table 2 Structure of the study sample by sex and injector status, 2007 NPEBBV&RBS

Sex	Ever Inject Drugs		Total
	No	Yes	
Men	315 (47%)	354 (53%)	669 (100%)
Women	19 (27%)	52 (73%)	71 (100%)
Total	334 (45%)	406 (55%)	740 (100%)

Summary 2007

Table 3 Demographic characteristics of prison entrants by state (2007)

	State							
	ACT	NSW	Qld	SA	Tas	Vic	WA	Total
N° of sites	1	3	1	3	3	2	4	17
N° surveyed	4	245	157	28	46	162	98	740
N° (%) Male	4 (100)	204 (83)	157 (100)	27 (96)	40 (87)	149 (92)	88 (90)	669 (90)
Median age (years)	38.6	31.1	29.0	31.0	29.5	32.0	31.0	30.6
Age range	37 – 45	18 – 71	17 – 63	19 – 63	19 – 58	18 – 77	19 – 65	17 – 77
N° (%) Indigenous	--	48 (20)	23 (15)	6 (21)	8 (17)	9 (6)	34 (35)	128 (18)
N° (%) Aust. Born	3 (75)	191 (78)	144 (92)	24 (86)	45 (98)	129 (80)	81 (83)	617 (83)

Table 4 Injecting drug use and smoking status by state (2007)

	State							
	ACT	NSW	Qld	SA	Tas	Vic	WA	Total
N° (%) with IDU history	2 (50)	132 (54)	91 (58)	17 (61)	22 (48)	87 (54)	55 (56)	406 (55)
Last drug injected								
Amphetamine (Speed, Ice)	1 (50)	64 (49)	57 (63)	16 (94)	16 (73)	37 (43)	47 (85)	238 (59)
Anabolic steroids	--	--	--	--	--	--	--	--
Cocaine	--	5 (4)	1 (1)	--	--	1 (1)	--	7 (2)
Heroin	1 (50)	53 (40)	20 (22)	1 (6)	1 (5)	43 (49)	7 (13)	126 (31)
Heroin + amphetamine	--	3 (2)	2 (2)	--	--	4 (5)	1 (2)	10 (3)
Heroin + Cocaine	--	1 (<1)	--	--	--	--	--	1 (<1)
Methadone	--	4 (3)	2 (2)	--	--	--	--	6 (2)
Morphine	--	2 (2)	4 (4)	--	4 (18)	2 (2)	--	12 (3)
Other	--	--	4 (4)	--	1 (5)	--	--	5 (1)
Not reported	--	--	1 (1)	--	--	--	--	1 (<1)
N° (%) injected last month								
No, did not inject	1 (50)	44 (33)	44 (48)	5 (29)	6 (27)	27 (31)	25 (46)	152 (37)
Yes, injected	1 (50)	85 (64)	44 (48)	12 (71)	16 (73)	60 (69)	30 (55)	248 (61)
Not reported	--	3 (2)	3 (3)	--	--	--	--	6 (2)
Places injected last month								
Prison	--	3 (4)	1 (2)	--	1 (6)	1 (2)	1 (3)	7 (3)
Own home	--	65 (76)	39 (89)	10 (83)	15 (94)	47 (78)	23 (77)	199 (80)
Friend's home	1 (100)	46 (54)	27 (61)	7 (58)	13 (81)	32 (53)	11 (37)	137 (55)
Dealer's home	--	23 (27)	19 (43)	5 (42)	4 (25)	15 (25)	8 (27)	74 (30)
Street, park, beach	--	38 (45)	20 (45)	4 (33)	3 (19)	21 (35)	9 (30)	95 (38)
Car	1 (100)	36 (42)	21 (48)	5 (42)	10 (63)	34 (57)	5 (17)	112 (45)
Public toilet	1 (100)	25 (29)	16 (36)	3 (25)	4 (25)	16 (27)	4 (13)	69 (28)
Commercial shooting room	--	7 (8)	--	--	--	--	--	7 (3)
MSIC*	--	10 (12)	--	--	--	--	--	10 (4)
Squat	--	8 (9)	1 (2)	1 (8)	--	3 (5)	1 (3)	14 (6)
Other	--	--	1 (2)	2 (17)	--	6 (10)	3 (10)	12 (5)
Used new fit for all injections last month								
All injections	1 (100)	49 (58)	28 (64)	11 (92)	13 (81)	44 (73)	16 (53)	162 (65)
Most of the time	--	16 (19)	9 (20)	1 (8)	2 (13)	13 (22)	11 (37)	52 (21)
Half of the time	--	7 (8)	4 (9)	--	--	--	--	11 (4)
Some of the time	--	10 (12)	3 (7)	--	--	2 (3)	3 (10)	18 (7)
Not reported	--	3 (4)	--	--	1 (6)	1 (2)	--	5 (2)
Ever smoked a full cigarette (%)								
No	--	14 (6)	19 (12)	4 (14)	1 (2)	13 (8)	8 (8)	59 (8)
Yes	4 (100)	231 (94)	138 (88)	24 (86)	45 (98)	149 (92)	90 (92)	681 (92)
Current smoker (%)								
No	--	35 (14)	19 (12)	6 (21)	5 (11)	28 (17)	18 (18)	111 (14)
Yes	4 (100)	210 (86)	138 (88)	22 (79)	41 (89)	134 (83)	79 (81)	628 (85)
Not reported	--	--	--	--	--	--	1 (1)	1 (<1)

* Medically Supervised Injecting Centre in Sydney.

Table 5 HIV antibody prevalence by state, sex and injector status (2007)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HIV
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV		
ACT	2	0 (0)	1	0 (0)	--	--	--	--	3	0 (0)
NSW	84	1 (1)	75	1 (1)	27	1 (4)	10	0 (0)	196	3 (2)
Qld	77	1 (1)	59	0 (0)	--	--	--	--	136	1 (<1)
SA	11	0 (0)	9	0 (0)	--	--	--	--	20	0 (0)
Tas	16	0 (0)	17	0 (0)	--	--	--	--	33	0 (0)
Vic	59	0 (0)	49	0 (0)	5	0 (0)	4	0 (0)	117	0 (0)
WA	38	0 (0)	36	0 (0)	5	0 (0)	2	0 (0)	81	0 (0)
Total	287	2 (<1)	246	1 (<1)	37	1 (3)	16	0 (0)	586	4 (<1)

† Excludes equivocal test results and missing values.

Table 6 Hepatitis C antibody prevalence by state, sex and injector status (2007)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HCV
	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV		
ACT	2	1 (50)	1	0 (0)	--	--	--	--	3	1 (33)
NSW	84	57 (68)	76	2 (3)	28	23 (82)	9	1 (11)	197	83 (42)
Qld	77	41 (53)	58	2 (3)	--	--	--	--	135	43 (32)
SA	12	6 (50)	9	1 (11)	--	--	--	--	21	7 (33)
Tas	15	7 (47)	17	1 (6)	--	--	--	--	32	8 (25)
Vic	59	40 (68)	49	2 (4)	7	6 (86)	4	1 (25)	119	49 (41)
WA	38	14 (37)	37	1 (3)	5	2 (40)	2	0 (0)	82	17 (21)
Total	287	166 (58)	247	9 (4)	40	31 (78)	15	2 (13)	589	208 (35)

† Excludes equivocal test results and missing values.

Table 7 Hepatitis B core-antibody prevalence by state, sex and injector status (2007)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HBV
	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV		
ACT	--	--	--	--	--	--	--	--	--	--
NSW	85	33 (39)	76	11 (14)	28	9 (32)	10	1 (10)	199	54 (27)
Qld	78	8 (10)	59	4 (7)	--	--	--	--	137	12 (9)
SA	--	--	1	1 (100)	--	--	--	--	1	1 (100)
Tas	15	3 (20)	17	0 (0)	--	--	--	--	32	3 (9)
Vic	56	23 (41)	49	2 (4)	6	2 (33)	4	0 (0)	115	27 (23)
WA	38	16 (42)	37	4 (11)	5	2 (40)	2	1 (50)	82	23 (28)
Total	272	83 (31)	239	22 (9)	39	13 (33)	16	2 (13)	566	120 (21)

† Excludes equivocal test results and missing values.

Table 8 Hepatitis B virus immune status (2007)

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	2	2 (100)	--	--	--
NSW	198	89 (45)	48 (24)	6 (3)	55 (28)
Qld	137	68 (50)	12 (9)	1 (<1)	56 (41)
SA	1	--	1 (100)	--	--
Tas	14	2 (14)	3 (21)	--	9 (64)
Vic	120	71 (59)	26 (22)	4 (3)	19 (16)
WA	82	45 (55)	21 (26)	2 (2)	--
Total	554	277 (50)	111 (20)	13 (2)	153 (28)

**National
2004 & 2007**

Table 9 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 8		N = 17	
N° surveyed	N = 357	N = 247	N = 406	N = 334
Sex (%)				
Male	118 (93)	228 (92)	354 (87)	315 (94)
Female	9 (7)	19 (8)	52 (13)	19 (6)
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	341 (96)	240 (97)	385 (95)	328 (98)
Bisexual	11 (3)	3 (1)	6 (2)	2 (<1)
Homosexual	5 (1)	3 (1)	9 (2)	1 (<1)
Unsure	--	--	2 (<1)	--
Not reported	--	1 (<1)	4 (<1)	3 (<1)
Age and duration of injection (years)				
Median age (years)	30	34	32	29
Age range	17 – 58	17 – 75	18 – 54	17 – 77
Age group (%)				
<25 years	95 (27)	69 (28)	70 (17)	120 (36)
25+ years	260 (72)	178 (72)	335 (83)	214 (64)
Not reported	2 (<1)	--	1 (<1)	--
Median age 1 st IDU (years)	18	--	18	--
Age range	9 – 41	--	8 – 44	--
No. not reported	8	--	9	--
Median years IDU	10	--	12	--
Range	<1 – 37	--	<1 – 36	--
Duration of drug injection (%)				
<3 years	36 (10)	--	24 (6)	--
3+ years	311 (87)	--	372 (92)	--
Not reported	10 (3)	--	10 (2)	--
Aboriginal and Torres Strait Islander origin (%)				
No	285 (80)	209 (85)	320 (79)	283 (85)
Yes	64 (18)	36 (15)	78 (19)	50 (15)
Not reported	8 (2)	2 (<1)	8 (2)	1 (<1)
Residential remoteness in 12 months before prison				
Highly accessible/accessible	325 (91)	215 (87)	362 (89)	286 (86)
Moderately accessible	9 (3)	6 (2)	11 (3)	14 (4)
Remote/very remote	13 (4)	14 (6)	11 (3)	11 (3)
Not reported	10 (3)	12 (5)	22 (5)	23 (7)
Region/Country of birth (%)				
Australia	310 (87)	182 (74)	354 (87)	263 (79)
Other Oceania	12 (3)	17 (7)	9 (2)	13 (4)
Asia	13 (4)	14 (6)	19 (5)	20 (6)
UK & Ireland	8 (2)	9 (4)	7 (2)	7 (2)
Other	13 (4)	23 (9)	15 (4)	27 (8)
Not reported	1 (<1)	2 (<1)	2 (<1)	4 (1)
Main language spoke at home by parents (%)				
English speaking	328 (92)	208 (84)	365 (90)	268 (80)
Non-English speaking	28 (8)	37 (15)	40 (10)	64 (19)
Not reported	--	2 (<1)	1 (<1)	2 (<1)
First time in prison (%)				
No	302 (85)	149 (60)	336 (83)	161 (48)
Yes	55 (15)	98 (40)	69 (17)	171 (51)
Not reported	--	--	1 (<1)	2 (<1)
Lifetime imprisonments (%)				
One	55 (15)	98 (40)	69 (17)	171 (51)
Two to four	178 (50)	117 (47)	163 (40)	119 (36)
Five to nine	87 (24)	17 (7)	95 (23)	23 (7)
Ten or more	32 (9)	3 (1)	60 (15)	10 (3)
Not reported	5 (1)	12 (5)	19 (5)	11 (3)

Table 9 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	129 (36)	137 (55)	113 (34)	47 (29)
Yes	220 (62)	98 (40)	214 (64)	111 (68)
Not reported	8 (2)	12 (5)	10 (3)	5 (3)
Frequency of injection last month (%)				
Not last month	125 (35)	--	152 (37)	--
Less than weekly	47 (13)	--	54 (13)	--
Weekly not daily	28 (8)	--	52 (13)	--
Daily or more	154 (43)	--	142 (35)	--
Not reported	3 (<1)	--	6 (2)	--
Ever smoked full cigarette (%)*				
No	--	--	14 (3)	45 (14)
Yes	--	--	392 (97)	289 (87)
Not reported	--	--	--	--
Median age first smoked (years)	--	--	14	14
Age range	--	--	5 – 36	4 – 31
Current smoker (%)*				
No	--	--	26 (6)	85 (25)
Yes	--	--	379 (93)	249 (75)
Not reported	--	--	1 (<1)	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	13 (3)	22 (9)
5 to 10 cigarettes a day	--	--	98 (26)	60 (24)
11 to 20 cigarettes a day	--	--	154 (41)	85 (34)
Over 20 cigarettes a day	--	--	113 (30)	81 (33)
Not reported	--	--	2 (<1)	1 (<1)

* Smoking questions were not asked in 2004 survey.

Table 10 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)	N = 357	N = 406
Amphetamine (Speed, Ice)	206 (58)	238 (59)
Anabolic steroids	1 (<1)	--
Cocaine	7 (2)	7 (2)
Heroin	115 (32)	126 (31)
Heroin + amphetamine	--	(3)
Heroin + Cocaine	2 (<1)	1 (<1)
Methadone	7 (2)	6 (1)
Morphine	9 (3)	12 (3)
Other	8 (2)	5 (1)
Not reported	--	1 (<1)
N° Injected last month	N = 232	N = 248
Places injected last month (%)**		
Prison	8 (3)	7 (3)
Own home	181 (78)	199 (80)
Friend's home	117 (50)	137 (55)
Dealer's home	51 (22)	74 (30)
Street, park, beach	73 (31)	95 (38)
Car	82 (35)	112 (45)
Public toilet	56 (24)	69 (28)
Commercial injecting room	8 (3)	7 (3)
MSIC*	9 (4)	10 (4)
Squat	19 (8)	14 (6)
Other place	5 (2)	12 (5)
Use of sterile needles & syringes last month (%)		
All injections	160 (69)	162 (65)
Most of the time	38 (16)	52 (21)
Half of the time	14 (6)	11 (4)
Some of the time	17 (7)	18 (7)
Not last month	2 (<1)	--
Not reported	1 (<1)	5 (2)
Re-used someone else's used needle & syringe last month (%)		
None	196 (84)	198 (80)
Once	6 (3)	10 (4)
Twice	14 (6)	10 (4)
3-5 times	7 (3)	7 (3)
>5 times	7 (3)	19 (8)
Not reported	2 (<1)	4 (2)
Number of people needle & syringe was re-used after last month (%)		
None	197 (85)	198 (78)
One	20 (9)	31 (12)
Two	7 (3)	3 (1)
Three to five	4 (2)	4 (2)
More than five	2 (<1)	--
Don't know	--	5 (2)
Not reported	2 (<1)	13 (5)
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	18 (8)	25 (10)
Casual sex partner	2 (<1)	2 (<1)
Close friend	7 (3)	13 (5)
Acquaintance	5 (2)	5 (2)
Other	5 (2)	5 (2)
Equipment used after someone else last month (%)**		
Spoon	49 (21)	76 (30)
Water	39 (17)	63 (25)
Filter	34 (15)	57 (23)
Tourniquet	18 (8)	31 (13)
Drug mix	33 (14)	49 (20)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 11 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334
Any treatment/therapy for drug use (%)				
No	195 (55)	228 (92)	125 (31)	182 (54)
Yes	161 (45)	17 (7)	250 (62)	42 (13)
Not reported	1 (<1)	2 (<1)	31 (8)	110 (33)
History of methadone maintenance treatment (%)				
Currently	53 (15)	3 (1)	50 (12)	--
Previously	76 (21)	2 (<1)	92 (23)	--
Never	226 (63)	240 (97)	225 (55)	--
Not reported	2 (<1)	2 (<1)	39 (10)	--
History of other pharmacotherapy treatment (%)				
Currently	19 (5)	3 (1)	28 (7)	--
Previously	49 (14)	1 (<1)	95 (23)	--
Never	284 (80)	241 (98)	268 (66)	--
Not reported	5 (1)	2 (<1)	15 (4)	--

Table 12 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	N = 233	N = 248
From an NSP last month (%)		
Daily or almost daily	31 (13)	30 (12)
A couple of times each week	38 (16)	57 (22)
Less than weekly	33 (14)	38 (15)
Once last month	39 (17)	29 (12)
Not in the last month	57 (24)	45 (18)
Not reported	35 (15)	52 (21)
From a chemist last month (%)		
Daily or almost daily	17 (7)	14 (6)
A couple of times each week	36 (16)	32 (13)
Less than weekly	51 (22)	35 (14)
Once last month	38 (17)	32 (13)
Not in the last month	86 (37)	84 (34)
Not reported	2 (<1)	51 (21)

Table 13 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334
Sex last month (%)				
No	93 (26)	75 (30)	107 (26)	84 (25)
Yes	263 (74)	168 (68)	298 (73)	248 (74)
Not reported	1 (<1)	4 (2)	1 (<1)	2 (<1)
Condom use at last sex (%)				
No	270 (76)	175 (71)	327 (81)	239 (72)
Yes	87 (24)	69 (28)	75 (18)	94 (28)
Not reported	--	3 (1)	4 (<1)	1 (<1)
Condom use with regular sex partner(s) last month (%)*				
No	160 (86)	112 (81)	189 (84)	149 (74)
Sometimes	14 (7)	12 (9)	24 (11)	31 (15)
Always	13 (7)	14 (10)	12 (5)	22 (11)
Condom use with new sex partner(s) last month (%)*				
No	27 (55)	9 (47)	44 (59)	11 (28)
Sometimes	8 (16)	3 (16)	14 (19)	15 (38)
Always	14 (29)	7 (37)	16 (22)	14 (35)
Condom use with casual sex partner(s) last month (%)*				
No	41 (49)	18 (47)	66 (69)	19 (35)
Sometimes	14 (17)	6 (16)	15 (16)	18 (33)
Always	28 (34)	14 (37)	15 (16)	17 (31)
Sex work last month (%)				
No	349 (98)	240 (97)	392 (97)	323 (97)
Yes	6 (2)	2 (<1)	10 (2)	5 (1)
Not reported	2 (<1)	5 (2)	4 (<1)	6 (2)
Condom used at last sex work last month (%)				
No	3 (43)	1 (50)	4 (40)	1 (20)
Yes	4 (57)	1 (50)	5 (50)	2 (40)
Not reported	--	--	1 (10)	2 (40)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 14 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334
Previous HIV test (%)				
Yes, last year	168 (47)	46 (19)	182 (45)	80 (24)
>1 year ago	117 (33)	72 (29)	159 (39)	99 (30)
Never tested	71 (20)	126 (51)	61 (15)	155 (46)
Not reported	1 (<1)	3 (1)	4 (1)	--
HBV infection (%)				
No	278 (78)	226 (91)	329 (81)	311 (93)
Yes	51 (14)	5 (2)	47 (12)	6 (2)
Don't know	28 (8)	16 (6)	29 (7)	12 (4)
Not reported	--	--	1 (<1)	5 (1)
HBV vaccination (%)*				
No	82 (27)	116 (48)	125 (31)	162 (49)
Yes	188 (61)	78 (32)	239 (59)	124 (37)
Don't know	36 (12)	44 (18)	35 (9)	45 (13)
Not reported	--	4 (2)	7 (2)	3 (1)
Previous HCV test (%)				
Yes, last year	155 (43)	42 (17)	178 (44)	75 (22)
>1 year ago	138 (39)	48 (20)	180 (44)	83 (25)
Never tested	61 (17)	154 (63)	48 (12)	174 (52)
Not reported	3 (<1)	3 (<1)	--	1 (<1)
Any HCV treatment (%)**	N = 149	N = 7	N = 197	N = 11
Interferon	--	--	1 (<1)	--
Interferon & Ribavirin	1 (<1)	1 (14)	--	--
Pegasys & Ribavirin	--	--	1 (<1)	--
Other	--	--	--	--
No treatment	148 (99)	6 (86)	195 (99)	11 (100)
Not reported	--	--	--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	1 (<1)	1 (14)	--	--
Pegasys & Ribavirin	--	--	1 (<1)	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 15 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	240	2 (<1)	23	0 (0)	263	2 (<1)
Non-IDU	172	1 (<1)	12	0 (0)	184	1 (<1)
p value		0.8		--		0.8
2007						
IDU	287	2 (<1)	37	1 (3)	324	3 (<1)
Non-IDU	246	1 (<1)	16	0 (0)	262	1 (<1)
p value		0.7		0.5		0.4

† Excludes equivocal test results and missing values.

Table 16 HIV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	407	1 (<1)	30	0 (0)	437	1 (<1)
Bisexual	2	1 (50)	5	0 (0)	7	1 (14)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
Heterosexual	522	2 (<1)	44	1 (2)	566	3 (<1)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
Unsure	1	0 (0)	1	0 (0)	2	0 (0)
p value		<0.001		1.0		<0.001

† Excludes equivocal test results and missing values.

Table 17 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Non-Indigenous	340	1 (<1)	25	0 (0)	365	1 (<1)
Indigenous	68	2 (3)	10	0 (0)	78	2 (3)
p value		0.06		--		0.08
2007						
Non-Indigenous	433	3 (<1)	35	1 (3)	468	4 (<1)
Indigenous	93	0 (0)	17	0 (0)	110	0 (0)
p value		0.4		0.5		0.3

† Excludes equivocal test results and missing values.

Table 18 HIV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Highly accessible/accessible	372	3 (100)	30	0 (0)	402	3 (100)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	18	0 (0)	2	0 (0)	20	0 (0)
p value		0.9		--		0.9
2007						
Highly accessible/accessible	470	3 (1)	45	1 (2)	515	4 (1)
Moderately accessible	16	0 (0)	1	0 (0)	17	0 (0)
Remote/very remote	20	0 (0)	1	0 (0)	21	0 (0)
p value		0.9		1.0		0.9

† Excludes equivocal test results and missing values.

Table 19 Self-reported exposure to HIV versus HIV serology by sex†

Self-report HIV	HIV Serology					
	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Positive	1	1 (100)	--	--	1	1 (100)
Negative	240	2 (<1)	23	0 (0)	263	2 (<1)
Not sure	19	0 (0)	4	0 (0)	23	0 (0)
p value		<0.001		--		<0.001
2007						
Positive	6	0 (0)	--	--	6	0 (0)
Negative	334	2 (<1)	36	1 (3)	370	3 (<1)
Not sure	25	0 (0)	5	0 (0)	30	0 (0)
p value		0.9		0.7		0.9

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 20 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	242	130 (54)	23	19 (83)	265	149 (56)
Non-IDU	174	7 (4)	12	0 (0)	186	7 (4)
p value		<0.001		<0.001		<0.001
2007						
IDU	287	166 (58)	40	31 (78)	327	197 (60)
Non-IDU	247	9 (4)	15	2 (13)	262	11 (4)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 21 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	411	136 (33)	31	16 (52)	442	152 (34)
Bisexual	2	0 (0)	4	3 (75)	6	3 (50)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.7
2007						
Heterosexual	523	172 (33)	45	24 (53)	568	196 (35)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	6	2 (33)	2	2 (100)	8	4 (50)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.8		0.4		0.3

† Excludes equivocal test results and missing values.

Table 22 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	36	1 (3)	1	0 (0)	37	1 (3)
20 – 24	91	25 (27)	4	2 (50)	95	27 (28)
25 – 29	89	28 (31)	9	6 (67)	98	34 (35)
30 + years	205	84 (41)	20	9 (45)	225	93 (41)
p value		<0.001		0.5		<0.001
2007						
< 20 years	35	2 (6)	1	0 (0)	36	2 (6)
20 – 24	117	22 (19)	6	4 (67)	123	26 (21)
25 – 29	114	44 (39)	16	11 (69)	130	55 (42)
30 + years	267	107 (40)	32	18 (56)	299	125 (42)
p value		<0.001		0.5		<0.001

† Excludes equivocal test results and missing values.

Table 23 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	28	1 (4)	1	0 (0)	29	1 (3)
3 to 5 years	25	11 (44)	2	1 (50)	27	12 (44)
6 to 10 years	75	34 (45)	7	6 (86)	82	40 (49)
10 + years	111	84 (76)	12	11 (92)	123	95 (77)
p value		<0.001		0.1		<0.001
2007						
<3 years	19	4 (21)	1	1 (100)	20	5 (25)
3 to 5 years	29	12 (41)	3	2 (67)	32	14 (44)
6 to 10 years	69	28 (41)	17	12 (71)	86	40 (47)
10 + years	161	116 (72)	19	16 (84)	180	132 (73)
p value		<0.001		0.7		<0.001

† Excludes equivocal test results and missing values.

Table 24 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	22	1 (5)	129	65 (50)	151	66 (44)
Heroin	1	0 (0)	75	63 (84)	76	63 (83)
More than one	5	0 (0)	23	15 (65)	28	15 (54)
Other/not reported	1	0 (0)	5	5(100)	6	5 (83)
p value		1.0		<0.001		<0.001
2007						
Amphetamine (Speed, Ice)	17	3 (18)	178	83 (47)	195	86 (44)
Heroin	3	2 (67)	90	76 (84)	93	78 (84)
More than one	--	--	11	10 (91)	11	10 (91)
Other/not reported	--	--	19	17 (89)	19	17 (89)
p value		0.07		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 25 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	11	0 (0)	40	30 (75)	51	30 (59)
Daily or more	9	1 (11)	101	70 (69)	110	71 (65)
p value		0.3		0.2		0.1
2007						
Less than daily	3	1 (33)	77	45 (58)	80	46 (58)
Daily or more	5	2 (40)	110	86 (78)	115	88 (77)
p value		0.9		<0.01		<0.001

† Excludes equivocal test results and missing values.

Table 26 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	19	1 (5)	103	76 (74)	122	77 (63)
Yes	2	0 (0)	38	25 (66)	40	25 (63)
p value		0.1		0.7		0.8
2007						
No	8	3 (38)	143	97 (68)	151	100 (66)
Yes	--	--	36	28 (78)	36	28 (78)
p value		--		0.3		0.2

† Excludes equivocal test results and missing values.

Table 27 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	12	0 (0)	80	51 (64)	92	51 (55)
Yes	17	1 (6)	148	94 (64)	165	95 (58)
p value		0.4		1.0		0.7
2007						
No	5	1 (20)	86	53 (62)	91	54 (59)
Yes	6	3 (50)	156	114 (73)	162	117 (72)
p value		0.3		0.07		0.04

† Excludes equivocal test results and missing values.

Table 28 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	104	14 (13)	11	1 (9)	115	15 (13)
2 to 4	211	68 (32)	17	11 (65)	228	79 (35)
5 to 9	68	38 (56)	4	4 (100)	72	42 (58)
10 +	23	16 (70)	3	3 (100)	26	19 (73)
p value		<0.001		0.001		<0.001
2007						
1	170	9 (5)	21	9 (43)	191	18 (9)
2 to 4	210	66 (31)	20	13 (65)	230	79 (34)
5 to 9	82	54 (66)	8	7 (88)	90	61 (68)
10 +	52	39 (75)	4	3 (75)	56	42 (75)
p value		<0.001		0.1		<0.001

† Excludes equivocal test results and missing values.

Table 29 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	345	112 (32)	24	13 (54)	369	125 (34)
Indigenous	68	24 (35)	10	5 (50)	78	29 (37)
p value		0.7		0.8		0.5
2007						
Non-Indigenous	435	136 (31)	36	19 (53)	471	155 (33)
Indigenous	92	34 (37)	18	13 (72)	110	47 (43)
p value		0.3		0.2		0.05

† Excludes equivocal test results and missing values.

Table 30 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	156	5 (3)	210	119 (57)	366	124 (34)
Indigenous	28	1 (4)	49	28 (57)	77	29 (38)
p value		0.9		0.9		0.6
2007						
Non-Indigenous	221	9 (4)	250	146 (58)	471	155 (33)
Indigenous	40	2 (5)	70	45 (64)	110	47 (43)
p value		0.8		0.4		0.05

† Excludes equivocal test results and missing values.

Table 31 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	375	128 (34)	31	18 (58)	406	146 (36)
Moderately accessible	10	2 (20)	1	0 (0)	11	2 (18)
Remote/very remote	18	2 (11)	2	0 (0)	20	2 (10)
p value		0.09		0.2		0.03
2007						
Highly accessible/accessible	471	161 (34)	47	28 (60)	518	189 (36)
Moderately accessible	16	2 (13)	1	0 (0)	17	2 (12)
Remote/very remote	20	3 (15)	1	0 (0)	21	3 (14)
p value		0.04		0.2		0.01

† Excludes equivocal test results and missing values.

Table 32 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	338	118 (35)	33	19 (58)	371	137 (37)
Other Oceania	23	2 (9)	--	--	23	2 (9)
Asia	18	10 (56)	2	0 (0)	20	10 (50)
UK & Ireland	9	2 (22)	--	--	9	2 (22)
Other	27	5 (19)	--	--	27	5 (19)
p value		<0.01		0.1		<0.01
2007						
Australia	450	149 (33)	47	28 (60)	497	177 (36)
Other Oceania	17	3 (18)	2	1 (50)	19	4 (21)
Asia	29	14 (48)	3	1 (33)	32	15 (47)
UK & Ireland	9	3 (33)	1	1 (100)	10	4 (40)
Other	27	5 (19)	2	2 (100)	29	7 (24)
p value		0.2		0.6		0.3

† Excludes equivocal test results and missing values.

Table 33 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	368	120 (33)	31	17 (55)	399	137 (34)
Non-English speaking	47	17 (36)	4	2 (50)	51	19 (37)
p value		0.6		0.9		0.7
2007						
English speaking	464	150 (32)	50	30 (60)	514	180 (35)
Non-English speaking	69	24 (35)	5	3 (60)	74	27 (36)
p value		0.3		1.0		0.4

† Excludes equivocal test results and missing values.

Table 34 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	88	87 (99)	16	16 (100)	104	103 (99)
Negative	138	25 (18)	7	1 (14)	145	26 (18)
Not sure	22	13 (59)	2	1 (50)	24	14 (58)
p value		<0.001		<0.001		<0.001
2007						
Positive	125	120 (96)	29	28 (97)	154	148 (96)
Negative	211	33 (16)	13	2 (15)	224	35 (16)
Not sure	25	10 (40)	4	2 (50)	29	12 (41)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 35 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	244	12 (5)	24	1 (4)	268	13 (5)
Non-IDU	172	0 (0)	12	0 (0)	184	0 (0)
p value		<0.01		0.5		<0.01
2007						
IDU	288	9 (3)	38	2 (5)	326	11 (3)
Non-IDU	247	3 (1)	14	0 (0)	261	3 (1)
p value		0.1		0.4		0.08

† Excludes equivocal test results and missing values.

Table 36 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	239	64 (27)	23	7 (30)	264	71 (27)
Non-IDU	172	14 (8)	10	3 (30)	182	17 (9)
p value		<0.001		1.0		<0.001
2007						
IDU	272	83 (31)	39	13 (33)	311	96 (31)
Non-IDU	239	22 (9)	16	2 (13)	255	24 (9)
p value		<0.001		0.1		<0.001

† Excludes equivocal test results and missing values.

Table 37 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	406	78 (19)	29	9 (31)	435	87 (20)
Bisexual	2	0 (0)	4	1 (25)	6	1 (17)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.6		0.8		0.7
2007						
Heterosexual	501	104 (21)	45	12 (27)	546	116 (21)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	5	1 (20)	2	1 (50)	7	2 (29)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.2		0.5

† Excludes equivocal test results and missing values.

Table 38 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	37	1 (3)	1	0 (0)	38	1 (3)
20 – 24	89	11 (12)	5	2 (40)	94	13 (14)
25 – 29	89	17 (19)	8	2 (25)	97	19 (20)
30 + years	201	49 (24)	19	6 (32)	220	55 (25)
p value		<0.01		0.9		<0.01
2007						
< 20 years	32	2 (6)	1	0 (0)	33	2 (6)
20 – 24	115	11 (10)	6	0 (0)	121	11 (9)
25 – 29	110	24 (22)	15	2 (13)	125	26 (21)
30 + years	253	68 (27)	33	13 (39)	286	81 (28)
p value		<0.001		0.09		<0.001

† Excludes equivocal test results and missing values.

Table 39 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	29	2 (7)	1	0 (0)	30	2 (7)
3 to 5 years	23	2 (9)	3	1 (33)	26	3 (12)
6 to 10 years	76	18 (24)	7	3 (43)	83	21 (25)
10 + years	108	41 (38)	12	3 (25)	120	44 (37)
p value		<0.01		0.8		<0.01
2007						
<3 years	19	2 (11)	1	0 (0)	20	2 (10)
3 to 5 years	29	5 (17)	3	0 (0)	32	5 (16)
6 to 10 years	66	17 (26)	17	4 (24)	83	21 (25)
10 + years	149	55 (37)	18	9 (50)	167	64 (38)
p value		0.02		0.2		<0.01

† Excludes equivocal test results and missing values.

Table 40 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	23	2 (9)	130	38 (22)	153	40 (26)
Heroin	1	0 (0)	70	22 (31)	71	22 (31)
More than one	5	0 (0)	23	7 (30)	28	7 (25)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.9		0.9		0.8
2007						
Amphetamine (Speed, Ice)	17	2 (12)	165	41 (25)	182	43 (24)
Heroin	3	0 (0)	87	35 (40)	90	35 (39)
More than one	--	--	11	5 (45)	11	5 (45)
Other/not reported	--	--	19	9 (47)	19	9 (47)
p value		0.5		0.02		0.01

† Excludes equivocal test results and missing values.

Table 41 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	11	1 (19)	41	20 (49)	52	21 (40)
Daily or more	10	0 (0)	99	26 (26)	109	26 (24)
p value		0.3		0.01		0.02
2007						
Less than daily	3	0 (0)	73	24 (33)	76	24 (32)
Daily or more	6	0 (0)	102	39 (38)	108	39 (36)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 42 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	20	1 (5)	101	33 (33)	121	34 (28)
Yes	2	0 (0)	39	13 (33)	41	13 (32)
p value		0.7		0.9		0.8
2007						
No	9	0 (0)	135	47 (35)	144	47 (33)
Yes	--	--	32	13 (41)	32	13 (41)
p value		--		0.5		0.4

† Excludes equivocal test results and missing values.

Table 43 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	12	0 (0)	79	29 (37)	91	29 (32)
Yes	18	2 (11)	145	37 (26)	163	39 (24)
p value		0.2		0.2		0.6
2007						
No	5	2 (40)	81	25 (31)	86	27 (31)
Yes	6	0 (0)	148	49 (33)	154	49 (32)
p value		0.9		0.7		0.9

† Excludes equivocal test results and missing values.

Table 44 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	103	9 (9)	9	3 (33)	112	12 (11)
2 to 4	211	40 (19)	17	4 (24)	228	44 (19)
5 to 9	67	22 (33)	4	1 (25)	71	23 (32)
10 +	22	6 (27)	3	2 (67)	25	8 (32)
p value		<0.01		0.5		<0.01
2007						
1	163	15 (9)	21	6 (29)	184	21 (11)
2 to 4	204	44 (22)	21	2 (10)	225	46 (20)
5 to 9	76	24 (32)	7	4 (57)	83	28 (34)
10 +	48	16 (33)	4	1 (25)	52	17 (33)
p value		<0.01		0.08		<0.01

† Excludes equivocal test results and missing values.

Table 45 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	340	57 (17)	23	7 (30)	363	64 (18)
Indigenous	68	20 (29)	9	2 (22)	77	22 (29)
p value		0.02		0.6		0.03
2007						
Non-Indigenous	416	67 (16)	36	8 (22)	452	75 (17)
Indigenous	88	37 (42)	18	7 (39)	106	44 (42)
p value		<0.001		0.2		<0.001

† Excludes equivocal test results and missing values.

Table 46 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	154	14 (9)	206	50 (24)	360	64 (18)
Indigenous	26	3 (12)	50	19 (38)	76	22 (29)
p value		0.7		0.05		0.03
2007						
Non-Indigenous	215	12 (6)	237	63 (27)	452	75 (17)
Indigenous	39	12 (31)	67	32 (48)	106	44 (42)
p value		<0.001		0.01		<0.001

† Excludes equivocal test results and missing values.

Table 47 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	370	66 (18)	28	8 (29)	398	74 (19)
Moderately accessible	10	1 (10)	1	0 (0)	11	1 (9)
Remote/very remote	18	7 (39)	2	0 (0)	20	7 (35)
p value		0.06		0.6		0.1
2007						
Highly accessible/accessible	454	89 (20)	47	13 (28)	501	102 (20)
Moderately accessible	15	1 (7)	1	0 (0)	16	1 (6)
Remote/very remote	17	7 (41)	1	1 (100)	18	8 (44)
p value		0.04		0.2		0.02

† Excludes equivocal test results and missing values.

Table 48 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	337	63 (19)	31	8 (26)	368	71 (19)
Other Oceania	23	6 (26)	--	--	23	6 (26)
Asia	15	6 (40)	2	2 (100)	17	8 (47)
UK & Ireland	9	1 (11)	--	--	9	1 (11)
Other	26	2 (8)	--	--	26	2 (8)
p value		0.1		0.07		0.02
2007						
Australia	431	86 (20)	47	11 (23)	478	97 (20)
Other Oceania	17	5 (29)	2	1 (50)	19	6 (32)
Asia	29	7 (24)	3	1 (33)	32	8 (25)
UK & Ireland	8	3 (38)	1	0 (0)	9	3 (33)
Other	24	4 (17)	2	2 (100)	26	6 (23)
p value		0.6		0.2		0.7

† Excludes equivocal test results and missing values.

Table 49 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	367	66 (18)	29	7 (24)	396	73 (18)
Non-English speaking	43	12 (28)	4	3 (75)	47	15 (32)
p value		0.1		0.04		0.03
2007						
English speaking	444	86 (19)	49	12 (24)	493	98 (20)
Non-English speaking	66	18 (27)	6	3 (50)	72	21 (29)
p value		0.1		0.2		0.07

† Excludes equivocal test results and missing values.

Table 50 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	270	117 (43)	60 (22)	13 (5)	80 (30)
Non-IDU	185	134 (72)	17 (9)	0 (0)	34 (18)
p value					<0.001
2007					
IDU	308	111 (36)	90 (29)	10 (3)	97 (31)
Non-IDU	246	166 (67)	21 (9)	3 (1)	56 (23)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 51 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	445	245 (55)	76 (17)	13 (3)	111 (25)
Bisexual	7	4 (57)	1 (14)	0 (0)	2 (29)
Homosexual	3	2 (67)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	534	269 (50)	108 (20)	11 (2)	146 (27)
Homosexual	5	2 (40)	--	--	3 (60)
Bisexual	7	3 (43)	1 (14)	1 (14)	2 (29)
Unsure	2	1 (50)	1 (50)	--	146 (27)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 52 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	38	23 (61)	0 (0)	1 (3)	14 (37)
20 – 24	96	53 (55)	10 (10)	4 (4)	29 (30)
25 – 29	100	57 (57)	16 (16)	3 (3)	24 (24)
30 + years	226	123 (54)	51 (23)	5 (2)	47 (21)
p value					0.02
2007					
< 20 years	34	21 (62)	3 (9)	0 (0)	10 (29)
20 – 24	117	59 (50)	9 (8)	2 (2)	47 (40)
25 – 29	121	54 (45)	24 (20)	3 (2)	40 (33)
30 + years	281	142 (51)	75 (27)	8 (3)	56 (20)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 53 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	115	85 (74)	10 (9)	2 (2)	18 (16)
2 to 4	232	124 (53)	39 (17)	8 (3)	61 (26)
5 to 9	74	25 (34)	21 (28)	1 (1)	27 (36)
10 +	25	11 (44)	6 (24)	2 (8)	6 (24)
p value					<0.001
2007					
1	182	130 (71)	19 (10)	3 (2)	30 (16)
2 to 4	215	109 (51)	42 (20)	5 (2)	59 (27)
5 to 9	83	16 (19)	27 (33)	3 (4)	37 (45)
10 +	52	13 (25)	15 (29)	2 (4)	22 (42)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 54 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	372	223 (60)	57 (15)	9 (2)	83 (22)
Indigenous	78	26 (33)	18 (23)	4 (5)	30 (38)
p value					<0.001
2007					
Non-Indigenous	442	242 (55)	70 (16)	8 (2)	122 (28)
Indigenous	104	32 (31)	40 (38)	5 (5)	27 (26)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 55 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	409	231 (56)	64 (16)	12 (3)	102 (25)
Moderately accessible	11	6 (55)	1 (9)	0 (0)	4 (36)
Remote/very remote	20	7 (35)	7 (35)	0 (0)	6 (30)
p value					0.2
2007					
Highly accessible/accessible	494	248 (50)	92 (19)	13 (3)	141 (29)
Moderately accessible	14	13 (93)	1 (7)	0 (0)	0 (0)
Remote/very remote	15	3 (20)	9 (60)	0 (0)	3 (20)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 56 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	403	222 (55)	65 (16)	9 (2)	107 (27)
Non-English	51	28 (55)	12 (24)	4 (8)	7 (14)
p value					0.02
2007					
English	482	248 (51)	94 (20)	8 (2)	132 (27)
Non-English	71	29 (41)	16 (23)	5 (7)	21 (30)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 57 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	128	14 (11)	8	3 (38)	136	17 (13)
Yes	163	81 (50)	12	5 (42)	175	86 (49)
Not sure	46	9 (20)	6	2 (33)	52	11 (21)
p value		<0.001		0.9		<0.001
2007						
No	144	17 (12)	21	4 (19)	165	21 (13)
Yes	196	111 (57)	18	11 (61)	214	122 (57)
Not sure	47	9 (19)	1	0 (0)	48	9 (19)
p value		<0.001		0.02		<0.001

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded. Yes to self-reported immunisation includes any immunisation against HBV.

New South Wales 2004 & 2007

Table 58 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 2		N = 3	
N° surveyed	N = 183	N = 127	N = 132	N = 113
Sex (%)				
Male	152 (83)	118 (93)	101 (77)	103 (91)
Female	30 (16)	9 (7)	31 (23)	10 (9)
Transgender	1 (<1)	--	--	--
Sexual identity (%)				
Heterosexual	171 (93)	123 (97)	120 (91)	110 (97)
Bisexual	7 (4)	1 (<1)	4 (3)	--
Homosexual	5 (3)	2 (2)	5 (4)	--
Unsure	--	--	--	--
Not reported	--	1 (<1)	3 (2)	3 (3)
Age and duration of injection (years)				
Median age (years)	30	32	31	31
Age range	18 – 58	18 – 75	19 – 53	18 – 71
Age group (%)				
<25 years	47 (26)	39 (31)	22 (17)	37 (33)
25+ years	136 (74)	88 (69)	109 (83)	76 (67)
Not reported	--	--	1 (<1)	0 (0)
Median age 1 st IDU (years)	18	--	18	--
Age range	9 – 41	--	8 – 35	--
Median years IDU	10	--	13	--
Range	<1 – 31	--	<1 – 36	--
Duration of drug injection (%)				
<3 years	16 (9)	--	6 (5)	--
3+ years	163 (89)	--	122 (92)	--
Not reported	4 (2)	--	4 (3)	--
Aboriginal and Torres Strait Islander origin (%)				
No	155 (85)	118 (93)	93 (70)	97 (86)
Yes	28 (15)	9 (7)	33 (25)	15 (13)
Not reported	--	--	6 (5)	1 (<1)
Residential remoteness in 12 months before prison				
Highly accessible/accessible	174 (95)	117 (92)	121 (92)	104 (92)
Moderately accessible	3 (2)	2 (2)	1 (1)	1 (1)
Remote/very remote	3 (2)	--	--	--
Not reported	3 (2)	8 (6)	10 (8)	8 (7)
Region/Country of birth (%)				
Australia	156 (85)	87 (69)	118 (89)	73 (65)
Other Oceania	3 (2)	8 (6)	2 (2)	9 (8)
Asia	11 (6)	11 (9)	7 (5)	13 (12)
UK & Ireland	3 (2)	5 (4)	1 (<1)	2 (2)
Other	10 (5)	16 (13)	3 (2)	13 (12)
Not reported	--	--	1 (<1)	3 (3)
Main language spoke at home by parents (%)				
English speaking	159 (87)	99 (78)	115 (87)	74 (65)
Non-English speaking	24 (13)	28 (22)	17 (13)	39 (35)
Not reported	--	--	--	--
First time in prison (%)				
No	157 (86)	59 (46)	112 (85)	63 (56)
Yes	26 (14)	68 (54)	19 (14)	50 (44)
Not reported	--	--	1 (<1)	--
Lifetime imprisonments (%)				
One	26 (14)	68 (54)	19 (14)	50 (44)
Two to four	84 (46)	44 (35)	50 (38)	49 (43)
Five to nine	50 (27)	9 (7)	32 (24)	7 (6)
Ten or more	20 (11)	2 (2)	27 (20)	3 (3)
Not reported	3 (2)	4 (3)	4 (3)	4 (4)

Table 58 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	84 (46)	97 (76)	35 (31)	14 (22)
Yes	99 (54)	27 (21)	76 (67)	48 (76)
Not reported	--	3 (2)	2 (2)	1 (2)
Frequency of injection last month (%)				
Not last month	55 (30)	--	44 (33)	--
Less than weekly	29 (16)	--	22 (17)	--
Weekly not daily	14 (8)	--	14 (11)	--
Daily or more	83 (45)	--	49 (37)	--
Not reported	2 (1)	--	3 (2)	--
Ever smoked full cigarette (%)*				
No	--	--	4 (3)	10 (9)
Yes	--	--	128 (97)	103 (91)
Not reported	--	--	--	--
Median age first smoked (years)	--	--	13	14
Age range	--	--	6 – 30	4 – 31
Current smoker (%)*				
No	--	--	8 (6)	27 (24)
Yes	--	--	124 (94)	86 (76)
Not reported	--	--	--	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	4 (3)	10 (12)
5 to 10 cigarettes a day	--	--	26 (21)	16 (19)
11 to 20 cigarettes a day	--	--	61 (49)	31 (36)
Over 20 cigarettes a day	--	--	32 (26)	29 (34)
Not reported	--	--	1 (<1)	--

* Smoking questions were not asked in 2004 survey.

Table 59 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)	N = 183	N = 132
Amphetamine (Speed, Ice)	73 (40)	64 (48)
Anabolic steroids	1 (1)	--
Cocaine	7 (4)	5 (4)
Heroin	86 (47)	53 (40)
Heroin + amphetamine	--	3 (2)
Heroin + Cocaine	2 (1)	1 (1)
Methadone	6 (3)	4 (3)
Morphine	1 (1)	2 (2)
Other	7 (4)	--
Not reported	--	--
N° Injected last month	N = 128	N = 88
Places injected last month (%)**		
Prison	3 (2)	3 (3)
Own home	99 (77)	65 (76)
Friend's home	54 (42)	46 (54)
Dealer's home	21 (16)	23 (27)
Street, park, beach	40 (31)	38 (45)
Car	37 (29)	36 (42)
Public toilet	29 (23)	25 (29)
Commercial injecting room	6 (5)	7 (8)
MSIC*	5 (4)	10 (12)
Squat	10 (8)	8 (9)
Other place	5 (4)	--
Not reported	--	3 (3)
Use of sterile needles & syringes last month (%)		
All injections	86 (67)	49 (58)
Most of the time	20 (16)	16 (19)
Half of the time	8 (6)	7 (8)
Some of the time	12 (9)	10 (12)
Not last month	2 (2)	--
Not reported	--	3 (4)
Re-used someone else's used needle & syringe last month (%)		
None	116 (91)	68 (80)
Once	4 (3)	7 (8)
Twice	3 (2)	2 (2)
3-5 times	4 (3)	3 (4)
>5 times	1 (<1)	4 (5)
Not reported	--	1 (1)
Number of people needle & syringe was re-used after last month (%)		
None	117 (91)	68 (77)
One	8 (6)	12 (14)
Two	2 (2)	--
Three to five	1 (<1)	--
More than five	--	--
Not reported	--	8 (9)
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	4 (3)	7 (8)
Casual sex partner	1 (<1)	--
Close friend	3 (2)	2 (2)
Acquaintance	3 (2)	2 (2)
Other	1 (<1)	1 (1)
Equipment used after someone else last month (%)**		
Spoon	28 (22)	26 (31)
Water	19 (15)	23 (27)
Filter	17 (13)	20 (24)
Tourniquet	10 (8)	11 (13)
Drug mix	18 (14)	17 (20)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 60 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113
Any treatment/therapy for drug use (%)				
No	89 (49)	118 (93)	24 (18)	76 (67)
Yes	93 (51)	9 (7)	100 (76)	15 (13)
Not reported	1 (<1)	--	8 (6)	22 (19)
History of methadone maintenance treatment (%)				
Currently	44 (24)	--	25 (19)	--
Previously	50 (27)	2 (2)	39 (30)	--
Never	88 (48)	125 (98)	57 (43)	--
Not reported	1 (<1)	--	11 (8)	--
History of other pharmacotherapy treatment (%)				
Currently	9 (5)	--	4 (3)	--
Previously	31 (17)	1 (<1)	35 (27)	--
Never	139 (77)	126 (98)	89 (67)	--
Not reported	1 (<1)	--	4 (3)	--

Table 61 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	N = 129	N = 85
From an NSP last month (%)		
Daily or almost daily	17 (6)	11 (13)
A couple of times each week	21 (7)	18 (21)
Less than weekly	14 (5)	13 (15)
Once last month	24 (8)	15 (18)
Not in the last month	28 (9)	12 (14)
Not reported	25 (8)	16 (19)
From a chemist last month (%)		
Daily or almost daily	5 (2)	5 (6)
A couple of times each week	17 (6)	8 (9)
Less than weekly	30 (10)	9 (11)
Once last month	19 (6)	11 (13)
Not in the last month	54 (17)	37 (44)
Not reported	4 (3)	15 (18)

Table 62 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113
Sex last month (%)				
No	47 (26)	38 (30)	39 (30)	28 (25)
Yes	136 (74)	86 (68)	93 (70)	84 (74)
Not reported	--	--	--	1 (<1)
Condom use at last sex (%)				
No	136 (74)	85 (67)	114 (86)	90 (80)
Yes	47 (26)	39 (31)	15 (11)	22 (19)
Not reported			3 (2)	1 (<1)
Condom use with regular sex partner(s) last month (%)*				
No	83 (84)	57 (81)	69 (88)	57 (77)
Sometimes	8 (8)	7 (10)	8 (10)	9 (12)
Always	8 (8)	6 (9)	1 (<1)	8 (11)
Condom use with new sex partner(s) last month (%)*				
No	6 (27)	2 (22)	17 (63)	5 (36)
Sometimes	6 (27)	1 (11)	5 (19)	5 (36)
Always	10 (45)	6 (67)	5 (19)	4 (29)
Condom use with casual sex partner(s) last month (%)*				
No	17 (40)	8 (40)	17 (74)	6 (43)
Sometimes	9 (21)	4 (20)	4 (17)	5 (36)
Always	17 (40)	8 (40)	2 (9)	3 (21)
Sex work last month (%)				
No	178 (97)	122 (96)	126 (95)	103 (91)
Yes	5 (3)	--	3 (2)	5 (4)
Not reported	--	5 (4)	3 (2)	5 (4)
Condom used at last sex work last month (%)				
No	2 (50)	--	--	1 (20)
Yes	3 (60)	--	2 (67)	2 (40)
Not reported	--	--	1 (33)	2 (40)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 63 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113
Previous HIV test (%)				
Yes, last year	96 (52)	23 (18)	52 (39)	25 (22)
>1 year ago	59 (32)	31 (25)	62 (47)	34 (30)
Never tested	27 (15)	72 (57)	17 (13)	54 (48)
Not reported	1 (<1)	--	1 (<1)	--
HBV infection (%)				
No	131 (72)	115 (91)	97 (73)	106 (94)
Yes	34 (19)	3 (2)	26 (20)	4 (4)
Don't know	18 (10)	9 (7)	8 (6)	3 (3)
Not reported	--	--	1 (<1)	--
HBV vaccination (%)*				
No	65 (36)	58 (46)	43 (33)	60 (53)
Yes	87 (48)	33 (26)	70 (53)	36 (32)
Don't know	30 (16)	33 (26)	13 (10)	15 (13)
Not reported	--	3 (2)	6 (5)	2 (2)
Previous HCV test (%)				
Yes, last year	23 (13)	84 (67)	43 (33)	22 (19)
>1 year ago	85 (46)	23 (18)	77 (58)	30 (27)
Never tested	72 (39)	17 (13)	12 (9)	59 (52)
Unsure	-	--	--	1 (<1)
Not reported	2 (1)	1 (<1)	--	1 (<1)
Any HCV treatment (%)**	N = 85	N = 2	N = 80	N = 3
Interferon	--	--	--	--
Interferon & Ribavirin	1 (1)	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--
No treatment	84 (99)	2 (100)	80 (100)	3 (100)
Not reported	--	--	--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 64 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	104	2 (2)	16	0 (0)	120	2 (2)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.2		--		0.2
2007						
IDU	84	1 (1)	27	1 (4)	111	2 (2)
Non-IDU	75	1 (1)	10	0 (0)	85	1 (1)
p value		0.9		0.5		0.7

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 65 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	108	72 (67)	16	13 (81)	124	85 (69)
Non-IDU	75	2 (3)	5	0 (0)	80	2 (3)
p value		<0.001		<0.01		<0.001
2007						
IDU	84	57 (68)	28	23 (82)	112	80 (71)
Non-IDU	76	2 (3)	9	1 (11)	85	3 (3)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 66 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	180	73 (41)	18	11 (61)	198	84 (42)
Bisexual	--	--	3	2 (67)	3	2 (67)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.8		0.9		0.7
2007						
Heterosexual	155	59 (38)	29	16 (55)	184	75 (41)
Bisexual	1	0 (0)	3	3 (100)	4	3 (75)
Homosexual	2	0 (0)	2	2 (100)	4	2 (50)
Unsure	--	--	--	--	--	--
p value		0.4		0.2		0.4

† Excludes equivocal test results and missing values.

Table 67 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	44	16 (36)	3	2 (67)	47	18 (38)
25 – 29	40	14 (35)	4	3 (75)	44	17 (39)
30 + years	86	44 (51)	13	8 (62)	99	52 (53)
p value		0.003		0.6		0.002
2007						
< 20 years	8	1 (13)	1	0 (0)	9	1 (11)
20 – 24	32	5 (16)	6	4 (67)	38	9 (24)
25 – 29	31	11 (35)	11	9 (82)	42	20 (48)
30 + years	88	42 (48)	19	11 (58)	107	53 (50)
p value		0.005		0.3		0.03

† Excludes equivocal test results and missing values.

Table 68 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	11	1 (9)	1	0 (0)	12	1 (8)
3 to 5 years	11	7 (64)	2	1 (50)	13	8 (62)
6 to 10 years	35	20 (57)	5	4 (80)	40	24 (60)
10 + years	50	44 (88)	8	8 (100)	58	52 (90)
p value		<0.001		0.06		<0.001
2007						
<3 years	4	3 (75)	1	1 (100)	5	4 (80)
3 to 5 years	5	3 (60)	2	1 (50)	7	4 (57)
6 to 10 years	17	7 (41)	14	11 (79)	31	18 (58)
10 + years	55	43 (78)	11	10 (91)	66	53 (80)
p value		0.04		0.5		0.1

† Excludes equivocal test results and missing values.

Table 69 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	6	1 (17)	42	26 (62)	48	27 (56)
Heroin	1	0 (0)	55	47 (85)	56	47 (84)
More than one	--	--	9	6 (67)	6	5 (83)
Other/not reported	1	0 (0)	5	5 (100)	15	8 (53)
p value		0.6		0.03		0.008
2007						
Amphetamine (Speed, Ice)	3	3 (100)	49	28 (57)	52	31 (60)
Heroin	2	1 (50)	43	36 (84)	45	37 (82)
More than one	--	--	4	4 (100)	4	4 (100)
Other/not reported	--	--	8	7 (88)	8	7 (88)
p value		0.2		0.01		0.003

† Excludes equivocal test results and missing values.

Table 70 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	6	0 (0)	21	17 (81)	27	17 (63)
Daily or more	2	1 (50)	52	39 (75)	54	40 (74)
p value		0.08		0.8		0.2
2007						
Less than daily	2	1 (50)	24	17 (71)	26	18 (69)
Daily or more	1	1 (100)	42	33 (79)	43	34 (79)
p value		0.4		0.5		0.5

† Excludes equivocal test results and missing values.

Table 71 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	8	1 (13)	53	44 (83)	61	45 (74)
Yes	1	0 (0)	20	12 (60)	21	12 (57)
p value		0.7		0.01		0.02
2007						
No	3	2 (67)	50	39 (78)	53	41 (77)
Yes	--	--	12	8 (67)	12	8 (67)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 72 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	53	39 (74)	59	39 (66)
Yes	6	1 (17)	58	45 (78)	64	46 (72)
p value		0.3		0.6		0.5
2007						
No	1	1 (100)	30	22 (73)	31	23 (74)
Yes	2	2 (100)	58	45 (78)	60	47 (78)
p value		--		0.7		0.7

† Excludes equivocal test results and missing values.

Table 73 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	61	9 (15)	6	1 (17)	67	10 (15)
2 to 4	72	33 (46)	10	7 (70)	82	40 (49)
5 to 9	32	19 (59)	3	3 (100)	35	22 (63)
10 +	15	12 (80)	2	2 (100)	17	14 (82)
p value		<0.001		0.04		<0.001
2007						
1	40	5 (13)	13	5 (38)	53	10 (19)
2 to 4	67	19 (28)	14	10 (71)	81	29 (36)
5 to 9	25	18 (72)	5	5 (100)	30	23 (77)
10 +	22	16 (73)	4	3 (75)	26	19 (73)
p value		<0.001		0.07		<0.001

† Excludes equivocal test results and missing values.

Table 74 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	163	63 (39)	17	10 (59)	180	73 (41)
Indigenous	20	11 (55)	4	3 (75)	24	14 (58)
p value		0.2		0.6		0.1
2007						
Non-Indigenous	124	38 (31)	24	12 (50)	148	50 (34)
Indigenous	30	16 (53)	12	11 (92)	42	27 (64)
p value		0.02		0.01		<0.001

† Excludes equivocal test results and missing values.

Table 75 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	77	2 (3)	103	71 (69)	180	73 (41)
Indigenous	3	0 (0)	21	14 (67)	24	14 (58)
p value		0.8		0.8		0.1
2007						
Non-Indigenous	74	2 (3)	74	48 (65)	148	50 (34)
Indigenous	10	1 (10)	32	26 (81)	42	27 (64)
p value		0.2		0.09		<0.001

† Excludes equivocal test results and missing values.

Table 76 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison, and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	171	70 (41)	21	13 (62)	192	83 (43)
Moderately accessible	3	1 (33)	--	--	3	1 (33)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	151	55 (36)	30	19 (63)	181	74 (41)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.5		0.2		0.2

† Excludes equivocal test results and missing values.

Table 77 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	138	60 (43)	19	13 (68)	157	73 (46)
Other Oceania	7	0 (0)	--	--	7	0 (0)
Asia	14	8 (57)	2	0 (0)	16	8 (50)
UK & Ireland	5	2 (40)	--	--	5	2 (40)
Other	19	4 (21)	--	--	19	4 (21)
p value		0.04		0.06		0.04
2007						
Australia	127	52 (41)	32	21 (66)	159	73 (46)
Other Oceania	8	1 (13)	1	1 (100)	9	2 (22)
Asia	14	5 (36)	2	0 (0)	16	5 (31)
UK & Ireland	--	--	--	--	--	--
Other	9	0 (0)	2	2 (100)	11	2 (18)
p value		0.08		0.1		0.1

† Excludes equivocal test results and missing values.

Table 78 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	146	59 (40)	18	12 (67)	164	71 (43)
Non-English speaking	37	15 (41)	3	1 (33)	40	16 (40)
p value		1.0		0.3		0.7
2007						
English speaking	121	48 (40)	33	22 (67)	154	70 (45)
Non-English speaking	39	11 (28)	4	2 (50)	43	13 (30)
p value		0.2		0.5		0.07

† Excludes equivocal test results and missing values.

Table 79 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	45	44 (98)	12	12 (100)	57	56 (98)
Negative	45	12 (27)	4	1 (25)	49	13 (27)
Not sure	14	9 (64)	1	0 (0)	15	9 (60)
p value		<0.001		0.002		<0.001
2007						
Positive	44	42 (95)	20	19 (95)	64	61 (95)
Negative	55	8 (15)	9	2 (22)	64	10 (16)
Not sure	5	4 (80)	4	2 (50)	9	6 (67)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 80 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	108	6 (6)	16	0 (0)	124	6 (5)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.04		--		0.05
2007						
IDU	85	1 (1)	27	2 (7)	112	3 (3)
Non-IDU	76	3 (4)	10	0 (0)	86	3 (3)
p value		0.3		0.4		0.7

† Excludes equivocal test results and missing values.

Table 81 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	105	35 (33)	16	3 (19)	121	38 (31)
Non-IDU	74	6 (8)	5	3 (60)	79	9 (11)
p value		<0.001		0.08		0.001
2007						
IDU	85	33 (39)	28	9 (32)	113	42 (37)
Non-IDU	76	11 (14)	10	1 (10)	86	12 (14)
p value		0.001		0.2		0.0

† Excludes equivocal test results and missing values.

Table 82 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	176	41 (23)	18	5 (28)	194	46 (24)
Bisexual	--	--	3	1 (33)	3	1 (33)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.3		0.8		0.6
2007						
Heterosexual	156	44 (28)	30	8 (27)	186	52 (28)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	2	0 (0)	2	1 (50)	4	1 (25)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.5

† Excludes equivocal test results and missing values.

Table 83 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	43	9 (21)	3	1 (33)	46	10 (22)
25 – 29	40	8 (20)	4	0 (0)	44	8 (18)
30 + years	83	24 (29)	13	5 (38)	96	29 (30)
p value		0.1		0.5		0.06
2007						
< 20 years	8	0 (0)	1	0 (0)	9	0 (0)
20 – 24	32	5 (16)	6	0 (0)	38	5 (13)
25 – 29	31	7 (23)	11	2 (18)	42	9 (21)
30 + years	89	32 (36)	20	8 (40)	109	40 (37)
p value		0.03		0.2		0.01

† Excludes equivocal test results and missing values.

Table 84 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	11	0 (0)	1	0 (0)	12	0 (0)
3 to 5 years	9	2 (22)	2	0 (0)	11	2 (18)
6 to 10 years	35	12 (34)	5	1 (20)	40	13 (33)
10 + years	49	21 (43)	8	2 (25)	57	23 (40)
p value		0.05		0.8		0.04
2007						
<3 years	4	0 (0)	1	0 (0)	5	0 (0)
3 to 5 years	5	1 (20)	2	0 (0)	7	1 (14)
6 to 10 years	17	6 (35)	14	3 (21)	31	9 (29)
10 + years	56	25 (45)	11	6 (55)	67	31 (46)
p value		0.2		0.2		0.05

† Excludes equivocal test results and missing values.

Table 85 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	6	0 (0)	42	16 (38)	48	16 (33)
Heroin	1	0 (0)	52	18 (35)	53	18 (34)
More than one	4	0 (0)	9	3 (33)	13	3 (23)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.9		0.7
2007						
Amphetamine (Speed, Ice)	3	0 (0)	50	16 (32)	53	16 (30)
Heroin	2	0 (0)	43	18 (42)	45	18 (40)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	8	5 (63)	8	5 (63)
p value		--		0.4		0.3

† Excludes equivocal test results and missing values.

Table 86 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	6	0 (0)	21	10 (48)	27	10 (37)
Daily or more	2	0 (0)	50	14 (28)	52	14 (27)
p value		--		0.1		0.4
2007						
Less than daily	2	0 (0)	25	6 (24)	27	6 (22)
Daily or more	1	0 (0)	42	18 (43)	43	18 (42)
p value		--		0.2		0.1

† Excludes equivocal test results and missing values.

Table 87 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	8	0 (0)	51	16 (31)	59	16 (27)
Yes	1	0 (0)	20	8 (40)	21	8 (38)
p value		--		0.5		0.3
2007						
No	3	0 (0)	51	18 (35)	54	18 (33)
Yes	--	--	12	5 (42)	12	5 (42)
p value		--		0.7		0.6

† Excludes equivocal test results and missing values.

Table 88 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	52	20 (38)	58	20 (34)
Yes	6	0 (0)	56	18 (32)	62	18 (29)
p value		--		0.5		0.6
2007						
No	1	0 (0)	30	11 (37)	31	11 (35)
Yes	2	0 (0)	59	26 (44)	61	26 (43)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 89 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	60	4 (7)	6	3 (50)	66	7 (11)
2 to 4	72	19 (26)	10	1 (10)	82	20 (24)
5 to 9	31	13 (42)	3	1 (33)	34	14 (41)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		0.001		0.3		0.003
2007						
1	40	3 (8)	13	4 (31)	53	7 (13)
2 to 4	67	20 (30)	15	1 (7)	82	21 (26)
5 to 9	26	10 (38)	5	3 (60)	31	13 (42)
10 +	22	10 (45)	4	1 (25)	26	11 (42)
p value		0.004		0.01		0.008

† Excludes equivocal test results and missing values.

Table 90 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	158	33 (21)	17	5 (29)	175	38 (22)
Indigenous	21	8 (38)	4	1 (25)	25	9 (36)
p value		0.08		0.9		0.1
2007						
Non-Indigenous	125	29 (23)	25	6 (24)	150	35 (23)
Indigenous	30	15 (50)	12	4 (33)	42	19 (45)
p value		0.003		0.5		0.005

† Excludes equivocal test results and missing values.

Table 91 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	76	9 (12)	99	29 (29)	175	38 (22)
Indigenous	3	0 (0)	22	9 (41)	25	9 (36)
p value		0.5		0.3		0.1
2007						
Non-Indigenous	75	8 (11)	75	27 (36)	150	35 (23)
Indigenous	10	4 (40)	32	15 (47)	42	19 (45)
p value		0.01		0.3		0.005

† Excludes equivocal test results and missing values.

Table 92 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	167	39 (23)	21	6 (29)	188	45 (24)
Moderately accessible	3	0 (0)	--	--	3	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.5		--		0.5
2007						
Highly accessible/accessible	152	40 (26)	31	9 (29)	183	49 (27)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.6		0.5		0.4

† Excludes equivocal test results and missing values.

Table 93 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	138	32 (23)	19	4 (21)	157	36 (23)
Other Oceania	7	3 (43)	--	--	7	3 (43)
Asia	11	4 (36)	2	2 (100)	13	6 (46)
UK & Ireland	5	1 (20)	--	--	5	1 (20)
Other	18	1 (6)	--	--	18	1 (6)
p value		0.2		0.02		0.08
2007						
Australia	128	35 (27)	33	6 (18)	161	41 (25)
Other Oceania	8	3 (38)	1	1 (100)	9	4 (44)
Asia	14	3 (21)	2	1 (50)	16	4 (25)
UK & Ireland	--	--	--	--	--	--
Other	9	3 (33)	2	2 (100)	11	5 (45)
p value		0.8		0.02		0.4

† Excludes equivocal test results and missing values.

Table 94 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	146	32 (22)	18	4 (22)	164	36 (22)
Non-English speaking	33	9 (27)	3	2 (67)	36	11 (31)
p value		0.5		0.1		0.3
2007						
English speaking	122	34 (28)	33	7 (21)	155	41 (26)
Non-English speaking	39	10 (26)	5	3 (60)	44	13 (30)
p value		0.8		0.07		0.7

† Excludes equivocal test results and missing values.

Table 95 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	124	60 (40)	33 (27)	6 (5)	25 (20)
Non-IDU	80	62 (78)	9 (11)	0 (0)	9 (11)
p value					<0.001
2007					
IDU	112	36 (32)	39 (35)	3 (3)	34 (30)
Non-IDU	86	53 (62)	9 (10)	3 (3)	21 (24)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 96 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	198	119 (60)	41 (21)	6 (3)	32 (16)
Bisexual	3	1 (33)	1 (33)	0 (0)	1 (33)
Homosexual	3	2 (37)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					0.9
2007					
Heterosexual	185	85 (46)	47 (25)	5 (3)	185 (100)
Homosexual	4	1 (25)	0 (0)	0 (0)	4 (100)
Bisexual	4	1 (25)	0 (0)	1 (25)	4 (100)
Unsure	--	--	--	--	--
p value					0.4

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 97 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	14	11 (79)	0 (0)	0 (0)	3 (21)
20 – 24	46	27 (59)	8 (17)	2 (4)	9 (20)
25 – 29	44	29 (66)	7 (16)	1 (2)	7 (16)
30 + years	100	55 (55)	27 (27)	3 (3)	15 (15)
p value					0.5
2007					
< 20 years	9	7 (78)	0 (0)	0 (0)	2 (22)
20 – 24	38	21 (55)	4 (11)	1 (3)	12 (32)
25 – 29	41	14 (34)	8 (20)	1 (2)	18 (44)
30 + years	109	46 (42)	36 (33)	4 (4)	23 (21)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 98 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	67	52 (78)	6 (9)	1 (1)	8 (12)
2 to 4	83	46 (55)	17 (20)	4 (4)	16 (19)
5 to 9	35	14 (40)	14 (40)	0 (0)	7 (20)
10 +	16	8 (50)	5 (31)	1 (6)	2 (13)
p value					<0.01
2007					
1	53	37 (70)	6 (11)	1 (2)	9 (17)
2 to 4	81	41 (51)	18 (22)	3 (4)	19 (23)
5 to 9	31	2 (6)	11 (35)	2 (6)	16 (52)
10 +	26	6 (23)	11 (42)	0 (0)	9 (35)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 99 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	179	112 (63)	35 (20)	4 (2)	28 (16)
Indigenous	25	10 (40)	7 (28)	2 (8)	6 (24)
p value					0.1
2007					
Non-Indigenous	149	76 (51)	32 (21)	3 (2)	38 (26)
Indigenous	42	10 (24)	16 (38)	3 (7)	13 (31)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 100 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	192	115 (60)	40 (21)	6 (3)	31 (16)
Moderately accessible	3	2 (67)	0 (0)	0 (0)	1 (33)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.4
2007					
Highly accessible/accessible	182	84 (46)	43 (24)	6 (3)	49 (27)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 101 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	164	98 (60)	33 (20)	3 (2)	30 (18)
Non-English	40	24 (60)	9 (23)	3 (8)	4 (10)
p value					0.2
2007					
English	154	74 (48)	38 (25)	3 (2)	39 (25)
Non-English	44	15 (34)	10 (23)	3 (7)	16 (36)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 102 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	56	5 (9)	3	1 (33)	59	6 (10)
Yes	50	19 (38)	10	4 (40)	60	23 (38)
Not sure	34	4 (12)	2	1 (50)	36	5 (14)
p value		<0.001		0.9		<0.001
2007						
No	49	8 (16)	13	3 (23)	62	11 (18)
Yes	54	30 (56)	13	9 (69)	67	39 (58)
Not sure	12	4 (33)	--	--	12	4 (33)
p value		<0.001		0.02		<0.001

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded. Yes to self-reported immunisation includes any immunisation against HBV.

Queensland 2004 & 2007

Table 103 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 1		N = 1	
N° surveyed	N = 82	N = 58	N = 91	N = 66
Sex (%)				
Male	80 (100)	58 (100)	91 (100)	66 (100)
Female	--	--	--	--
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	81 (99)	56 (97)	90 (99)	66 (100)
Bisexual	1 (1)	2 (3)	--	--
Homosexual	--	--	--	--
Unsure	--	--	--	--
Not reported	--	--	1 (1)	--
Age and duration of injection (years)				
Median age (years)	29	36	29	27
Age range	17 – 53	17 – 67	18 – 47	17 – 63
Age group (%)				
<25 years	28 (34)	12 (21)	21 (23)	29 (44)
25+ years	54 (64)	46 (79)	70 (77)	37 (56)
Not reported				
Median age 1 st IDU (years)	17	--	17	--
Age range	11 – 38	--	11 – 34	--
No. not reported			5	--
Median years IDU	9	--	10	--
Range	<1 – 28	--	<1 – 33	--
Duration of drug injection (%)				
<3 years	9 (11)	--	6 (7)	--
3+ years	73 (89)	--	80 (88)	--
Not reported			5 (5)	--
Aboriginal and Torres Strait Islander origin (%)				
No	74 (90)	52 (90)	77 (85)	57 (86)
Yes	8 (10)	6 (10)	14 (15)	9 (14)
Not reported	--	--	--	--
Residential remoteness in 12 months before prison				
Highly accessible/accessible	80 (98)	52 (90)	82 (90)	60 (91)
Moderately accessible	--	1 (2)	1 (1)	2 (3)
Remote/very remote	2 (2)	2 (3)	2 (2)	1 (2)
Not reported	--	3 (5)	6 (7)	3 (5)
Region/Country of birth (%)				
Australia	71 (87)	40 (69)	83 (91)	61 (92)
Other Oceania	8 (10)	8 (14)	1 (1)	1 (2)
Asia	2 (2)	2 (3)	6 (7)	1 (2)
UK & Ireland	1 (1)	3 (5)	--	--
Other	--	5 (9)	--	3 (5)
Not reported	--	--	1 (1)	--
Main language spoke at home by parents (%)				
English speaking	79 (96)	52 (90)	86 (95)	63 (95)
Non-English speaking	3 (4)	6 (10)	5 (5)	3 (5)
Not reported			--	--
First time in prison (%)				
No	81 (99)	53 (91)	80 (88)	33 (50)
Yes	1 (1)	5 (9)	11 (12)	32 (48)
Not reported	--	--	--	1 (2)
Lifetime imprisonments (%)				
One	1 (1)	5 (9)	11 (12)	32 (48)
Two to four	57 (70)	47 (81)	48 (53)	25 (38)
Five to nine	19 (23)	4 (7)	20 (22)	3 (5)
Ten or more	5 (6)	1 (2)	10 (11)	4 (6)
Not reported	--	1 (2)	2 (2)	2 (3)

Table 103 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	2 (2)	5 (9)	32 (40)	11 (32)
Yes	80 (98)	53 (91)	46 (58)	22 (65)
Not reported	--	--	2 (3)	1 (3)
Frequency of injection last month (%)				
Not last month	32 (39)	--	44 (48)	--
Less than weekly	6 (7)	--	10 (11)	--
Weekly not daily	7 (9)	--	6 (7)	--
Daily or more	37 (45)	--	28 (31)	--
Not reported			3 (3)	--
Ever smoked full cigarette (%)*				
No	--	--	5 (5)	14 (21)
Yes	--	--	86 (95)	52 (79)
Not reported	--	--	--	--
Median age first smoked (years)	--	--	14	14
Age range	--	--	6 – 25	6 – 22
Current smoker (%)*				
No	--	--	5 (6)	14 (21)
Yes	--	--	86 (95)	52 (79)
Not reported			--	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	5 (6)	4 (8)
5 to 10 cigarettes a day	--	--	19 (22)	11 (21)
11 to 20 cigarettes a day	--	--	28 (33)	15 (29)
Over 20 cigarettes a day	--	--	34 (40)	21 (40)
Not reported	--	--	--	1 (2)

* Smoking questions were not asked in 2004 survey.

Table 104 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)	N = 82	N = 91
Amphetamine (Speed, Ice)	59 (72)	57 (63)
Anabolic steroids	--	--
Cocaine	--	1 (1)
Heroin	20 (24)	20 (22)
Heroin + amphetamine	--	2 (2)
Heroin + Cocaine	--	--
Methadone	1 (1)	2 (2)
Morphine	2 (2)	4 (4)
Other	--	4 (4)
Not reported	--	1 (1)
N° Injected last month	N = 50	N = 44
Places injected last month (%)**		
Prison	3 (6)	1 (2)
Own home	45 (90)	39 (89)
Friend's home	37 (74)	27 (61)
Dealer's home	23 (46)	19 (43)
Street, park, beach	25 (50)	20 (45)
Car	31 (62)	21 (48)
Public toilet	21 (42)	16 (36)
Commercial injecting room	2 (4)	--
MSIC*	4 (8)	--
Squat	9 (18)	1 (2)
Other place	--	1 (2)
Use of sterile needles & syringes last month (%)		
All injections	37 (74)	28 (64)
Most of the time	8 (16)	9 (20)
Half of the time	4 (8)	4 (9)
Some of the time	1 (2)	3 (7)
Not last month	--	--
Not reported	--	--
Re-used someone else's used needle & syringe last month (%)		
None	39 (78)	33 (75)
Once	1 (2)	2 (5)
Twice	4 (8)	3 (7)
3-5 times	2 (4)	3 (7)
>5 times	4 (8)	3 (7)
Not reported	--	--
Number of people needle & syringe was re-used after last month (%)		
None	39 (78)	33 (75)
One	8 (16)	5 (11)
Two	2 (4)	1 (2)
Three to five	1 (2)	2 (5)
More than five	--	--
Don't know	--	3 (7)
Not reported	--	--
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	8 (16)	6 (14)
Casual sex partner	1 (2)	1 (2)
Close friend	2 (4)	5 (11)
Acquaintance	1 (2)	1 (2)
Other	1 (2)	--
Equipment used after someone else last month (%)**		
Spoon	11 (22)	20 (46)
Water	42 (84)	18 (41)
Filter	42 (84)	19 (43)
Tourniquet	2 (4)	10 (23)
Drug mix	7 (14)	18 (41)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 105 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66
Any treatment/therapy for drug use (%)				
No	50 (61)	55 (95)	48 (53)	9 (14)
Yes	32 (38)	2 (3)	24 (26)	--
Not reported	--	1 (2)	19 (21)	57 (86)
History of methadone maintenance treatment (%)				
Currently	3 (4)	2 (3)	2 (2)	--
Previously	17 (21)	--	9 (10)	--
Never	62 (76)	56 (97)	62 (68)	--
Not reported	--	--	18 (20)	--
History of other pharmacotherapy treatment (%)				
Currently	66 (80)	56 (97)	7 (8)	--
Previously	4 (5)	2 (3)	9 (10)	--
Never	12 (15)	--	64 (70)	--
Not reported	--	--	11 (12)	--

Table 106 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	N = 50	N = 44
From an NSP last month (%)		
Daily or almost daily	11 (22)	4 (9)
A couple of times each week	10 (20)	7 (16)
Less than weekly	8 (16)	8 (18)
Once last month	10 (20)	3 (7)
Not in the last month	11 (22)	6 (14)
Not reported	--	16 (36)
From a chemist last month (%)		
Daily or almost daily	4 (8)	5 (11)
A couple of times each week	12 (24)	2 (5)
Less than weekly	12 (24)	12 (27)
Once last month	7 (14)	5 (11)
Not in the last month	15 (30)	4 (9)
Not reported	--	16 (36)

Table 107 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66
Sex last month (%)				
No	13 (16)	15 (26)	26 (29)	20 (30)
Yes	69 (84)	43 (74)	64 (70)	46 (70)
Not reported	--	--	1 (1)	--
Condom use at last sex (%)				
No	66 (80)	44 (76)	69 (76)	45 (68)
Yes	16 (20)	14 (24)	21 (23)	21 (32)
Not reported	--	--	1 (1)	--
Condom use with regular sex partner(s) last month (%)*				
No	47 (94)	29 (81)	33 (75)	29 (85)
Sometimes	3 (6)	2 (6)	4 (9)	4 (12)
Always	--	5 (14)	7 (16)	1 (3)
Condom use with new sex partner(s) last month (%)*				
No	8 (100)	2 (100)	1 (100)	--
Sometimes	--	--	--	1 (50)
Always	--	--	--	1 (50)
Condom use with casual sex partner(s) last month (%)*				
No	10 (50)	3 (33)	17 (85)	5 (42)
Sometimes	2 (10)	--	1 (5)	4 (33)
Always	8 (40)	6 (67)	2 (10)	3 (25)
Sex work last month (%)				
No	81 (99)	57 (98)	90 (99)	66 (100)
Yes	--	1 (2)	--	--
Not reported	1 (1)	--	1 (1)	--
Condom used at last sex work last month (%)				
No	--	--	--	--
Yes	--	1 (100)	--	--
Not reported	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 108 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66
Previous HIV test (%)				
Yes, last year	33 (40)	10 (17)	59 (65)	26 (39)
>1 year ago	33 (40)	26 (45)	24 (26)	25 (38)
Never tested	16 (20)	22 (38)	7 (8)	15 (23)
Not reported	--	--	1 (1)	--
HBV infection (%)				
No	76 (93)	56 (97)	88 (97)	61 (92)
Yes	6 (7)	1 (2)	2 (2)	--
Don't know	--	1 (2)	1 (1)	1 (2)
Not reported	--	--	--	4 (6)
HBV vaccination (%)*				
No	13 (16)	27 (47)	14 (15)	17 (26)
Yes	69 (84)	31 (53)	72 (79)	42 (64)
Don't know	--	--	5 (5)	7 (11)
Not reported	--	--	--	--
Previous HCV test (%)				
Yes, last year	30 (37)	9 (16)	6 (7)	15 (23)
>1 year ago	43 (52)	21 (36)	60 (66)	28 (42)
Never tested	9 (11)	28 (48)	25 (27)	23 (35)
Not reported	--	--	--	--
Any HCV treatment (%)**	N = 36	N = 2	N = 41	N = 2
Interferon	--	--	1 (2)	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--
No treatment	36 (100)	2 (100)	40 (98)	2 (100)
Not reported	--	--	--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 109 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	77	0 (0)	--	--	77	0 (0)
Non-IDU	53	1 (2)	--	--	53	1 (2)
P value		0.2		--		0.2
2007						
IDU	77	1 (1)	--	--	77	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
P value		0.4		--		0.4

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 110 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
IDU	75	36 (48)	--	--	75	36 (48)
Non-IDU	54	2 (4)	--	--	54	2 (4)
p value		<0.001		--		<0.001
2007						
IDU	77	41 (53)	--	--	77	41 (53)
Non-IDU	58	2 (3)	--	--	58	2 (3)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 111 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	127	38 (30)	--	--	127	38 (30)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.4		--		0.4
2007						
Heterosexual	134	42 (31)	--	--	134	42 (31)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 112 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	27	6 (22)	--	--	27	6 (22)
25 – 29	24	11 (46)	--	--	24	11 (46)
30 + years	67	21 (31)	--	--	67	21 (31)
p value		0.04		--		0.04
2007						
< 20 years	13	1 (8)	--	--	13	1 (8)
20 – 24	32	10 (31)	--	--	32	10 (31)
25 – 29	36	13 (36)	--	--	36	13 (36)
30 + years	54	19 (35)	--	--	54	19 (35)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 113 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	8	0 (0)	--	--	8	0 (0)
3 to 5 years	9	1 (11)	--	--	9	1 (11)
6 to 10 years	22	10 (45)	--	--	22	10 (45)
10 + years	36	25 (69)	--	--	36	25 (69)
p value		<0.001		--		<0.001
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	5 (50)	--	--	10	5 (50)
6 to 10 years	23	9 (39)	--	--	23	9 (39)
10 + years	34	22 (65)	--	--	34	22 (65)
p value		0.1		--		0.1

† Excludes equivocal test results and missing values.

Table 114 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	46	20 (43)	54	20 (37)
Heroin	--	--	19	15 (79)	19	15 (79)
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.03		0.007
2007						
Amphetamine (Speed, Ice)	4	0 (0)	46	19 (41)	50	19 (38)
Heroin	1	1 (100)	13	10 (77)	14	1 (79)
More than one	--	--	2	2 (100)	2	2 (100)
Other/not reported	--	--	6	5 (83)	6	5 (83)
p value		0.03		0.02		0.002

† Excludes equivocal test results and missing values.

Table 115 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	2	0 (0)	9	7 (78)	11	7 (64)
Daily or more	3	0 (0)	30	18 (60)	33	18 (55)
p value		--		0.09		0.6
2007						
Less than daily	1	0 (0)	13	6 (46)	14	6 (43)
Daily or more	1	1 (100)	21	15 (71)	22	16 (73)
p value		0.2		0.1		0.07

† Excludes equivocal test results and missing values.

Table 116 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	5	0 (0)	28	16 (57)	33	16 (48)
Yes	0	0 (0)	11	9 (82)	11	9 (82)
p value		--		0.1		0.05
2007						
No	2	1 (50)	25	12 (48)	27	13 (48)
Yes	--	--	7	7 (100)	7	7 (100)
p value		--		0.01		0.005

† Excludes equivocal test results and missing values.

Table 117 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	1	1(100)	1	1(100)
Yes	8	0 (0)	66	35 (53)	74	35 (47)
p value		--		0.4		0.3
2007						
No	2	0 (0)	24	9 (38)	26	9 (35)
Yes	2	1 (50)	33	26 (79)	35	27 (77)
p value		0.2		0.002		0.001

† Excludes equivocal test results and missing values.

Table 118 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	5	1 (20)	--	--	5	1 (20)
2 to 4	97	24 (25)	--	--	97	24 (25)
5 to 9	20	10 (50)	--	--	20	10 (50)
10 +	6	3 (50)	--	--	6	3 (50)
p value		0.09		--		0.09
2007						
1	40	0 (0)	--	--	40	0 (0)
2 to 4	64	22 (34)	--	--	64	22 (34)
5 to 9	17	11 (65)	--	--	17	11 (65)
10 +	12	9 (75)	--	--	12	9 (75)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 119 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	115	34 (30)	--	--	115	34 (30)
Indigenous	14	4 (29)	--	--	14	4 (29)
p value		0.9		--		0.9
2007						
Non-Indigenous	116	36 (31)	--	--	116	36 (31)
Indigenous	19	7 (37)	--	--	19	7 (37)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 120 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	48	2 (4)	67	32 (48)	115	34 (30)
Indigenous	6	0 (0)	8	4 (50)	14	4 (29)
p value		0.6		0.9		0.9
2007						
Non-Indigenous	50	1 (2)	66	35 (53)	116	36 (31)
Indigenous	8	1 (13)	11	6 (55)	19	7 (37)
p value		0.1		0.9		0.6

† Excludes equivocal test results and missing values.

Table 121 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	123	37 (30)	--	--	123	37 (30)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Highly accessible/accessible	123	40 (33)	--	--	123	40 (33)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	0 (0)	--	--	3	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 122 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	104	34 (33)	--	--	104	34 (33)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.1		--		0.1
2007						
Australia	124	38 (31)	--	--	124	38 (31)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	4 (67)	--	--	6	4 (67)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 123 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	121	36 (30)	--	--	121	36 (30)
Non-English speaking	8	2 (25)	--	--	8	2 (25)
p value		0.8		--		0.8
2007						
English speaking	128	40 (31)	--	--	128	40 (31)
Non-English speaking	7	3 (43)	--	--	7	3 (43)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 124 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	29	29 (100)	--	--	29	29 (100)
Negative	61	5 (8)	--	--	61	5 (8)
Not sure	4	2 (50)	--	--	4	2 (50)
p value		<0.001		--		<0.001
2007						
Positive	30	27 (90)	--	--	30	27 (90)
Negative	80	11 (14)	--	--	80	11 (14)
Not sure	7	4 (57)	--	--	7	4 (57)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 125 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	77	3 (4)	--	--	77	3 (4)
Non-IDU	54	0 (0)	--	--	54	0 (0)
p value		0.1		--		0.1
2007						
IDU	78	1 (1)	--	--	78	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 126 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	74	12 (16)	--	--	74	12 (16)
Non-IDU	54	5 (9)	--	--	54	5 (9)
p value		0.3		--		0.3
2007						
IDU	78	8 (10)	--	--	78	8 (10)
Non-IDU	59	4 (7)	--	--	59	4 (7)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 127 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	126	17 (13)	--	--	126	17 (13)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6
2007						
Heterosexual	136	12 (9)	--	--	136	12 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 128 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	12	1 (8)	--	--	12	1 (8)
20 – 24	26	1 (4)	--	--	26	1 (4)
25 – 29	24	3 (13)	--	--	24	3 (13)
30 + years	66	12 (18)	--	--	66	12 (18)
p value		0.3		--		0.3
2007						
< 20 years	13	2 (15)	--	--	13	2 (15)
20 – 24	33	1 (3)	--	--	33	1 (3)
25 – 29	36	4 (11)	--	--	36	4 (11)
30 + years	55	5 (9)	--	--	55	5 (9)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 129 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	9	0 (0)	--	--	9	0 (0)
6 to 10 years	22	2 (9)	--	--	22	2 (9)
10 + years	34	9 (26)	--	--	34	9 (26)
p value		0.1		--		0.1
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	0 (0)	--	--	10	0 (0)
6 to 10 years	23	2 (9)	--	--	23	2 (9)
10 + years	35	3 (9)	--	--	35	3 (9)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 130 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	9	1 (11)	46	7 (15)	55	8 (15)
Heroin	--	--	17	4 (24)	17	4 (24)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	--	--	--	--
p value		--		0.6		0.6
2007						
Amphetamine (Speed, Ice)	4	1 (25)	47	4 (9)	51	5 (10)
Heroin	1	0 (0)	13	0 (0)	14	0 (0)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	6	1 (17)	6	1 (17)
p value		0.6		0.6		0.5

† Excludes equivocal test results and missing values.

Table 131 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	2	0 (0)	9	5 (56)	11	5 (45)
Daily or more	4	0 (0)	29	4 (14)	33	4 (12)
p value		--		0.01		0.01
2007						
Less than daily	1	0 (0)	13	2 (15)	14	2 (14)
Daily or more	1	0 (0)	21	1 (5)	22	1 (5)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 132 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	27	6 (22)	33	6 (18)
Yes	0	0 (0)	11	3 (27)	11	3 (27)
p value		--		0.7		0.5
2007						
No	2	0 (0)	25	3 (12)	27	3 (11)
Yes	--	--	7	0 (0)	7	0 (0)
p value		--		0.3		0.4

† Excludes equivocal test results and missing values.

Table 133 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	1	1(100)	1	1(100)
Yes	9	1 (11)	64	11 (17)	73	12 (16)
p value		--		0.7		0.4
2007						
No	2	1 (50)	25	3 (12)	27	4 (15)
Yes	2	0 (0)	33	2 (6)	35	2 (6)
p value		0.3		0.4		0.2

† Excludes equivocal test results and missing values.

Table 134 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	5	0 (0)	--	--	5	0 (0)
2 to 4	96	12 (13)	--	--	96	12 (13)
5 to 9	20	4 (20)	--	--	20	4 (20)
10 +	6	1 (17)	--	--	6	1 (17)
p value		0.7		--		0.7
2007						
1	40	2 (5)	--	--	40	2 (5)
2 to 4	66	10 (15)	--	--	66	10 (15)
5 to 9	17	0 (0)	--	--	17	0 (0)
10 +	12	0 (0)	--	--	12	0 (0)
p value		0.08		--		0.08

† Excludes equivocal test results and missing values.

Table 135 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	114	15 (13)	--	--	114	15 (13)
Indigenous	14	2 (14)	--	--	14	2 (14)
p value		0.9		--		0.9
2007						
Non-Indigenous	117	7 (6)	--	--	117	7 (6)
Indigenous	20	5 (25)	--	--	20	5 (25)
p value		0.005		--		0.005

† Excludes equivocal test results and missing values.

Table 136 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	48	5 (10)	66	10 (15)	114	15 (13)
Indigenous	6	0 (0)	8	2 (25)	14	2 (14)
p value		0.7		0.5		0.9
2007						
Non-Indigenous	50	1 (2)	67	6 (9)	117	7 (6)
Indigenous	9	3 (33)	11	2 (18)	20	5 (25)
p value		0.001		0.4		0.005

† Excludes equivocal test results and missing values.

Table 137 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	122	15 (12)	--	--	122	15 (12)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	2 (67)	--	--	3	2 (67)
p value		0.02		--		0.02
2007						
Highly accessible/accessible	125	9 (7)	--	--	125	9 (7)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 138 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	103	12 (12)	--	--	103	12 (12)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.07		--		0.07
2007						
Australia	126	11 (9)	--	--	126	11 (9)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	0 (0)	--	--	6	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 139 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	120	14 (12)	--	--	120	14 (12)
Non-English speaking	8	3 (38)	--	--	8	3 (38)
p value		0.04		--		0.04
2007						
English speaking	130	11 (8)	--	--	130	11 (8)
Non-English speaking	7	1 (14)	--	--	7	1 (14)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 140 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	77	29 (38)	10 (13)	3 (4)	35 (45)
Non-IDU	54	35 (65)	5 (9)	0 (0)	14 (26)
p value					0.02
2007					
IDU	78	30 (38)	8 (10)	1 (1)	39 (50)
Non-IDU	59	38 (64)	4 (7)	0 (0)	17 (29)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 141 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	129	62 (48)	15 (12)	3 (2)	49 (38)
Bisexual	2	2 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	136	68 (50)	12 (9)	0 (0)	56 (41)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 142 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	12	5 (42)	0 (0)	1 (8)	6 (50)
20 – 24	28	12 (43)	2 (7)	0 (0)	14 (50)
25 – 29	24	9 (38)	2 (8)	1 (4)	12 (50)
30 + years	67	38 (57)	11 (16)	1 (1)	17 (25)
p value					0.1
2007					
< 20 years	13	8 (62)	2 (15)	0 (0)	3 (23)
20 – 24	33	11 (33)	1 (3)	0 (0)	21 (64)
25 – 29	36	18 (50)	4 (11)	0 (0)	14 (39)
30 + years	55	31 (53)	5 (9)	1 (2)	18 (33)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 143 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	5	4 (80)	0 (0)	0 (0)	1 (20)
2 to 4	98	50 (51)	12 (12)	2 (2)	34 (35)
5 to 9	21	6 (29)	3 (14)	0 (0)	12 (57)
10 +	6	3 (50)	0 (0)	1 (17)	2 (33)
p value					0.2
2007					
1	40	31 (78)	2 (5)	0 (0)	7 (18)
2 to 4	66	26 (39)	10 (15)	1 (2)	29 (44)
5 to 9	17	7 (41)	0 (0)	0 (0)	10 (59)
10 +	12	3 (25)	0 (0)	0 (0)	9 (75)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 144 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	117	60 (51)	13 (11)	3 (3)	41 (35)
Indigenous	14	4 (29)	2 (14)	0 (0)	8 (57)
p value					0.3
2007					
Non-Indigenous	117	61 (52)	7 (6)	0 (0)	49 (42)
Indigenous	20	7 (35)	5 (25)	1 (5)	7 (35)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 145 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	125	62 (50)	13 (10)	3 (2)	47 (38)
Moderately accessible	1	1 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.1
2007					
Highly accessible/accessible	125	61 (49)	9 (7)	1 (1)	54 (43)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	1 (33)	1 (33)	0 (0)	1 (33)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 146 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	123	62 (50)	13 (11)	2 (2)	46 (37)
Non-English	8	2 (25)	2 (25)	1 (13)	3 (38)
p value					0.1
2007					
English	130	65 (50)	11 (8)	1 (1)	53 (42)
Non-English	7	3 (43)	1 (14)	0 (0)	3 (43)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 147 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	32	4 (13)	--	--	32	4 (13)
Yes	81	45 (56)	--	--	81	45 (56)
Not sure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
No	26	3 (12)	--	--	26	3 (12)
Yes	88	52 (59)	--	--	88	52 (59)
Not sure	10	1 (10)	--	--	10	1 (10)
p value		<0.001		--		<0.001

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded. Yes to self-reported immunisation includes any immunisation against HBV.

Tasmania
2004 & 2007

Table 148 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 2		N = 3	
N° surveyed	N = 26	N = 15	N = 22	N = 24
Sex (%)				
Male	22 (85)	14 (93)	19 (86)	21 (88)
Female	4 (15)	1 (7)	3 (14)	3 (13)
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	25 (96)	15 (100)	21 (95)	23 (96)
Bisexual	1 (4)	--	--	1 (4)
Homosexual	--	--	1 (5)	--
Unsure	--	--	--	--
Not reported	--	--	--	--
Age and duration of injection (years)				
Median age (years)	25	42	32	26
Age range	21 – 48	17 – 64	21 – 45	19 – 58
Age group (%)				
<25 years	2 (8)	3 (20)	1 (5)	11 (46)
25+ years	24 (92)	12 (80)	21 (95)	13 (54)
Not reported				
Median age 1 st IDU (years)	20	--	19	--
Age range	14 – 30	--	12 – 40	--
No. not reported	--	--	--	--
Median years IDU	10	--	10	--
Range	1 – 32	--	<1 – 27	--
Duration of drug injection (%)				
<3 years	1 (4)	--	1 (5)	--
3+ years	23 (88)	--	21 (95)	--
Not reported	2 (8)	--	--	--
Aboriginal and Torres Strait Islander origin (%)				
No	16 (62)	9 (60)	18 (82)	20 (83)
Yes	2 (8)	4 (27)	4 (18)	4 (17)
Not reported	8 (31)	2 (13)	--	--
Residential remoteness in 12 months before prison				
Highly accessible/accessible	20 (77)	11 (73)	13 (59)	18 (75)
Moderately accessible	2 (8)	1 (7)	6 (27)	4 (17)
Remote/very remote	--	2 (13)	3 (14)	2 (8)
Not reported	4 (15)	1 (7)	--	--
Region/Country of birth (%)				
Australia	26 (100)	13 (87)	22 (100)	23 (96)
Other Oceania	--	--	--	--
Asia	--	--	--	--
UK & Ireland	--	--	--	--
Other	--	--	--	1 (4)
Not reported	--	2 (13)	--	--
Main language spoke at home by parents (%)				
English speaking	26 (100)	13 (87)	22 (100)	23 (96)
Non-English speaking	--	--	--	1 (4)
Not reported	--	2 (13)	--	--
First time in prison (%)				
No	17 (65)	10 (67)	19 (86)	12 (50)
Yes	9 (35)	5 (33)	3 (14)	12 (50)
Not reported	--	--	--	--
Lifetime imprisonments (%)				
One	9 (35)	5 (33)	3 (14)	12 (50)
Two to four	8 (31)	5 (33)	10 (45)	9 (38)
Five to nine	6 (23)	1 (7)	6 (27)	3 (13)
Ten or more	2 (8)	--	2 (9)	--
Not reported	1 (4)	4 (27)	1 (5)	--

Table 148 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	12 (46)	7 (47)	5 (26)	5 (42)
Yes	11 (42)	4 (27)	13 (68)	7 (58)
Not reported	3 (12)	4 (27)	1 (5)	--
Frequency of injection last month (%)				
Not last month	12 (46)	--	6 (27)	--
Less than weekly	2 (8)	--	4 (18)	--
Weekly not daily	6 (23)	--	4 (18)	--
Daily or more	5 (19)	--	8 (36)	--
Not reported	1 (4)	--	--	--
Ever smoked full cigarette (%)*				
No	--	--	--	1 (4)
Yes	--	--	22 (100)	23 (96)
Not reported	--	--	--	--
Median age first smoked (years)	--	--	14	14
Age range	--	--	7 – 36	6 – 17
Current smoker (%)*				
No	--	--	1 (5)	4 (17)
Yes	--	--	21 (95)	20 (83)
Not reported	--	--	--	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	--	1 (5)
5 to 10 cigarettes a day	--	--	4 (19)	3 (15)
11 to 20 cigarettes a day	--	--	8 (38)	9 (45)
Over 20 cigarettes a day	--	--	9 (43)	7 (35)
Not reported	--	--	--	--

* Smoking questions were not asked in 2004 survey.

Table 149 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)	N = 26	N = 22
Amphetamine (Speed, Ice)	20 (77)	16 (73)
Anabolic steroids	--	--
Cocaine	--	--
Heroin	2 (8)	1 (5)
Heroin + amphetamine	--	--
Heroin + Cocaine	--	--
Methadone	--	--
Morphine	3 (12)	4 (18)
Other	1 (4)	1 (5)
Not reported	--	--
N° Injected last month	N = 14	N = 16
Places injected last month (%)**		
Prison	1 (8)	1 (6)
Own home	11 (79)	15 (94)
Friend's home	7 (50)	13 (81)
Dealer's home	2 (14)	4 (25)
Street, park, beach	2 (14)	3 (19)
Car	7 (50)	10 (63)
Public toilet	4 (29)	4 (25)
Commercial injecting room	--	--
MSIC*	--	--
Squat	--	--
Other place	--	--
Use of sterile needles & syringes last month (%)		
All injections	12 (86)	13 (81)
Most of the time	1 (7)	2 (13)
Half of the time	1 (7)	--
Some of the time	--	--
Not last month	--	--
Not reported	--	1 (6)
Re-used someone else's used needle & syringe last month (%)		
None	12 (86)	14 (88)
Once	1 (7)	1 (6)
Twice	1 (7)	--
3-5 times	--	1 (6)
>5 times	--	--
Not reported	--	--
Number of people needle & syringe was re-used after last month (%)		
None	12 (86)	14 (88)
One	1 (7)	1 (6)
Two	--	--
Three to five	--	--
More than five	--	--
Don't know	--	1 (6)
Not reported	1 (7)	--
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	1 (7)	2 (13)
Casual sex partner	--	--
Close friend	--	--
Acquaintance	1 (7)	--
Other	--	--
Equipment used after someone else last month (%)**		
Spoon	1 (7)	3 (19)
Water	4 (29)	2 (13)
Filter	2 (14)	1 (6)
Tourniquet	1 (7)	--
Drug mix	1 (7)	2 (13)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 150 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24
Any treatment/therapy for drug use (%)				
No	10 (38)	14 (93)	9 (41)	16 (67)
Yes	16 (62)	--	13 (59)	4 (17)
Not reported	--	1 (7)	--	4 (17)
History of methadone maintenance treatment (%)				
Currently	3 (12)	--	3 (14)	--
Previously	6 (23)	--	2 (9)	--
Never	16 (62)	14 (93)	17 (77)	--
Not reported	1 (4)	1 (7)	--	--
History of other pharmacotherapy treatment (%)				
Currently	2 (8)	--	--	--
Previously	2 (8)	--	5 (23)	--
Never	21 (81)	14 (93)	17 (77)	--
Not reported	1 (4)	1 (7)	--	--

Table 151 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	N = 14	N = 16
From an NSP last month (%)		
Daily or almost daily	--	1 (6)
A couple of times each week	2 (14)	5 (31)
Less than weekly	4 (29)	1 (6)
Once last month	--	1 (6)
Not in the last month	--	1 (6)
Not reported	8 (57)	7 (44)
From a chemist last month (%)		
Daily or almost daily	2 (14)	--
A couple of times each week	1 (7)	3 (19)
Less than weekly	1 (7)	3 (19)
Once last month	6 (43)	--
Not in the last month	4 (29)	2 (13)
Not reported	--	8 (50)

Table 152 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24
Sex last month (%)				
No	9 (35)	8 (53)	6 (27)	3 (13)
Yes	17 (65)	7 (47)	16 (73)	21 (88)
Not reported	--	--	--	--
Condom use at last sex (%)				
No	22 (85)	10 (67)	19 (86)	23 (96)
Yes	4 (15)	5 (33)	3 (14)	1 (4)
Not reported	--	--	--	--
Condom use with regular sex partner(s) last month (%)*				
No	9 (90)	4 (57)	10 (91)	13 (76)
Sometimes	1 (10)	1 (14)	1 (9)	4 (24)
Always	--	2 (29)	--	--
Condom use with new sex partner(s) last month (%)*				
No	1 (50)	--	2 (100)	1 (100)
Sometimes	1 (50)	--	--	--
Always	--	--	--	--
Condom use with casual sex partner(s) last month (%)*				
No	5 (71)	--	4 (100)	3 (60)
Sometimes	2 (29)	--	--	--
Always	--	--	--	2 (40)
Sex work last month (%)				
No	25 (96)	15 (100)	21 (95)	24 (100)
Yes	1 (4)	--	1 (5)	--
Not reported	--	--	--	--
Condom used at last sex work last month (%)				
No	--	--	1 (100)	--
Yes	1 (100)	--	--	--
Not reported	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 153 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24
Previous HIV test (%)				
Yes, last year	13 (50)	5 (22)	3 (14)	11 (46)
>1 year ago	8 (31)	4 (27)	7 (32)	5 (21)
Never tested	5 (19)	5 (33)	12 (55)	8 (33)
Not reported	--	1 (7)	--	--
HBV infection (%)				
No	19 (73)	14 (93)	20 (91)	23 (96)
Yes	6 (23)	--	--	1 (4)
Don't know	1 (4)	1 (7)	2 (9)	--
Not reported			--	--
HBV vaccination (%)*				
No	12 (46)	11 (73)	9 (41)	10 (42)
Yes	11 (42)	4 (27)	12 (55)	10 (42)
Don't know	6 (23)	--	1 (5)	4 (17)
Not reported			--	--
Previous HCV test (%)				
Yes, last year	9 (35)	4 (27)	5 (23)	11 (46)
>1 year ago	11 (42)	3 (20)	7 (32)	7 (29)
Never tested	6 (23)	8 (53)	10 (45)	6 (25)
Not reported			--	--
Any HCV treatment (%)**	N = 12	N = 1	N = 7	N = 1
Interferon	--	--	--	--
Interferon & Ribavirin	--	1 (100)	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--
No treatment	12 (100)	--	7 (100)	1 (100)
Not reported	--	--	--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 154 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	15	0 (0)	2	0 (0)	17	0 (0)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		--
2007						
IDU	16	0 (0)	--	--	16	0 (0)
Non-IDU	17	0 (0)	--	--	17	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 155 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	16	10 (63)	2	2 (100)	18	12 (67)
Non-IDU	9	1 (11)	--	--	9	1 (11)
p value		0.01		--		<0.01
2007						
IDU	15	7 (47)	--	--	15	7 (47)
Non-IDU	17	1 (6)	--	--	17	1 (6)
p value		0.008		--		0.008

† Excludes equivocal test results and missing values.

Table 156 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	25	11 (44)	1	1 (100)	26	12 (46)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		0.3
2007						
Heterosexual	32	8 (25)	--	--	32	8 (25)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 157 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	1 (50)	--	--	2	1 (50)
25 – 29	8	2 (25)	3	2 (67)	11	4 (36)
30 + years	16	9 (56)	--	--	16	9 (56)
p value		0.4		--		0.6
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	1 (13)	--	--	8	1 (13)
25 – 29	6	1 (17)	--	--	6	1 (17)
30 + years	17	6 (35)	--	--	17	6 (35)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 158 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	6	2 (33)	1	1 (100)	7	3 (43)
10 + years	9	8 (89)	1	1 (100)	10	9 (90)
p value		0.03		--		0.04
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	1 (25)	--	--	4	1 (25)
10 + years	10	6 (60)	--	--	10	6 (60)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 159 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	9	6 (67)	9	6 (67)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	7	5 (71)	7	5 (71)
Other/not reported	--	--	--	--	--	--
p value		--		0.7		0.7
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	3 (30)	11	3 (27)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	3 (100)	3	3 (100)
p value		--		0.06		0.04

† Excludes equivocal test results and missing values.

Table 160 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	5	3 (60)	5	3 (60)
Daily or more	--	--	4	4 (100)	4	4 (100)
p value		--		0.3		0.3
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 161 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		0.4		0.4
2007						
No	1	0 (0)	10	4 (40)	11	4 (36)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 162 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	6	2 (100)
p value		--		0.7		0.7
2007						
No	--	--	4	3 (75)	4	3 (75)
Yes	--	--	10	4 (40)	10	4 (40)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 163 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	10	4 (40)	--	--	10	4 (40)
2 to 4	9	4 (44)	--	--	9	4 (44)
5 to 9	4	3 (75)	1	1(100)	5	4 (80)
10 +	--	--	1	1(100)	1	1 (100)
p value		0.5		--		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	3 (20)	--	--	15	3 (20)
5 to 9	9	4 (44)	--	--	9	4 (44)
10 +	1	1 (100)	--	--	1	1 (100)
p value		0.06		--		0.06

† Excludes equivocal test results and missing values.

Table 164 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	16	9 (56)	1	1 (100)	17	10 (59)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.5		--		0.4
2007						
Non-Indigenous	28	6 (21)	--	--	28	6 (21)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 165 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	5	0 (0)	11	9 (82)	16	9 (56)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.6		0.6
2007						
Non-Indigenous	16	1 (6)	12	5 (42)	28	6 (21)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		0.8		0.4		0.2

† Excludes equivocal test results and missing values.

Table 166 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	19	8 (42)	2	2 (100)	21	10 (48)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	24	7 (29)	--	--	24	7 (29)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 167 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	25	11 (44)	2	2 (100)	27	13 (48)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	8 (26)	--	--	31	8 (26)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
P value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 168 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	25	11 (44)	2	2 (100)	27	13 (48)
Non-English speaking	--	--	--	--	--	--
p value		--		--		--
2007						
English speaking	31	8 (26)	--	--	31	8 (26)
Non-English speaking	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 169 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	7	2 (29)	--	--	7	2 (29)
Not sure	2	1 (50)	--	--	2	1 (50)
p value		0.01		--		0.006
2007						
Positive	4	4 (100)	--	--	4	4 (100)
Negative	11	1 (9)	--	--	11	1 (9)
Not sure	4	1 (25)	--	--	4	1 (25)
p value		0.003		--		0.003

† Excludes equivocal test results and missing values.

HBV prevalence

Table 170 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	15	0 (0)	3	1 (33)	18	1 (6)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		0.5
2007						
IDU	14	1 (7)	--	--	14	1 (7)
Non-IDU	16	0 (0)	--	--	16	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 171 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	16	6 (38)	3	2 (67)	19	8 (42)
Non-IDU	9	0 (0)	--	--	9	0 (0)
P value		0.04		--		0.02
2007						
IDU	15	3 (20)	--	--	15	3 (20)
Non-IDU	17	0 (0)	--	--	17	0 (0)
P value		0.05		--		0.05

† Excludes equivocal test results and missing values.

Table 172 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	25	6 (24)	2	2 (100)	27	8 (30)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		0.08		0.5
2007						
Heterosexual	32	3 (9)	--	--	32	3 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 173 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	8	3 (38)	3	1 (33)	11	4 (36)
30 + years	16	3 (19)	--	--	16	3 (19)
p value		0.6		0.3		0.7
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	0 (0)	--	--	8	0 (0)
25 – 29	6	0 (0)	--	--	6	0 (0)
30 + years	17	3 (18)	--	--	17	3 (18)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 174 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	1	1 (100)	1	1 (100)
6 to 10 years	6	1 (17)	1	1 (100)	7	2 (29)
10 + years	9	4 (44)	1	0 (0)	10	4 (40)
p value		0.3		0.2		0.4
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	0 (0)	--	--	4	0 (0)
10 + years	10	3 (30)	--	--	10	3 (30)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 175 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	10	5 (50)	10	5 (50)
Heroin	--	--	1	0 (0)	1	0 (0)
More than one	--	--	7	2 (29)	7	2 (29)
Other/not reported	--	--	--	--	--	--
p value		--		0.4		0.4
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	1 (10)	11	1 (9)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	1 (33)	3	1 (33)
p value		--		0.1		0.08

† Excludes equivocal test results and missing values.

Table 176 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	6	1 (17)	6	1 (17)
Daily or more	--	--	4	3 (75)	4	3 (75)
p value		--		0.07		0.07
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		1.0		0.9

† Excludes equivocal test results and missing values.

Table 177 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	3	1 (33)	3	1 (33)
p value		--		0.9		0.9
2007						
No	1	0 (0)	10	2 (20)	11	2 (18)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 178 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	7	2 (29)	7	2 (29)
p value		--		0.5		0.5
2007						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	10	2 (20)	10	2 (20)
p value		--		0.8		0.8

† Excludes equivocal test results and missing values.

Table 179 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	10	3 (30)	--	--	10	3 (30)
2 to 4	9	1 (11)	1	1 (100)	10	2 (20)
5 to 9	4	1 (25)	1	0 (0)	5	1 (20)
10 +	--	--	1	1 (100)	1	1 (100)
p value		0.6		0.2		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	1 (7)	--	--	15	1 (7)
5 to 9	9	2 (22)	--	--	9	2 (22)
10 +	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 180 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	16	4 (25)	2	1 (50)	18	5 (28)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Non-Indigenous	28	1 (4)	--	--	28	1 (4)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.003		--		0.003

† Excludes equivocal test results and missing values.

Table 181 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	5	0 (0)	12	5 (42)	17	5 (29)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.3		0.9
2007						
Non-Indigenous	16	0 (0)	12	1 (8)	28	1 (4)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		--		0.02		0.003

† Excludes equivocal test results and missing values.

Table 182 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	19	3 (16)	2	1 (50)	21	4 (19)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.5
2007						
Highly accessible/accessible	24	2 (8)	--	--	24	2 (8)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 183 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	25	6 (24)	3	2 (67)	28	8 (29)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	3 (10)	--	--	31	3 (10)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 184 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	25	6 (24)	3	2 (67)	28	8 (29)
Non-English speaking	--	--	--	--	--	--
p value		--		--		--
2007						
English speaking	31	3 (10)	--	--	31	3 (10)
Non-English speaking	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 185 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	20	7 (35)	7 (35)	1 (5)	5 (25)
Non-IDU	9	8 (89)	0 (0)	0 (0)	1 (11)
p value					0.05
2007					
IDU	7	2 (29)	3 (43)	0 (0)	2 (29)
Non-IDU	7	0 (0)	0 (0)	0 (0)	7 (100)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 186 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	28	14 (50)	7 (25)	1 (4)	6 (21)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.8
2007					
Heterosexual	14	2 (14)	3 (21)	0 (0)	9 (64)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 187 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	3	1 (33)	0 (0)	1 (33)	1 (33)
25 – 29	12	7 (58)	4 (33)	0 (0)	1 (8)
30 + years	16	9 (56)	3 (19)	0 (0)	4 (25)
p value					0.1
2007					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	4	0 (0)	0 (0)	0 (0)	4 (100)
25 – 29	1	0 (0)	0 (0)	0 (0)	1 (100)
30 + years	8	2 (25)	3 (38)	0 (0)	3 (38)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 188 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	10	5 (50)	3 (30)	0 (0)	2 (20)
2 to 4	10	8 (80)	1 (10)	1 (10)	0 (0)
5 to 9	6	1 (17)	1 (17)	0 (0)	4 (67)
10 +	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.05
2007					
1	4	0 (0)	0 (0)	0 (0)	4 (100)
2 to 4	4	1 (25)	1 (25)	0 (0)	2 (50)
5 to 9	5	0 (0)	2 (40)	0 (0)	3 (60)
10 +	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 189 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	18	9 (50)	4 (22)	1 (6)	4 (22)
Indigenous	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.8
2007					
Non-Indigenous	12	2 (17)	1 (8)	0 (0)	9 (75)
Indigenous	2	0 (0)	2 (100)	0 (0)	0 (0)
p value					0.01

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 190 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	22	12 (55)	4 (18)	0 (0)	6 (27)
Moderately accessible	2	1 (50)	1 (50)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7
2007					
Highly accessible/accessible	13	2 (15)	2 (15)	0 (0)	9 (69)
Moderately accessible	1	0 (0)	1 (100)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.1

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 191 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	29	15 (52)	7 (24)	1 (3)	6 (21)
Non-English	--	--	--	--	--
p value					--
2007					
English	14	2 (14)	3 (21)	0 (0)	9 (64)
Non-English	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 192 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	9	0 (0)	--	--	9	0 (0)
Yes	10	6 (60)	1	0 (0)	11	6 (55)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		0.01		--		0.02
2007						
No	1	0 (0)	--	--	1	0 (0)
Yes	9	8 (89)	--	--	9	8 (89)
Not sure	1	1 (100)	--	--	1	1 (100)
p value		0.08		--		0.08

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Yes to self-reported immunisation includes any immunisation against HBV.

Victoria 2007

Table 193 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	--		N = 2	
N ^o surveyed	--	--	N = 87	N = 75
Sex (%)				
Male	--	--	78 (90)	71 (95)
Female	--	--	9 (10)	4 (5)
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	--	--	84 (97)	73 (97)
Bisexual	--	--	1 (1)	1 (1)
Homosexual	--	--	--	1 (1)
Unsure	--	--	2 (2)	--
Not reported	--	--	--	--
Age and duration of injection (years)				
Median age (years)	--	--	32	32
Age range	--	--	18 – 54	18 – 77
Age group (%)				
<25 years	--	--	12 (14)	22 (29)
25+ years	--	--	75 (86)	53 (71)
Not reported	--	--	--	--
Median age 1 st IDU (years)	--	--	18	--
Age range	--	--	10 – 35	--
No. not reported	--	--	--	--
Median years IDU	--	--	12	--
Range	--	--	<1 – 29	--
Duration of drug injection (%)				
<3 years	--	--	4 (5)	--
3+ years	--	--	83 (95)	--
Not reported	--	--	--	--
Aboriginal and Torres Strait Islander origin (%)				
No	--	--	80 (92)	73 (97)
Yes	--	--	7 (8)	2 (3)
Not reported	--	--	--	--
Residential remoteness in 12 months before prison				
Highly accessible/accessible	--	--	83 (95)	66 (88)
Moderately accessible	--	--	2 (2)	5 (7)
Remote/very remote	--	--	1 (1)	--
Not reported	--	--	1 (1)	4 (5)
Region/Country of birth (%)				
Australia	--	--	67 (77)	62 (83)
Other Oceania	--	--	3 (3)	2 (3)
Asia	--	--	6 (7)	4 (5)
UK & Ireland	--	--	4 (5)	1 (1)
Other	--	--	7 (8)	5 (7)
Not reported	--	--	--	1 (1)
Main language spoke at home by parents (%)				
English speaking	--	--	72 (83)	59 (79)
Non-English speaking	--	--	14 (16)	14 (19)
Not reported	--	--	1 (1)	2 (3)
First time in prison (%)				
No	--	--	69 (79)	25 (33)
Yes	--	--	18 (21)	50 (67)
Not reported	--	--	--	--
Lifetime imprisonments (%)				
One	--	--	18 (21)	50 (67)
Two to four	--	--	33 (38)	17 (23)
Five to nine	--	--	24 (28)	6 (8)
Ten or more	--	--	12 (14)	2 (3)
Not reported	--	--	--	--

Table 193 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	--	--	22 (32)	6 (24)
Yes	--	--	47 (68)	19 (76)
Not reported			--	--
Frequency of injection last month (%)				
Not last month	--	--	27 (31)	--
Less than weekly	--	--	7 (8)	--
Weekly not daily	--	--	17 (20)	--
Daily or more	--	--	36 (41)	--
Not reported			--	--
Ever smoked full cigarette (%)*				
No	--	--	1 (1)	12 (16)
Yes	--	--	86 (99)	63 (84)
Not reported			--	--
Median age first smoked (years)	--	--	13	15
Age range	--	--	5 – 25	9 – 30
Current smoker (%)*				
No	--	--	4 (5)	24 (32)
Yes	--	--	83 (95)	51 (68)
Not reported			--	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	1 (1)	2 (4)
5 to 10 cigarettes a day	--	--	30 (36)	19 (37)
11 to 20 cigarettes a day	--	--	32 (39)	16 (31)
Over 20 cigarettes a day	--	--	20 (24)	14 (27)
Not reported			--	--

* Smoking questions were not asked in 2004 survey.

Table 194 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)		
Amphetamine (Speed, Ice)	--	37 (43)
Anabolic steroids	--	--
Cocaine	--	1 (1)
Heroin	--	43 (49)
Heroin + amphetamine	--	4 (5)
Heroin + Cocaine	--	--
Methadone	--	--
Morphine	--	2 (2)
Other	--	--
Not reported	--	--
N° Injected last month	--	N = 60
Places injected last month (%)**		
Prison	--	1 (2)
Own home	--	47 (78)
Friend's home	--	32 (53)
Dealer's home	--	15 (25)
Street, park, beach	--	21 (35)
Car	--	34 (57)
Public toilet	--	16 (27)
Commercial injecting room	--	--
MSIC*	--	--
Squat	--	3 (5)
Other place	--	6 (10)
Use of sterile needles & syringes last month (%)		
All injections	--	44 (73)
Most of the time	--	13 (22)
Half of the time	--	--
Some of the time	--	2 (3)
Not last month	--	--
Not reported	--	1 (2)
Re-used someone else's used needle & syringe last month (%)		
None	--	50 (83)
Once	--	3 (5)
Twice	--	2 (3)
3-5 times	--	1 (2)
>5 times	--	1 (2)
Not reported	--	3 (5)
Number of people needle & syringe was re-used after last month (%)		
None	--	50 (83)
One	--	3 (5)
Two	--	2 (3)
Three to five	--	1 (2)
More than five	--	1 (2)
Don't know	--	--
Not reported	--	3 (5)
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	--	6 (10)
Casual sex partner	--	--
Close friend	--	3 (5)
Acquaintance	--	--
Other	--	1 (2)
Equipment used after someone else last month (%)**		
Spoon	--	22 (37)
Water	--	10 (17)
Filter	--	11 (18)
Tourniquet	--	4 (7)
Drug mix	--	6 (10)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 195 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75
Any treatment/therapy for drug use (%)				
No	--	--	14 (16)	42 (56)
Yes	--	--	71 (82)	13 (17)
Not reported			2 (2)	20 (27)
History of methadone maintenance treatment (%)				
Currently	--	--	37 (43)	--
Previously	--	--	16 (18)	--
Never	--	--	32 (37)	--
Not reported			2 (2)	--
History of other pharmacotherapy treatment (%)				
Currently	--	--	40 (46)	--
Previously	--	--	12 (14)	--
Never	--	--	35 (40)	--
Not reported			--	--

Table 196 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	--	N = 60
From an NSP last month (%)		
Daily or almost daily	--	13 (22)
A couple of times each week	--	23 (38)
Less than weekly	--	8 (13)
Once last month	--	7 (12)
Not in the last month	--	9 (15)
Not reported	--	--
From a chemist last month (%)		
Daily or almost daily	--	1 (2)
A couple of times each week	--	11 (18)
Less than weekly	--	5 (8)
Once last month	--	10 (17)
Not in the last month	--	33 (55)
Not reported	--	--

Table 197 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75
Sex last month (%)				
No	--	--	19 (22)	20 (27)
Yes	--	--	68 (78)	55 (73)
Not reported			--	--
Condom use at last sex (%)				
No	--	--	69 (79)	48 (64)
Yes	--	--	18 (21)	27 (36)
Not reported			--	--
Condom use with regular sex partner(s) last month (%)*				
No	--	--	41 (85)	33 (70)
Sometimes	--	--	7 (15)	7 (15)
Always	--	--	--	7 (15)
Condom use with new sex partner(s) last month (%)*				
No	--	--	10 (56)	1 (13)
Sometimes	--	--	3 (17)	3 (38)
Always	--	--	5 (28)	4 (50)
Condom use with casual sex partner(s) last month (%)*				
No	--	--	15 (58)	3 (33)
Sometimes	--	--	4 (15)	3 (33)
Always	--	--	7 (27)	3 (33)
Sex work last month (%)				
No	--	--	85 (98)	74 (99)
Yes	--	--	2 (2)	--
Not reported			--	1 (1)
Condom used at last sex work last month (%)				
No	--	--	--	--
Yes	--	--	2 (100)	--
Not reported			--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 198 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75
Previous HIV test (%)				
Yes, last year	--	--	43 (49)	13 (17)
>1 year ago	--	--	28 (32)	19 (25)
Never tested	--	--	16 (18)	43 (57)
Not reported			--	--
HBV infection (%)				
No	--	--	67 (77)	72 (96)
Yes	--	--	9 (10)	--
Don't know	--	--	11 (13)	2 (3)
Not reported			--	1 (1)
HBV vaccination (%)*				
No	--	--	25 (29)	43 (57)
Yes	--	--	51 (59)	20 (27)
Don't know	--	--	10 (11)	11 (15)
Not reported			1 (1)	1 (1)
Previous HCV test (%)				
Yes, last year	--	--	11 (13)	53 (71)
>1 year ago	--	--	41 (47)	10 (13)
Never tested	--	--	35 (40)	12 (16)
Not reported	--	--	--	--
Any HCV treatment (%)**			N = 46	N = 3
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	1 (2)	--
Other	--	--	--	--
No treatment	--	--	45 (98)	3 (100)
Not reported			--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	1 (2)	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 199 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	0 (0)	5	0 (0)	64	0 (0)
Non-IDU	49	0 (0)	4	0 (0)	53	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 200 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	49	2 (4)	4	1 (25)	53	3 (6)
Non-IDU	59	40 (68)	7	6 (86)	66	46 (70)
p value		<0.001		0.04		<0.001

† Excludes equivocal test results and missing values.

Table 201 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	106	42 (40)	9	6 (67)	115	48 (42)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.5		0.3		0.5

† Excludes equivocal test results and missing values.

Table 202 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	6	0 (0)	--	--	6	0 (0)
20 – 24	21	4 (19)	--	--	21	4 (19)
25 – 29	25	17 (68)	3	2 (67)	28	19 (68)
30 + years	56	21 (38)	8	5 (63)	64	26 (41)
p value		0.001		0.9		0.001

† Excludes equivocal test results and missing values.

Table 203 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	3	0 (0)	--	--	3	0 (0)
3 to 5 years	7	4 (57)	1	1 (100)	8	5 (63)
6 to 10 years	17	9 (53)	2	1 (50)	19	10 (53)
10 + years	32	27 (84)	4	4 (100)	36	31 (86)
p value		0.006		0.2		0.003

† Excludes equivocal test results and missing values.

Table 204 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	3	0 (0)	27	15 (56)	30	15 (50)
Heroin	--	--	30	26 (87)	30	26 (87)
More than one	--	--	4	3 (75)	4	3 (75)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.05		0.02

† Excludes equivocal test results and missing values.

Table 205 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	20	16 (80)	20	16 (80)
Daily or more	--	--	26	23 (88)	26	23 (88)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 206 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	36	30 (83)	36	30 (83)
Yes	--	--	9	8 (89)	9	8 (89)
p value		--		0.7		0.7

† Excludes equivocal test results and missing values.

Table 207 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	13	10 (77)	13	10 (77)
Yes	1	0 (0)	35	32 (91)	36	32 (89)
p value		--		0.2		0.3

† Excludes equivocal test results and missing values.

Table 208 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	2 (4)	6	3 (50)	54	5 (9)
2 to 4	33	17 (52)	3	2 (67)	36	19 (53)
5 to 9	17	15 (88)	2	2 (100)	19	17 (89)
10 +	10	8 (80)	--	--	10	8 (80)
p value		<0.001		0.4		<0.001

† Excludes equivocal test results and missing values.

Table 209 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	100	37 (37)	10	6 (60)	110	43 (39)
Indigenous	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.2		0.4		0.1

† Excludes equivocal test results and missing values.

Table 210 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	3 (6)	59	40 (68)	110	43 (39)
Indigenous	2	0 (0)	7	6 (86)	9	6 (67)
p value		0.7		0.3		0.1

† Excludes equivocal test results and missing values.

Table 211 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	98	42 (43)	11	7 (64)	109	49 (45)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.08		--		0.07

† Excludes equivocal test results and missing values.

Table 212 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	88	31 (35)	8	5 (63)	96	36 (38)
Other Oceania	3	1 (33)	1	0 (0)	4	1 (25)
Asia	8	5 (63)	1	1 (100)	9	6 (67)
UK & Ireland	3	3 (100)	1	1 (100)	4	4 (100)
Other	6	2 (33)	--	--	6	2 (33)
p value		0.1		0.4		0.6

† Excludes equivocal test results and missing values.

Table 213 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
p value		--		--		--
2007						
English speaking	93	34 (37)	10	6 (60)	103	40 (39)
Non-English speaking	14	7 (50)	1	1 (100)	15	8 (53)
p value		0.3		0.4		0.3

† Excludes equivocal test results and missing values.

Table 214 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	--	--	--	--	--	--
Negative	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
Positive	35	35 (100)	7	7 (100)	42	42 (100)
Negative	24	4 (17)	2	0 (0)	26	4 (15)
Not sure	2	0 (0)	--	--	2	0 (0)
p value		<0.001		0.003		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 215 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	4 (7)	6	0 (0)	65	4 (6)
Non-IDU	49	0 (0)	2	0 (0)	51	0 (0)
p value		0.06		--		0.07

† Excludes equivocal test results and missing values.

Table 216 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	56	23 (41)	6	2 (33)	62	25 (40)
Non-IDU	49	2 (4)	4	0 (0)	53	2 (4)
p value		<0.001		0.2		<0.001

† Excludes equivocal test results and missing values.

Table 217 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	103	25 (24)	8	1 (13)	111	26 (23)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.1		0.7

† Excludes equivocal test results and missing values.

Table 218 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	21	3 (14)	--	--	21	3 (14)
25 – 29	25	9 (36)	2	0 (0)	27	9 (33)
30 + years	54	13 (24)	8	2 (25)	62	15 (24)
p value		0.2		0.4		0.3

† Excludes equivocal test results and missing values.

Table 219 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	7	3 (43)	1	0 (0)	8	3 (38)
6 to 10 years	16	7 (44)	2	1 (50)	18	8 (44)
10 + years	29	13 (45)	3	1 (33)	32	14 (44)
p value		0.4		0.7		0.4

† Excludes equivocal test results and missing values.

Table 220 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	4	0 (0)	24	6 (25)	28	6 (21)
Heroin	--	--	28	15 (54)	28	15 (54)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.07		0.03

† Excludes equivocal test results and missing values.

Table 221 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	19	11 (58)	19	11 (58)
Daily or more	1	0 (0)	23	12 (52)	24	12 (50)
p value		--		0.7		0.6

† Excludes equivocal test results and missing values.

Table 222 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	1	0 (0)	35	18 (51)	36	18 (50)
Yes	--	--	6	4 (67)	6	4 (67)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 223 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	11	4 (36)	11	4 (36)
Yes	1	0 (0)	33	16 (48)	34	16 (47)
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 224 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	5 (10)	6	1 (17)	54	6 (11)
2 to 4	33	9 (27)	3	0 (0)	36	9 (25)
5 to 9	14	7 (50)	1	1 (100)	15	8 (53)
10 +	10	4 (40)	--	--	10	4 (40)
p value		0.008		0.09		0.003

† Excludes equivocal test results and missing values.

Table 225 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	97	20 (21)	9	2 (22)	106	22 (21)
Indigenous	8	5 (63)	1	0 (0)	9	5 (56)
p value		0.008		0.6		0.02

† Excludes equivocal test results and missing values.

Table 226 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	2 (4)	55	20 (36)	106	22 (21)
Indigenous	2	0 (0)	7	5 (71)	9	5 (56)
p value		0.8		0.08		0.02

† Excludes equivocal test results and missing values.

Table 227 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	96	25 (26)	10	2 (20)	106	27 (25)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 228 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	85	17 (20)	7	2 (29)	92	19 (21)
Other Oceania	3	0 (0)	1	0 (0)	4	0 (0)
Asia	8	4 (50)	1	0 (0)	9	4 (44)
UK & Ireland	3	3 (100)	1	0 (0)	4	3 (75)
Other	6	1 (17)	--	--	6	1 (17)
p value		0.006		0.8		0.04

† Excludes equivocal test results and missing values.

Table 229 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	--	--	--	--	--	--
Non-English speaking	--	--	--	--	--	--
p value		--		--		--
2007						
English speaking	90	19 (21)	9	2 (22)	99	21 (21)
Non-English speaking	14	5 (36)	1	0 (0)	15	5 (33)
p value		0.3		0.6		0.3

† Excludes equivocal test results and missing values.

Table 230 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	--	--	--	--	--
Non-IDU	--	--	--	--	--
p value					--
2007					
IDU	67	26 (39)	24 (36)	4 (6)	13 (9)
Non-IDU	53	45 (85)	2 (4)	0 (0)	6 (11)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 231 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	116	68 (59)	25 (22)	4 (3)	19 (16)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Unsure	2	1 (50)	1 (50)	0 (0)	0 (0)
p value					1.0

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 232 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	--	--	--	--	--
20 – 24	--	--	--	--	--
25 – 29	--	--	--	--	--
30 + years	--	--	--	--	--
p value					--
2007					
< 20 years	6	3 (50)	1 (17)	0 (0)	2 (33)
20 – 24	21	11 (52)	2 (10)	1 (5)	7 (33)
25 – 29	29	14 (48)	9 (31)	1 (3)	5 (17)
30 + years	64	43 (67)	14 (22)	2 (3)	5 (8)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 233 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	--	--	--	--	--
2 to 4	--	--	--	--	--
5 to 9	--	--	--	--	--
10 +	--	--	--	--	--
p value					--
2007					
1	55	42 (76)	6 (11)	1 (2)	6 (11)
2 to 4	36	24 (67)	8 (22)	1 (3)	3 (8)
5 to 9	19	3 (16)	10 (53)	0 (0)	6 (32)
10 +	10	2 (20)	2 (20)	2 (20)	4 (40)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 234 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	--	--	--	--	--
Indigenous	--	--	--	--	--
p value					--
2007					
Non-Indigenous	111	69 (62)	21 (19)	4 (4)	17 (15)
Indigenous	9	2 (22)	5 (56)	0 (0)	2 (22)
p value					0.05

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 235 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	--	--	--	--	--
Moderately accessible	--	--	--	--	--
Remote/very remote	--	--	--	--	--
p value					--
2007					
Highly accessible/accessible	110	62 (56)	25 (23)	4 (4)	19 (17)
Moderately accessible	6	6 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 236 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	--	--	--	--	--
Non-English	--	--	--	--	--
p value					--
2007					
English	104	62 (60)	22 (21)	2 (2)	18 (17)
Non-English	15	9 (60)	3 (20)	2 (13)	1 (7)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 237 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
No	38	3 (8)	4	0 (0)	42	3 (7)
Yes	26	12 (46)	5	2 (40)	31	14 (45)
Not sure	16	2 (13)	1	0 (0)	17	2 (12)
p value		0.001		0.3		<0.001

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded. Yes to self-reported immunisation includes any immunisation against HBV.

Western Australia 2004 & 2007

Table 238 Number (percentage) of respondents by demographic characteristics, injector status and year of survey

Demographic characteristics	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
Number of sites surveyed	N = 3		N = 4	
N° surveyed	N = 66	N = 47	N = 55	N = 43
Sex (%)				
Male	51 (77)	38 (81)	47 (85)	41 (95)
Female	15 (23)	9 (19)	8 (15)	2 (5)
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	64 (97)	46 (98)	53 (96)	43 (100)
Bisexual	2 (3)	--	--	--
Homosexual	--	1 (2)	2 (4)	--
Unsure			--	--
Not reported			--	--
Age and duration of injection (years)				
Median age (years)	30	30	33	27
Age range	27 – 35	18 – 60	19 – 53	19 – 65
Age group (%)				
<25 years	18 (27)	15 (32)	14 (25)	14 (33)
25+ years	43 (65)	32 (68)	41 (75)	29 (67)
Not reported	5 (8)	--	--	--
Median age 1 st IDU (years)	19	--	19	--
Age range	10 – 39	--	14 – 44	--
No. not reported			1	--
Median years IDU	8	--	12	--
Range	<1 – 26	--	<1 – 35	--
Duration of drug injection (%)				
<3 years	10 (16)	--	6 (11)	--
3+ years	52 (84)	--	48 (87)	--
Not reported		--	1 (2)	--
Aboriginal and Torres Strait Islander origin (%)				
No	40 (61)	30 (64)	36 (65)	26 (60)
Yes	26 (39)	17 (36)	17 (31)	17 (40)
Not reported			2 (4)	--
Residential remoteness in 12 months before prison				
Highly accessible/accessible	51 (77)	35 (74)	47 (85)	29 (67)
Moderately accessible	4 (6)	2 (4)	1 (2)	1 (2)
Remote/very remote	8 (12)	10 (21)	4 (7)	6 (14)
Not reported	3 (5)	--	3 (5)	7 (16)
Region/Country of birth (%)				
Australia	57 (86)	42 (90)	47 (85)	34 (79)
Other Oceania	1 (2)	1 (2)	3 (5)	1 (2)
Asia	--	1 (2)	--	2 (5)
UK & Ireland	4 (5)	1 (2)	1 (2)	4 (9)
Other	3 (5)	2 (4)	4 (7)	2 (5)
Not reported	1 (2)	--	--	--
Main language spoke at home by parents (%)				
English speaking	64 (96)	44 (94)	53 (96)	40 (93)
Non-English speaking	1 (2)	3 (6)	2 (4)	3 (7)
Not reported	1 (2)	--	--	--
First time in prison (%)				
No	47 (71)	27 (57)	40 (73)	21 (49)
Yes	19 (29)	20 (43)	15 (27)	21 (49)
Not reported	--	--	--	1 (2)
Lifetime imprisonments (%)				
One	19 (29)	20 (43)	15 (27)	21 (49)
Two to four	29 (44)	21 (45)	17 (31)	14 (33)
Five to nine	12 (18)	3 (6)	9 (16)	2 (5)
Ten or more	5 (8)	--	2 (4)	1 (2)
Not reported	1 (2)	3 (6)	12 (22)	5 (12)

Table 238 Number (percentage) of respondents by demographic characteristics, injector status and year of survey (cont.)

Imprisonment in last year (%)				
No	31 (47)	28 (60)	14 (35)	9 (41)
Yes	30 (45)	14 (30)	21 (53)	10 (45)
Not reported	5 (8)	5 (11)	5 (13)	3 (14)
Frequency of injection last month (%)				
Not last month	26 (39)	--	25 (45)	--
Less than weekly	10 (15)	--	9 (16)	--
Weekly not daily	1 (2)	--	6 (11)	--
Daily or more	29 (44)	--	15 (27)	--
Not reported				
Ever smoked full cigarette (%)*				
No	--	--	4 (7)	4 (9)
Yes	--	--	51 (93)	39 (91)
Not reported	--	--	--	--
Median age first smoked (years)	--	--	13	15
Age range	--	--	7 – 20	6 – 24
Current smoker (%)*				
No	--	--	7 (13)	11 (26)
Yes	--	--	47 (85)	32 (74)
Not reported	--	--	1 (2)	--
Smoking frequency (%)*				
Occasional – weekly or less	--	--	3 (6)	5 (16)
5 to 10 cigarettes a day	--	--	15 (31)	10 (31)
11 to 20 cigarettes a day	--	--	16 (33)	13 (41)
Over 20 cigarettes a day	--	--	13 (27)	4 (13)
Not reported	--	--	1 (2)	--

* Smoking questions were not asked in 2004 survey.

Table 239 Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey

Injecting behaviour	2004	2007
Last drug injected (%)	N = 66	N = 55
Amphetamine (Speed, Ice)	54 (82)	47 (85)
Anabolic steroids	--	--
Cocaine	--	--
Heroin	7 (11)	7 (13)
Heroin + amphetamine	--	1 (2)
Heroin + Cocaine	--	--
Methadone	3 (5)	--
Morphine	2 (3)	--
Other	--	--
Not reported	--	--
N° Injected last month	N = 40	N = 30
Places injected last month (%)**		
Prison	1 (3)	1 (3)
Own home	26 (65)	23 (77)
Friend's home	19 (48)	11 (37)
Dealer's home	5 (13)	8 (27)
Street, park, beach	6 (15)	9 (30)
Car	7 (18)	5 (17)
Public toilet	2 (5)	4 (13)
Commercial injecting room	--	--
MSIC*	--	--
Squat	--	1 (3)
Other place	--	3 (10)
Not reported	3 (8)	--
Use of sterile needles & syringes last month (%)		
All injections	26 (65)	16 (53)
Most of the time	9 (23)	11 (37)
Half of the time	1 (3)	--
Some of the time	4 (10)	3 (10)
Not last month	--	--
Not reported	1 (3)	--
Re-used someone else's used needle & syringe last month (%)		
None	29 (73)	21 (70)
Once	--	6 (20)
Twice	6 (15)	--
3-5 times	1 (3)	1 (3)
>5 times	2 (5)	2 (7)
Not reported	2 (5)	--
Number of people needle & syringe was re-used after last month (%)		
None	29 (73)	21 (70)
One	3 (8)	6 (20)
Two	3 (8)	--
Three to five	1 (3)	1 (3)
More than five	2 (5)	--
Don't know	--	1 (3)
Not reported	2 (5)	1 (3)
Relationship to people needle & syringe was re-used after last month (%)**		
Regular sex partner	5 (13)	3 (10)
Casual sex partner	--	1 (3)
Close friend	2 (5)	2 (7)
Acquaintance	--	2 (7)
Other	4 (10)	2 (7)
Equipment used after someone else last month (%)**		
Spoon	9 (23)	4 (13)
Water	8 (20)	8 (27)
Filter	7 (18)	4 (13)
Tourniquet	5 (13)	3 (10)
Drug mix	7 (18)	5 (17)

* Medically Supervised Injecting Centre in Sydney.

** More than one option could be selected.

Table 240 Number (percentage) of respondents by treatment for drug use, injector status and year of survey

Treatment for drug use	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43
Any treatment/therapy for drug use (%)				
No	41 (62)	41 (87)	23 (42)	31 (72)
Yes	25 (38)	6 (13)	30 (55)	8 (19)
Not reported			2 (4)	4 (9)
History of methadone maintenance treatment (%)				
Currently	3 (5)	1 (2)	2 (4)	--
Previously	3 (5)	--	7 (13)	--
Never	60 (90)	45 (96)	38 (69)	--
Not reported	--	1 (2)	8 (15)	--
History of other pharmacotherapy treatment (%)				
Currently	4 (6)	1 (2)	5 (9)	--
Previously	4 (6)	--	7 (13)	--
Never	58 (88)	45 (96)	43 (78)	--
Not reported	--	1 (2)	--	--

Table 241 Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey

Needle & Syringe acquisition	2004	2007
N° surveyed	N = 40	N = 30
From an NSP last month (%)		
Daily or almost daily	3 (8)	1 (3)
A couple of times each week	5 (13)	2 (7)
Less than weekly	7 (18)	3 (10)
Once last month	5 (13)	3 (10)
Not in the last month	18 (45)	17 (57)
Not reported	2 (5)	4 (13)
From a chemist last month (%)		
Daily or almost daily	6 (15)	3 (10)
A couple of times each week	6 (15)	8 (27)
Less than weekly	8 (20)	5 (17)
Once last month	6 (15)	5 (17)
Not in the last month	13 (33)	6 (20)
Not reported	1 (3)	3 (10)

Table 242 Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey

Sexual behaviour	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43
Sex last month (%)				
No	24 (36)	14 (30)	15 (27)	11 (26)
Yes	41 (62)	32 (68)	40 (73)	32 (74)
Not reported	1 (2)	1 (2)	--	--
Condom use at last sex (%)				
No	46 (70)	36 (77)	42 (76)	26 (60)
Yes	20 (30)	11 (23)	13 (24)	17 (40)
Not reported			--	--
Condom use with regular sex partner(s) last month (%)*				
No	21 (75)	22 (88)	27 (84)	13 (54)
Sometimes	2 (7)	2 (8)	4 (13)	6 (25)
Always	5 (18)	1 (4)	1 (3)	5 (21)
Condom use with new sex partner(s) last month (%)*				
No	12 (71)	5 (63)	10 (50)	4 (33)
Sometimes	1 (6)	2 (25)	5 (25)	5 (42)
Always	4 (24)	1 (13)	5 (25)	3 (25)
Condom use with casual sex partner(s) last month (%)*				
No	9 (69)	7 (78)	10 (59)	2 (18)
Sometimes	1 (8)	2 (22)	5 (29)	5 (45)
Always	3 (23)	--	2 (12)	4 (36)
Sex work last month (%)				
No	65 (100)	46 (98)	52 (95)	43 (100)
Yes	--	1 (2)	3 (5)	--
Not reported			--	--
Condom used at last sex work last month (%)				
No	--	--	--	--
Yes	--	1 (100)	3 (100)	--
Not reported	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 243 Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey

Testing & treatment	2004		2007	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43
Previous HIV test (%)				
Yes, last year	26 (39)	8 (7)	15 (27)	6 (14)
>1 year ago	17 (26)	11 (23)	25 (45)	11 (26)
Never tested	23 (35)	27 (57)	13 (24)	26 (60)
Not reported	--	1 (2)	2 (40)	--
HBV infection (%)				
No	52 (79)	41 (87)	38 (69)	37 (86)
Yes	5 (8)	1 (2)	10 (18)	1 (2)
Don't know	9 (14)	5 (11)	7 (13)	5 (12)
Not reported	--	--	--	--
HBV vaccination (%)*				
No	21 (32)	22 (47)	27 (49)	27 (63)
Yes	34 (52)	12 (26)	22 (40)	9 (21)
Don't know	11 (17)	12 (26)	6 (11)	7 (16)
Not reported	--	1 (2)	--	--
Previous HCV test (%)				
Yes, last year	31 (47)	6 (13)	20 (36)	5 (12)
>1 year ago	12 (18)	7 (15)	25 (45)	10 (23)
Never tested	23 (35)	33 (72)	10 (18)	28 (65)
Not reported	--	1 (<1)		
Any HCV treatment (%)**	N = 16	N = 2	N = 16	N = 1
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	16 (100)	2 (100)	--	--
No treatment	--	--	16 (100)	1 (100)
Not reported	--	--	--	--
Current HCV treatment				
Interferon	--	--	--	--
Interferon & Ribavirin	--	--	--	--
Pegasys & Ribavirin	--	--	--	--
Other	--	--	--	--

* Number (percentage) among participants not reporting HBV infection.

** Number (percentage) of those testing positive for hepatitis C antibody.

HIV antibody prevalence

Table 244 HIV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	44	0 (0)	5	0 (0)	49	0 (0)
Non-IDU	36	0 (0)	7	0 (0)	43	0 (0)
P value		--		--		--
2007						
IDU	38	0 (0)	5	0 (0)	43	0 (0)
Non-IDU	36	0 (0)	2	0 (0)	38	0 (0)
P value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 245 HCV antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	43	12 (28)	5	4 (80)	48	16 (33)
Non-IDU	36	2 (6)	7	0 (0)	43	2 (5)
p value		0.01		0.004		0.001
2007						
IDU	38	14 (37)	5	2 (40)	43	16 (37)
Non-IDU	37	1 (3)	2	0 (0)	39	1 (3)
p value		<0.001		0.3		<0.001

† Excludes equivocal test results and missing values.

Table 246 HCV antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	79	14 (18)	12	4 (33)	91	18 (20)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	14 (19)	7	2 (29)	80	16 (20)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 247 HCV antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	1 (9)	--	--	11	1 (9)
20 – 24	18	2 (11)	1	0 (0)	19	2 (11)
25 – 29	17	1 (6)	2	1 (50)	19	2 (11)
30 + years	36	10 (28)	7	1 (14)	43	11 (26)
p value		0.2		0.5		0.3
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	1 (8)	2	0 (0)	14	1 (7)
30 + years	38	13 (34)	5	2 (40)	43	15 (35)
p value		0.02		0.3		0.01

† Excludes equivocal test results and missing values.

Table 248 HCV antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	9	0 (0)	--	--	9	0 (0)
3 to 5 years	5	3 (60)	--	--	5	3 (60)
6 to 10 years	12	2 (17)	1	1 (100)	13	3 (23)
10 + years	16	7 (44)	3	2 (67)	19	9 (47)
p value		0.03		0.6		0.02
2007						
<3 years	5	--	--	--	5	0 (0)
3 to 5 years	7	--	--	--	7	0 (0)
6 to 10 years	6	1 (17)	1	0 (0)	7	1 (14)
10 + years	19	12 (63)	4	2 (50)	23	14 (61)
p value		0.003		0.4		0.002

† Excludes equivocal test results and missing values.

Table 249 HCV antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	32	13 (41)	40	13 (33)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	3 (60)	6	3 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5
2007						
Amphetamine (Speed, Ice)	5	0 (0)	34	12 (35)	39	12 (31)
Heroin	--	--	2	2 (100)	2	2 (100)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.09		0.07

† Excludes equivocal test results and missing values.

Table 250 HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	3	0 (0)	5	3 (60)	8	3 (38)
Daily or more	4	0 (0)	15	9 (60)	19	9 (47)
p value		--		0.06		0.6
2007						
Less than daily	--	--	11	2 (18)	11	2 (18)
Daily or more	2	0 (0)	11	9 (82)	13	9 (69)
p value		--		0.003		0.008

† Excludes equivocal test results and missing values.

Table 251 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	14	10 (71)	20	10 (50)
Yes	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		0.2		0.5
2007						
No	2	0 (0)	14	7 (50)	16	7 (44)
Yes	--	--	7	4 (57)	7	4 (57)
p value		--		0.8		0.3

† Excludes equivocal test results and missing values.

Table 252 HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	18	5 (28)	24	5 (21)
Yes	3	0 (0)	18	10 (56)	21	10 (48)
p value		--		0.09		0.06
2007						
No	2	0 (0)	11	6 (55)	13	6 (46)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.1		0.2

† Excludes equivocal test results and missing values.

Table 253 HCV antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	28	0 (0)	5	0 (0)	33	0 (0)
2 to 4	33	7 (21)	7	4 (57)	40	11 (28)
5 to 9	12	6 (50)	--	--	12	6 (50)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.001		0.04		0.001
2007						
1	28	2 (7)	2	1 (50)	30	3 (10)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	3 (30)	1	0 (0)	11	3 (27)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.03		0.7		0.07

† Excludes equivocal test results and missing values.

Table 254 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	51	6 (12)	6	2 (33)	57	8 (14)
Indigenous	31	8 (26)	6	2 (33)	37	10 (27)
p value		0.1		1.0		0.1
2007						
Non-Indigenous	49	12 (24)	2	1 (50)	51	13 (25)
Indigenous	25	3 (12)	5	1 (20)	30	4 (13)
p value		0.2		0.4		0.2

† Excludes equivocal test results and missing values.

Table 255 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	26	1 (4)	29	7 (24)	55	8 (15)
Indigenous	17	1 (6)	19	9 (47)	36	10 (28)
p value		0.8		0.1		0.1
2007						
Non-Indigenous	23	1 (4)	28	12 (43)	51	13 (25)
Indigenous	16	0 (0)	14	4 (29)	30	4 (13)
p value		0.4		0.4		0.2

† Excludes equivocal test results and missing values.

Table 256 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	62	13 (21)	8	3 (38)	70	16 (23)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	1 (8)	2	0 (0)	15	1 (7)
p value		0.3		0.5		0.2
2007						
Highly accessible/accessible	57	11 (19)	6	2 (33)	63	13 (21)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	9	1 (11)	1	0 (0)	10	1 (10)
p value		0.5		0.5		0.4

† Excludes equivocal test results and missing values.

Table 257 HCV antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	71	13 (18)	12	4 (33)	83	17 (20)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9
2007						
Australia	60	14 (23)	7	2 (29)	67	16 (24)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	1 (20)	--	--	5	1 (20)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 258 HCV antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English speaking	76	14 (18)	11	3 (27)	87	17 (20)
Non-English speaking	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.1		0.6
2007						
English speaking	71	14 (20)	7	2 (29)	78	16 (21)
Non-English speaking	4	1 (25)	--	--	4	1 (25)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 259 Self-reported exposure to HCV versus HCV serology by sex and year of survey†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	6	6 (100)	2	2 (100)	8	8 (100)
Negative	25	6 (24)	3	0 (0)	28	6 (21)
Not sure	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.003		0.05		<0.001
2007						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	31	5 (16)	2	0 (0)	33	5 (15)
Not sure	7	1 (14)	--	--	7	1 (14)
p value		<0.001		0.05		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 260 HBV surface-antigen prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	3 (7)	5	0 (0)	49	3 (6)
Non-IDU	35	0 (0)	7	0 (0)	42	0 (0)
p value		0.1		--		0.1
2007						
IDU	38	2 (5)	5	0 (0)	43	2 (5)
Non-IDU	37	0 (0)	2	0 (0)	39	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 261 HBV core-antibody prevalence by sex, injector status and year of survey†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	11 (25)	4	2 (50)	48	13 (27)
Non-IDU	35	3 (9)	5	0 (0)	40	3 (8)
p value		0.06		0.07		0.02
2007						
IDU	38	16 (42)	5	2 (40)	43	18 (42)
Non-IDU	37	4 (11)	2	1 (50)	39	5 (13)
p value		0.002		0.8		0.003

† Excludes equivocal test results and missing values.

Table 262 HBV core-antibody prevalence by sexual identity, sex and year of survey†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	79	14 (18)	9	2 (22)	88	16 (18)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	19 (26)	7	3 (43)	80	22 (28)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 263 HBV core-antibody prevalence by age group, sex and year of survey†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	18	1 (6)	1	0 (0)	19	1 (5)
25 – 29	17	3 (18)	1	1 (100)	18	4 (22)
30 + years	36	10 (28)	6	1 (17)	42	11 (26)
p value		0.08		0.2		0.08
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	4 (33)	2	0 (0)	14	4 (29)
30 + years	38	15 (39)	5	3 (60)	43	18 (42)
p value		0.02		0.2		0.01

† Excludes equivocal test results and missing values.

Table 264 HBV core-antibody prevalence by duration of drug injection, sex and year of survey†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	13	3 (23)	1	1 (100)	14	4 (29)
10 + years	16	7 (44)	3	1 (33)	19	8 (42)
p value		0.1		0.3		0.2
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	7	1 (14)	--	--	7	1 (14)
6 to 10 years	6	2 (33)	1	0 (0)	7	2 (29)
10 + years	19	11 (58)	4	2 (50)	23	13 (57)
p value		0.2		0.4		0.1

† Excludes equivocal test results and missing values.

Table 265 HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	8	1 (13)	32	10 (31)	40	11 (28)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	2 (40)	6	2 (33)
Other/not reported	--	--	--	--	--	--
p value		0.7		0.7		0.7
2007						
Amphetamine (Speed, Ice)	5	1 (20)	34	14 (41)	39	15 (38)
Heroin	--	--	2	1 (50)	2	1 (50)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5

† Excludes equivocal test results and missing values.

Table 266 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	3	1 (33)	5	4 (80)	8	5 (63)
Daily or more	4	0 (0)	16	5 (31)	20	5 (25)
p value		0.2		0.06		0.06
2007						
Less than daily	--	--	11	4 (36)	11	4 (36)
Daily or more	2	0 (0)	11	7 (64)	13	7 (54)
p value		--		0.2		0.4

† Excludes equivocal test results and missing values.

Table 267 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	1 (17)	15	8 (53)	21	9 (43)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.7		0.2		0.3
2007						
No	2	0 (0)	14	6 (43)	16	6 (38)
Yes	--	--	7	4 (57)	7	4 (57)
p value		--		0.5		0.4

† Excludes equivocal test results and missing values.

Table 268 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	18	6 (33)	24	6 (25)
Yes	3	1 (33)	18	6 (33)	21	7 (33)
p value		0.1		0.6		0.9
2007						
No	2	1 (50)	11	6 (55)	13	7 (54)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		0.4		0.1		0.08

† Excludes equivocal test results and missing values.

Table 269 HBV core-antibody by number of previous imprisonments, sex and year of survey†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	28	2 (7)	3	0 (0)	31	2 (6)
2 to 4	34	8 (24)	6	2 (23)	40	10 (25)
5 to 9	12	4 (33)	--	--	12	4 (33)
10 +	2	0 (0)	--	--	2	0 (0)
p value		0.2		0.3		0.1
2007						
1	28	5 (18)	2	1 (50)	30	6 (20)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	5 (50)	1	0 (0)	11	5 (45)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.04		0.7		0.08

† Excludes equivocal test results and missing values.

Table 270 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	52	5 (10)	4	1 (25)	56	6 (11)
Indigenous	30	9 (30)	5	1 (20)	35	10 (29)
p value		0.2		0.9		0.03
2007						
Non-Indigenous	49	10 (20)	2	0 (0)	51	10 (20)
Indigenous	25	9 (36)	5	3 (60)	30	12 (40)
p value		0.1		0.2		0.05

† Excludes equivocal test results and missing values.

Table 271 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	25	0 (0)	29	6 (21)	54	6 (11)
Indigenous	15	3 (20)	19	7 (37)	34	10 (29)
p value		0.02		0.2		0.03
2007						
Non-Indigenous	23	1 (4)	28	9 (32)	51	10 (20)
Indigenous	16	4 (25)	14	8 (57)	30	12 (40)
p value		0.06		0.1		0.05

† Excludes equivocal test results and missing values.

Table 272 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	62	9 (15)	5	1 (20)	67	10 (15)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	5 (38)	2	0 (0)	15	5 (33)
p value		0.08		0.7		0.1
2007						
Highly accessible/accessible	57	13 (23)	6	2 (33)	63	15 (24)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	9	5 (56)	1	1 (100)	10	6 (60)
p value		0.08		0.2		0.04

† Excludes equivocal test results and missing values.

Table 273 HBV core-antibody prevalence by region/country of birth, sex and year of survey†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	71	13 (18)	9	2 (22)	80	15 (19)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.2		--		0.2
2007						
Australia	60	19 (32)	7	3 (43)	67	22 (33)
Other Oceania	4	1 (25)	--	--	4	1 (25)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	0 (0)	--	--	5	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 274 HBV core-antibody prevalence by main language spoken at home by parents, sex and year of survey†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English speaking	76	14 (18)	8	1 (13)	84	15 (18)
Non-English speaking	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.05		0.5
2007						
English speaking	71	19 (27)	7	3 (43)	78	22 (28)
Non-English speaking	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 275 Hepatitis B virus immune status by injector status and year of survey†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	No (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	49	21 (43)	10 (20)	3 (6)	15 (31)
Non-IDU	42	29 (69)	3 (7)	0 (0)	10 (24)
p value					0.04
2007					
IDU	43	16 (27)	16 (37)	2 (5)	9 (21)
Non-IDU	39	29 (74)	5 (13)	0 (0)	5 (13)
p value					<0.01

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 276 Hepatitis B virus immune status by sexual identity and year of survey†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	90	50 (56)	13 (14)	3 (3)	24 (27)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.4
2007					
Heterosexual	80	44 (55)	20 (25)	2 (3)	14 (18)
Homosexual	--	--	--	--	--
Bisexual	2	1 (50)	1 (50)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.8

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 277 Hepatitis B virus immune status by age group and year of survey†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	11	6 (55)	0 (0)	0 (0)	5 (45)
20 – 24	19	13 (68)	0 (0)	1 (5)	5 (26)
25 – 29	20	12 (60)	3 (15)	1 (5)	4 (20)
30 + years	43	21 (49)	10 (23)	1 (2)	11 (26)
p value					0.3
2007					
< 20 years	5	3 (60)	0 (0)	0 (0)	2 (40)
20 – 24	20	16 (80)	1 (5)	0 (0)	3 (15)
25 – 29	14	8 (57)	3 (21)	1 (7)	2 (14)
30 + years	43	18 (42)	17 (40)	1 (2)	7 (16)
p value					0.09

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 278 Hepatitis B virus immune status by number of previous imprisonments and year of survey†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	33	24 (73)	1 (3)	1 (3)	7 (21)
2 to 4	41	20 (49)	9 (22)	1 (2)	11 (27)
5 to 9	12	4 (33)	3 (25)	1 (8)	4 (33)
10 +	2	0 (0)	0 (0)	0 (0)	2 (100)
p value					0.08
2007					
1	30	20 (67)	5 (17)	1 (3)	4 (13)
2 to 4	25	15 (60)	4 (16)	0 (0)	6 (24)
5 to 9	11	4 (36)	4 (36)	1 (9)	2 (18)
10 +	3	1 (33)	2 (67)	0 (0)	0 (0)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 279 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	58	42 (72)	5 (9)	1 (2)	10 (17)
Indigenous	36	10 (28)	8 (22)	2 (6)	16 (44)
p value					<0.001
2007					
Non-Indigenous	51	32 (63)	9 (18)	1 (2)	9 (18)
Indigenous	30	13 (43)	11 (37)	1 (2)	5 (17)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 280 Hepatitis B virus immune status by residential remoteness and year of survey†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	70	42 (60)	7 (10)	3 (4)	18 (26)
Moderately accessible	5	2 (40)	0 (0)	0 (0)	3 (60)
Remote/very remote	15	6 (40)	5 (33)	0 (0)	4 (27)
p value					0.1
2007					
Highly accessible/accessible	63	38 (60)	13 (21)	2 (3)	10 (16)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	10	2 (20)	6 (60)	0 (0)	2 (20)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 281 Hepatitis B virus immune status by main language spoken at home by parents and year of survey†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	87	47 (54)	12 (14)	3 (3)	25 (29)
Non-English	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.6
2007					
English	78	43 (55)	20 (26)	2 (3)	13 (17)
Non-English	4	2 (50)	1 (25)	0 (0)	1 (25)
p value					1.0

† Excludes equivocal test results and missing values.

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded.

Table 282 Self-reported hepatitis B immunisation versus serological testing and year of survey*

Self-report HBV immunisation	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	31	5 (16)	5	2 (40)	36	7 (19)
Yes	22	11 (50)	1	1 (100)	23	12 (52)
Not sure	11	5 (45)	4	1 (25)	15	6 (40)
p value		0.02		0.4		0.03
2007						
No	29	3 (10)	4	1 (25)	33	4 (12)
Yes	18	9 (50)	--	--	18	9 (50)
Not sure	8	1 (13)	--	--	8	1 (13)
p value		0.006		--		0.007

* HBV Surface-antibody level of ≥ 10 are considered immune. HBV core-antibody positive cases and HBV carriers have been excluded. Yes to self-reported immunisation includes any immunisation against HBV.

Methodological Notes

Due to the small numbers screened in South Australia and the ACT, findings for these jurisdictions are included in the report summary only.

Due to the small number (n=4) of those testing positive for HIV, this variable is presented by sex and injector status only for each jurisdiction. However, for the 2007 national summary HIV prevalence is also presented by sexual identity, Indigenous status, residential remoteness, and against self-reported HIV status.

Due to incomplete questionnaire data preventing the ascertainment of injector status, the main classification variable, 14 prisoners' data were excluded from the 2007 survey.

Percentages over 1 have been rounded up to the nearest whole number while those less than 1 are indicated as '<1'.

The Accessibility/Remoteness Index of Australia (ARIA) classification was developed in 1997 and is based on a continuous measure of remoteness developed by the National Key Centre for Social Applications of Geographical Information Systems (GISCA). In this classification, an ARIA category is allocated on the basis of the average ARIA index score (between 0 and 12) within an area (such as an SLA). The ARIA index score is based on the road distance from the closest service centres in each of four classes (as defined using 1996 census population data). ARIA index scores, and therefore ARIA categories, are capable of being updated over time as populations change.

ARIA categorises areas into 5 groups as follows:

1. Highly Accessible - relatively unrestricted accessibility to a wide range of goods and services and opportunities for social interaction.
2. Accessible - some restrictions to accessibility of some goods, services and opportunities for social interaction.
3. Moderately Accessible - significantly restricted accessibility of goods, services and opportunities for social interaction.
4. Remote - very restricted accessibility of goods, services and opportunities for social interaction.
5. Very Remote - very little accessibility of goods, services and opportunities for social interaction.

For the purposes of this report, 3 ARIA groupings were created: highly accessible + accessible, moderately accessible, and remote + very remote. Categories were allocated by using the postcode the individual had spent most time in during the 12 months before coming into prison.

Some tables have been regenerated for 2004 to ensure they are consistent with the 2007 data and therefore may differ slightly from those appearing in the 2004 National Prison Entrants' Bloodborne Virus Survey.⁴

Appendix 1 – Blood Tests, Test Kits and Testing Laboratories**Human Immunodeficiency Virus (HIV)**

AxSYM HIV Ag/Ab Combo Assay. ABBOTT (USA)

HIV ½ gO AxSym ABBOTT (USA)

Hepatitis B Surface-Antibody

Monolisa Anti-HBs 3.0 Enzyme Immunoassay. BIO-RAD (USA)

AxSYM HBs Enzyme Immunoassay ABBOTT (USA)

Hepatitis B (IgG & IgM) Core-Antibody[NSW]

Monolisa Anti-HBc Plus Enzyme Immunoassay. BIO-RAD (USA)

Monolisa HBc IgM Enzyme Immunoassay. BIO-RAD (USA)

AxSYM HBc Enzyme Immunoassay ABBOTT (USA)

Hepatitis B Surface-Antigen

Monolisa HbsAg Plus Enzyme Immunoassay. BIO-RAD (USA)

Monolisa HbsAg Confirmation Enzyme Immunoassay BIO-RAD (USA)

HbsAg/HbsAG Confirmatory AxSYM ABBOTT (USA)

HBsAg ABBOTT Architect System Immunoassay (USA)

Hepatitis B e-Antibody & e-Antigen

Monolisa Hbe (Hbe Ag-Ab detection Enzyme Immunoassay. BIO-RAD (USA)

AxSYM Hbe 2.0 AxSYM plus ABBOTT (USA)

Hepatitis C Antibody

Innotest HCV Ab IV INNOGENETICS (Belgium)

Anti-HCV IV Enzyme Immunoassay. MUREX (UK)

Monolisa Anti-HCV Enzyme Immunoassay Plus Version 2 BIO-RAD (USA)

Testing Centres:

ACT ACT Pathology, Canberra

NSW Institute of Clinical Pathology and Medical Research

Qld Queensland Health Pathology and Scientific Services

SA Institute of Medical and Veterinary Science

Tas Northern Tasmanian Pathology Service and State Reference Laboratory Microbiology
Department, Royal Hobart Hospital

Vic Dorevitch Pathology, Victoria

Melbourne Pathology, Victoria

WA PathWest Laboratory Medicine, Western Australia

13a. How often did you inject in the **last month**?

☐	1. More than 3 times most days
☐	2. 2 to 3 times most days
☐	3. Once a day
☐	4. More than weekly, not daily
☐	5. Less than weekly (1-5 days)
☐	6. Not in the last month

If you **did NOT inject in the last month** → **go to Q14**

13b. Tick all places you injected drugs in the **last month**?

☐	Prison
☐	Own home
☐	Friend's home
☐	Dealer's home
☐	Street, park or beach
☐	Car
☐	Public toilet
☐	Commercial "shooting" room
☐	MSIC (KX injecting centre in Sydney)
☐	Squat
☐	Other (specify)

13c. How often did you use a **NEW** sterile needle and syringe in the **last month**?

☐	1. All injections
☐	2. Most of the time
☐	3. Half of the time
☐	4. Some of the time
☐	5. Not last month

13d. Tick all equipment that you used **after anyone else** in the **last month**?

☐	Spoon	☐	Tourniquet
☐	Water	☐	Drug solution / mix
☐	Filter	☐	Did not share any

of above last month

13e. How many times **last month** did **someone else** inject you after injecting themselves or others

☐	1. More than 5 times
☐	2. 3 to 5 times
☐	3. Once or twice
☐	4. None

13f. How many times **last month** did you reuse a needle & syringe **after someone else** (including sex partner) had used it (even if it was cleaned)?

☐	1. More than 5 times
☐	2. 3 to 5 times
☐	3. Twice
☐	4. Once
☐	5. None → go to Q14

13g. How many **different** people (including your sex partner) have used a needle before you in the **last month** (even if cleaned)?

☐	1. More than 5 people
☐	2. 3 to 5 people
☐	3. 2 people
☐	4. 1 person
☐	5. Don't know how many

13h. Who were these people? (tick all that apply)

☐	Regular sex partner
☐	Other sex partners
☐	Close friend
☐	Acquaintance
☐	Other (specify)

14. How many times **last month** did you get needles & syringes from a **needle exchange**?

☐	1. Daily or almost daily
☐	2. A couple of times each week
☐	3. Less than weekly (2 to 5 times)
☐	4. Once last month
☐	5. Not in the last month

15. How many times **last month** did you get needles & syringes from a **pharmacy**?

☐	1. Daily or almost daily
☐	2. A couple of times each week
☐	3. Less than weekly (2 to 5 times)
☐	4. Once last month
☐	5. Not in the last month

16. When was the **last time** you re-used a needle after someone else?

☐	1. Last month
☐	2. In the last 2 to 6 months
☐	3. More than 6 months ago
☐	4. Never → go to Q18

17. Where was the **last place** you re-used a needle or syringe after someone else?

☐	Prison
☐	Own home
☐	Friend's home
☐	Dealer's home
☐	Street, park or beach
☐	Car
☐	Public toilet
☐	Commercial "shooting" room
☐	MSIC (KX injecting centre Sydney)
☐	Squat
☐	Other (specify)

18. Have you **ever** participated in the yearly finger-prick survey at a needle exchange in the community

☐	1. Yes
☐	2. No
☐	3. Don't remember

19a. Have you **ever** been on a methadone program?

☐	1. Yes, on it now
☐	2. Yes, in the past
☐	3. No, never

19b. Have you **ever** been on any other program, eg. naltrexone, buprenorphine or LAAM?

☐	1. Yes, on it now
☐	2. Yes, in the past
☐	3. No, never

19c. Have you **ever** had any other therapies for drug use, eg. detox, counselling, Narcotics Anonymous?

☐	1. Yes
☐	2. No

20.a Have you **ever** had hepatitis B infection?

☐	1. Yes
☐	2. No
☐	3. Unsure

21a. Have you **ever** had hep B vaccination?

☐	1. Yes
☐	2. No → go to Q22a
☐	3. Unsure → go to Q22a

21b. If **YES**, how many injections have you had?

☐	1. One
☐	2. Two
☐	3. 3 or more

22a. Have you been tested for HIV?
☐ 1. Yes, in the last year
☐ 2. Yes, more than a year ago
☐ 3. Never tested → **go to Q23a**

22b. If **YES**, what was the result of your **LAST** HIV test?
☐ 1. Did not have HIV
☐ 2. I have HIV infection
☐ 3. Don't know the result
☐ 4. Declined to answer

23a. Have you been tested for Hep C?
☐ 1. Yes, in the last year
☐ 2. Yes, more than a year ago
☐ 3. Never tested → **go to Q25**

23b. If **YES**, what was the result of your **LAST** Hep C test?
☐ 1. Did not have Hep C → **go to Q25**
☐ 2. I have Hep C
☐ 3. Don't know result

24b. What year did you find out that you had Hep C?

24c. Have you **EVER** had treatment for your Hep C?
 (Tick all that apply)
☐ 1. No treatment → **go to Q25**
☐ 2. Yes, Interferon
☐ 3. Yes, Interferon+Ribavirin
☐ 4. Yes, Pegasys + Ribavirin
☐ 5. Other (specify) _____

24d. If **YES**, are you having treatment for your Hep C **NOW**?
☐ 1. Yes, Interferon
☐ 2. Yes, Interferon+Ribavirin
☐ 3. Yes, Pegasys + Ribavirin
☐ 4. Other (specify) _____

25. Sexual identity?
☐ 1. Heterosexual
☐ 2. Bisexual
☐ 3. Gay/lesbian
☐ 4. Unsure

26. Did you use a condom (or dam) the **last time you had sex**?
☐ 1. Yes
☐ 2. No

27. Have you been **paid** for sex in the **last month**? (include non-cash payments)
☐ 1. Yes
☐ 2. No → **go to Q28a**

27a. If **yes** to Q27, did you use condoms (or dams) the last time **you were paid for sex**?
☐ 1. Yes
☐ 2. No

28a. How would you describe your sexual activity **last month**?
☐ 1. None → **end of questionnaire**
☐ 2. None, partner in prison → **end of questionnaire**
☐ 3. Casual sex only
☐ 4. Regular relationship
☐ 5. Regular and casual sex

If **SEX IN LAST MONTH**
 28b. How many **NEW** sex partners did you have sex **with** last month?

28c. Did you use **condoms** with your:
NEW sex partner(s) **last month**?
☐ 1. No ☐ 3. Every time
☐ 2. Sometimes ☐ 4. No new partner
CASUAL sex partner(s) **last month**?
☐ 1. No ☐ 3. Every time
☐ 2. Sometimes ☐ 4. No casual partner
REGULAR sex partner(s) **last month**?
☐ 1. No ☐ 3. Every time
☐ 2. Sometimes ☐ 4. No regular partner

29. Complete the following section **ONLY** if positive results from previous tests have been sighted in medical file and retesting is considered unnecessary.

Test	Tick if sighted	Date of test	Testing lab
HIV Ab+ve			
HBV SAb+ve			
HBV CAb+ve			
HBV SAg			
HCV Ab+ve			

List of Tables

Table 1	Reception centre, sex of prison receptions at the site, participants screened, and total number of receptions, 2007 NPEBBV&RBS	15
Table 2	Structure of the study sample by sex and injector status, 2007 NPEBBV&RBS	15
Table 3	Demographic characteristics of prison entrants by state (2007)	16
Table 4	Injecting drug use and smoking status by state (2007)	16
Table 5	HIV antibody prevalence by state, sex and injector status (2007)	17
Table 6	Hepatitis C antibody prevalence by state, sex and injector status (2007)	17
Table 7	Hepatitis B core-antibody prevalence by state, sex and injector status (2007)	17
Table 8	Hepatitis B virus immune status (2007)	18
Table 9	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	19
Table 10	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	21
Table 11	Number (percentage) of respondents by treatment for drug use, injector status and year of survey	22
Table 12	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	22
Table 13	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	23
Table 14	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	24
Table 15	HIV antibody prevalence by sex, injector status and year of survey	25
Table 16	HIV antibody prevalence by sexual identity, sex and year of survey	25
Table 17	HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	25
Table 18	HIV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	26
Table 19	Self-reported exposure to HIV versus HIV serology by gender	26
Table 20	HCV antibody prevalence by sex, injector status and year of survey	26
Table 21	HCV antibody prevalence by sexual identity, sex and year of survey	27
Table 22	HCV antibody prevalence by age group, sex and year of survey	27
Table 23	HCV antibody prevalence by duration of drug injection, sex and year of survey	27
Table 24	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	28
Table 25	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	28
Table 26	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	28
Table 27	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	29
Table 28	HCV antibody by number of previous imprisonments, gender and year of survey	29
Table 29	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	29
Table 30	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	30
Table 31	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	30
Table 32	HCV antibody prevalence by region/country of birth, sex and year of survey	30
Table 33	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	31
Table 34	Self-reported exposure to HCV versus HCV serology by gender and year of survey	31
Table 35	HBV surface-antigen prevalence by gender, injector status and year of survey	31
Table 36	HBV core-antibody prevalence by gender, injector status and year of survey	32
Table 37	HBV core-antibody prevalence by sexual identity, gender and year of survey	32
Table 38	HBV core-antibody prevalence by age group, gender and year of survey	32
Table 39	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	33
Table 40	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey	33
Table 41	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	33
Table 42	HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	34
Table 43	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	34
Table 44	HBV core-antibody by number of previous imprisonments, gender and year of survey	34
Table 45	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	35
Table 46	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	35
Table 47	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	35
Table 48	HBV core-antibody prevalence by region/country of birth, gender and year of survey	36

Table 49	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	36
Table 50	Hepatitis B virus immune status by injector status and year of survey	36
Table 51	Hepatitis B virus immune status by sexual identity and year of survey	37
Table 52	Hepatitis B virus immune status by age group and year of survey	37
Table 53	Hepatitis B virus immune status by number of previous imprisonments and year of survey	38
Table 54	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey	38
Table 55	Hepatitis B virus immune status by residential remoteness and year of survey	38
Table 56	Hepatitis B virus immune status by main language spoken at home by parents and year of survey	39
Table 57	Self-reported hepatitis B immunisation versus serological testing and year of survey	39
Table 58	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	40
Table 59	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	42
Table 60	Number (percentage) of respondents by treatment for drug use, injector status and year of survey	43
Table 61	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	43
Table 62	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	44
Table 63	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	45
Table 64	HIV antibody prevalence by sex, injector status and year of survey	46
Table 65	HCV antibody prevalence by sex, injector status and year of survey	46
Table 66	HCV antibody prevalence by sexual identity, sex and year of survey	46
Table 67	HCV antibody prevalence by age group, sex and year of survey	47
Table 68	HCV antibody prevalence by duration of drug injection, sex and year of survey	47
Table 69	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	47
Table 70	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	48
Table 71	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	48
Table 72	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	48
Table 73	HCV antibody by number of previous imprisonments, gender and year of survey	49
Table 74	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	49
Table 75	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	49
Table 76	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison, and year of survey	50
Table 77	HCV antibody prevalence by region/country of birth, sex and year of survey	50
Table 78	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	50
Table 79	Self-reported exposure to HCV versus HCV serology by gender and year of survey	51
Table 80	HBV surface-antigen prevalence by gender, injector status and year of survey	51
Table 81	HBV core-antibody prevalence by gender, injector status and year of survey	51
Table 82	HBV core-antibody prevalence by sexual identity, gender and year of survey	52
Table 83	HBV core-antibody prevalence by age group, gender and year of survey	52
Table 84	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	52
Table 85	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey	53
Table 86	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	53
Table 87	HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	53
Table 88	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	54
Table 89	HBV core-antibody by number of previous imprisonments, gender and year of survey	54
Table 90	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	54
Table 91	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	55
Table 92	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	55
Table 93	HBV core-antibody prevalence by region/country of birth, gender and year of survey	55
Table 94	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	56
Table 95	Hepatitis B virus immune status by injector status and year of survey	56
Table 96	Hepatitis B virus immune status by sexual identity and year of survey	56
Table 97	Hepatitis B virus immune status by age group and year of survey	57
Table 98	Hepatitis B virus immune status by number of previous imprisonments and year of survey	57
Table 99	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey	57
Table 100	Hepatitis B virus immune status by residential remoteness and year of survey	58

Table 101	Hepatitis B virus immune status by main language spoken at home by parents and year of survey	58
Table 102	Self-reported hepatitis B immunisation versus serological testing and year of survey	58
Table 103	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	59
Table 104	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	61
Table 105	Number (percentage) of respondents by treatment for drug use, injector status and year of survey	62
Table 106	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	62
Table 107	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	63
Table 108	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	64
Table 109	HIV antibody prevalence by sex, injector status and year of survey	65
Table 110	HCV antibody prevalence by sex, injector status and year of survey	65
Table 111	HCV antibody prevalence by sexual identity, sex and year of survey	65
Table 112	HCV antibody prevalence by age group, sex and year of survey	66
Table 113	HCV antibody prevalence by duration of drug injection, sex and year of survey	66
Table 114	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	66
Table 115	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	67
Table 116	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	67
Table 117	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey ..	67
Table 118	HCV antibody by number of previous imprisonments, gender and year of survey	68
Table 119	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	68
Table 120	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	68
Table 121	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	69
Table 122	HCV antibody prevalence by region/country of birth, sex and year of survey	69
Table 123	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey ..	69
Table 124	Self-reported exposure to HCV versus HCV serology by gender and year of survey	70
Table 125	HBV surface-antigen prevalence by gender, injector status and year of survey	70
Table 126	HBV core-antibody prevalence by gender, injector status and year of survey	70
Table 127	HBV core-antibody prevalence by sexual identity, gender and year of survey	71
Table 128	HBV core-antibody prevalence by age group, gender and year of survey	71
Table 129	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	71
Table 130	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey ...	72
Table 131	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	72
Table 132	HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	72
Table 133	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	73
Table 134	HBV core-antibody by number of previous imprisonments, gender and year of survey	73
Table 135	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	73
Table 136	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	74
Table 137	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	74
Table 138	HBV core-antibody prevalence by region/country of birth, gender and year of survey	74
Table 139	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	75
Table 140	Hepatitis B virus immune status by injector status and year of survey	75
Table 141	Hepatitis B virus immune status by sexual identity and year of survey	75
Table 142	Hepatitis B virus immune status by age group and year of survey	76
Table 143	Hepatitis B virus immune status by number of previous imprisonments and year of survey	76
Table 144	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey	76
Table 145	Hepatitis B virus immune status by residential remoteness and year of survey	77
Table 146	Hepatitis B virus immune status by main language spoken at home by parents and year of survey	77
Table 147	Self-reported hepatitis B immunisation versus serological testing and year of survey	77
Table 148	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	78
Table 149	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	80
Table 150	Number (percentage) of respondents by treatment for drug use, injector status and year of survey	81

Table 151	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	81
Table 152	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	82
Table 153	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	83
Table 154	HIV antibody prevalence by sex, injector status and year of survey	84
Table 155	HCV antibody prevalence by sex, injector status and year of survey	84
Table 156	HCV antibody prevalence by sexual identity, sex and year of survey	84
Table 157	HCV antibody prevalence by age group, sex and year of survey	85
Table 158	HCV antibody prevalence by duration of drug injection, sex and year of survey	85
Table 159	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey	85
Table 160	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	86
Table 161	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	86
Table 162	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey ..	86
Table 163	HCV antibody by number of previous imprisonments, gender and year of survey	87
Table 164	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	87
Table 165	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	87
Table 166	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	88
Table 167	HCV antibody prevalence by region/country of birth, sex and year of survey	88
Table 168	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey ..	88
Table 169	Self-reported exposure to HCV versus HCV serology by gender and year of survey	89
Table 170	HBV surface-antigen prevalence by gender, injector status and year of survey	89
Table 171	HBV core-antibody prevalence by gender, injector status and year of survey	89
Table 172	HBV core-antibody prevalence by sexual identity, gender and year of survey	90
Table 173	HBV core-antibody prevalence by age group, gender and year of survey	90
Table 174	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	90
Table 175	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey ..	91
Table 176	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	91
Table 177	HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	91
Table 178	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	92
Table 179	HBV core-antibody by number of previous imprisonments, gender and year of survey	92
Table 180	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	92
Table 181	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	93
Table 182	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	93
Table 183	HBV core-antibody prevalence by region/country of birth, gender and year of survey	93
Table 184	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	94
Table 185	Hepatitis B virus immune status by injector status and year of survey	94
Table 186	Hepatitis B virus immune status by sexual identity and year of survey	94
Table 187	Hepatitis B virus immune status by age group and year of survey	95
Table 188	Hepatitis B virus immune status by number of previous imprisonments and year of survey	95
Table 189	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey	95
Table 190	Hepatitis B virus immune status by residential remoteness and year of survey	96
Table 191	Hepatitis B virus immune status by main language spoken at home by parents and year of survey	96
Table 192	Self-reported hepatitis B immunisation versus serological testing and year of survey	96
Table 193	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	97
Table 194	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	99
Table 195	Number (percentage) of respondents by treatment for drug use, injector status and year of survey ...	100
Table 196	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	100
Table 197	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	101
Table 198	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	102
Table 199	HIV antibody prevalence by sex, injector status and year of survey	103
Table 200	HCV antibody prevalence by sex, injector status and year of survey	103

Table 201	HCV antibody prevalence by sexual identity, sex and year of survey	103
Table 202	HCV antibody prevalence by age group, sex and year of survey	104
Table 203	HCV antibody prevalence by duration of drug injection, sex and year of survey	104
Table 204	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	104
Table 205	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	105
Table 206	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey.....	105
Table 207	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	105
Table 208	HCV antibody by number of previous imprisonments, gender and year of survey	106
Table 209	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	106
Table 210	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	106
Table 211	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	107
Table 212	HCV antibody prevalence by region/country of birth, sex and year of survey.....	107
Table 213	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	107
Table 214	Self-reported exposure to HCV versus HCV serology by gender and year of survey.....	108
Table 215	HBV surface-antigen prevalence by gender, injector status and year of survey.....	108
Table 216	HBV core-antibody prevalence by gender, injector status and year of survey.....	108
Table 217	HBV core-antibody prevalence by sexual identity, gender and year of survey	109
Table 218	HBV core-antibody prevalence by age group, gender and year of survey	109
Table 219	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	109
Table 220	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey .	110
Table 221	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey.....	110
Table 222	HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey.....	110
Table 223	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	111
Table 224	HBV core-antibody by number of previous imprisonments, gender and year of survey	111
Table 225	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	111
Table 226	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey.....	112
Table 227	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	112
Table 228	HBV core-antibody prevalence by region/country of birth, gender and year of survey.....	112
Table 229	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	113
Table 230	Hepatitis B virus immune status by injector status and year of survey.....	113
Table 231	Hepatitis B virus immune status by sexual identity and year of survey.....	113
Table 232	Hepatitis B virus immune status by age group and year of survey.....	114
Table 233	Hepatitis B virus immune status by number of previous imprisonments and year of survey	114
Table 234	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey...	114
Table 235	Hepatitis B virus immune status by residential remoteness and year of survey.....	115
Table 236	Hepatitis B virus immune status by main language spoken at home by parents and year of survey...	115
Table 237	Self-reported hepatitis B immunisation versus serological testing and year of survey	115
Table 238	Number (percentage) of respondents by demographic characteristics, injector status and year of survey	116
Table 239	Number (percentage) of respondents by last drug injected, injecting behaviour in the month prior to survey and year of survey	118
Table 240	Number (percentage) of respondents by treatment for drug use, injector status and year of survey ...	119
Table 241	Number (percentage) of respondents by site of needle and syringe acquisition last month and year of survey	119
Table 242	Number (percentage) of respondents by sexual behaviour in the month prior to survey, injector status and year of survey	120
Table 243	Number (percentage) of respondents reporting previous testing for HIV, HBV and HCV infection, HBV vaccination and HCV treatment by injector status and year of survey	121
Table 244	HIV antibody prevalence by sex, injector status and year of survey.....	122
Table 245	HCV antibody prevalence by sex, injector status and year of survey	122
Table 246	HCV antibody prevalence by sexual identity, sex and year of survey	122
Table 247	HCV antibody prevalence by age group, sex and year of survey	123
Table 248	HCV antibody prevalence by duration of drug injection, sex and year of survey	123
Table 249	HCV antibody prevalence by last drug injected, duration of drug injection and year of survey.....	123
Table 250	HCV antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	124

Table 251	HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	124
Table 252	HCV antibody prevalence by imprisonment last year, duration of drug injection and year of survey	124
Table 253	HCV antibody by number of previous imprisonments, gender and year of survey	125
Table 254	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and year of survey	125
Table 255	HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	125
Table 256	HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	126
Table 257	HCV antibody prevalence by region/country of birth, sex and year of survey	126
Table 258	HCV antibody prevalence by main language spoken at home by parents, gender and year of survey	126
Table 259	Self-reported exposure to HCV versus HCV serology by gender and year of survey	127
Table 260	HBV surface-antigen prevalence by gender, injector status and year of survey	127
Table 261	HBV core-antibody prevalence by gender, injector status and year of survey	127
Table 262	HBV core-antibody prevalence by sexual identity, gender and year of survey	128
Table 263	HBV core-antibody prevalence by age group, gender and year of survey	128
Table 264	HBV core-antibody prevalence by duration of drug injection, gender and year of survey	128
Table 265	HBV core-antibody prevalence by last drug injected, duration of drug injection and year of survey	129
Table 266	HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and year of survey	129
Table 267	HBV core-antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and year of survey	129
Table 268	HBV core-antibody prevalence by imprisonment last year, duration of drug injection and year of survey	130
Table 269	HBV core-antibody by number of previous imprisonments, gender and year of survey	130
Table 270	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, gender and year of survey	130
Table 271	HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and year of survey	131
Table 272	HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and year of survey	131
Table 273	HBV core-antibody prevalence by region/country of birth, gender and year of survey	131
Table 274	HBV core-antibody prevalence by main language spoken at home by parents, gender and year of survey	132
Table 275	Hepatitis B virus immune status by injector status and year of survey	132
Table 276	Hepatitis B virus immune status by sexual identity and year of survey	132
Table 277	Hepatitis B virus immune status by age group and year of survey	133
Table 278	Hepatitis B virus immune status by number of previous imprisonments and year of survey	133
Table 279	Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and year of survey ..	133
Table 280	Hepatitis B virus immune status by residential remoteness and year of survey	134
Table 281	Hepatitis B virus immune status by main language spoken at home by parents and year of survey...	134
Table 282	Self-reported hepatitis B immunisation versus serological testing and year of survey	134

References

1. Christensen PB, Fisker N, Krarup HB, Liebert E, Jaroslavtsev N, Christensen K et al. Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. *Vaccine* 2004; 22:3897-3901.
2. Butler T, Levy M, Dolan K, Kaldor J. Drug use and its correlates in an Australian prisoner population. *Addiction Research and Theory* 2003; 11:89-101.
3. Gore S, Bird AG. Drugs in British prisons. *BMJ* 2000; 316:1256-1257.
4. Butler T, Hailstone S, Boonwaat L. National Prison Entrants' Bloodborne Virus Survey. 2005. Centre for Health Research in Criminal Justice & National Centre in HIV Epidemiology and Clinical Research, University of New South Wales. ISBN : 0 7347 37440.
5. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. *Australian & New Zealand Journal of Public Health* 1999; 23:377-384.
6. Butler TG, Dolan KA, Ferson MJ, McGuinness LM, Brown PR, Robertson PW. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. *Medical Journal of Australia* 1997; 166:127-130.
7. Crofts N, Stewart T, Hearne P. Spread of Blood borne viruses among Australian prison entrants. *BMJ* 1996; 310:285-288.
8. Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. *Eur J Epidemiol* 2000; 16:1043-1049.
9. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report 2003. 2003. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW.
10. Miller ER, Bi P, Ryan P. The prevalence of HCV antibody in South Australian prisoners. *Journal of Infection* 2006; 53:125-130.
11. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *J Epidemiology Community Health* 2008; 62:305-313.
12. Butler T, Kariminia A, Levy M, Kaldor J. Prisoners are at risk for hepatitis C transmission. *Eur J Epidemiol* 2004; 19:1119-1122.
13. Dolan K, Wodak A. HIV transmission in a prison system in an Australian state. *Medical Journal of Australia* 1999; 171:14-17.
14. Crofts N, Stewart T, Hearne P. Spread of Blood borne viruses among Australian prison entrants. *BMJ* 1996; 310:285-288.
15. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. *Epidemiol Infect* 2004; 132(June):409-415.
16. National Centre in HIV Epidemiology & Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Report. 2007. National Centre in HIV Epidemiology & Clinical Research, Sydney; Australian Institute of Health & Welfare, Canberra, ACT.
17. MacDonald M, Zhou J. Prevalence of HIV, HCV and injecting and sexual behaviour among IDU at Needle and Syringe Programs. Australian NSP Survey National Data Report. 2002. National Centre in HIV Epidemiology and Clinical Research, University of New South Wales.

